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 Cyclin E is the regulatory subunit of the cyclin E/CDK2 complex that 
mediates the G1-S phase transition. N-terminal cleavage of cyclin E by elastase in 
breast cancer generates two low molecular weight (LMW) isoforms that exhibit both 
enhanced kinase activity and resistance to p21 and p27 inhibition compared to full-
length cyclin E. Clinically, approximately 27% of breast cancer patients overexpress 
LMW-E and associate with poor survival. Therefore, we hypothesize that LMW-E 
disrupts normal mammary acinar morphogenesis and serves as the initial route into 
breast tumor development. We first demonstrate that LMW-E overexpression in 
non-tumorigenic hMECs is sufficient to induce tumor formation in athymic mice 
significantly more than overexpression of full-length cyclin E and requires CDK2-
associated kinase activity. Further in vivo passaging of these tumors augments 
LMW-E expression and tumorigenic potential. When subjected to acinar 
morphogenesis in vitro, LMW-E mediates significant morphological disruption by 
generating hyperproliferative and multi-acinar complexes. Proteomic analysis of 
patient tissues and tumor cells with high LMW-E expression reveals that the 
activation of the b-Raf-ERK1/2-mTOR pathway in concert with high LMW-E 
expression predicts poor patient survival. Combination treatment using roscovitine 
(CDK inhibitor) plus either rapamycin (mTOR inhibitor) or sorafenib (b-raf inhibitor) 
effectively prevented aberrant acinar formation in LMW-E-expressing cells by 
inducing the G1/S cell cycle arrest. In addition, the LMW-E-expressing tumor cells 
exhibit phenotypes characteristic of the EMT and enhanced cellular invasiveness.  
v 
These tumor cells also enrich for cells with CSC phenotypes such as increased 
CD44hi/CD24lo population, enhanced mammosphere formation, and upregulation of 
ALDH expression and enzymatic activity. Furthermore, the CD44hi/CD24lo 
population also shows positive correlation with LMW-E expression in both the tumor 
cell line model and breast cancer patient samples (p<0.0001 & p=0.0435, 
respectively). Combination treatment using doxorubicin and salinomycin 
demonstrates synergistic cytotoxic effects in cells with LMW-E expression but not in 
those with full-length cyclin E expression. Finally, ProtoArray microarray identifies 
Hbo1 as a novel substrate of the cyclin E/CDK2 complex and its overexpression 
results in enrichment for CSCs. Collectively, these data emphasize the strong 
oncogenic potential of LMW-E in mammary tumorigenesis and suggest possible 
therapeutic strategies to treat breast cancer patients with high LMW-E expression. 
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CHAPTER 1: INTRODUCTION TO THE ROLE OF CELL CYCLE IN BREAST 
CANCER 
 
1.1. THE MAMMARY GLAND AND BREAST CANCER DEVELOPMENT 
1.1a. Breast cancer statistics  
 The mammary gland is highly susceptible to tumor-initiating mutations and 
oncogenic modulations since the gland itself develops after birth and undergoes 
repeated cycles of remodeling and regression involving proliferation, differentiation, 
and apoptosis (1). Consequently, breast cancer is currently the second most 
common type of cancer in the United States with approximately 200,000 new cases 
and over 40,000 expected deaths in 2010. Although breast cancer incidence has 
been rising steadily mainly due to increased awareness, innovative treatment and 
disease management has dramatically improved patient outcome. Estimates from 
the National Cancer Institute suggested that approximately 2.5 million women who 
had a history of breast cancer were still survivors in 2006. However, despite 
development of better therapeutic practices that greatly improved patient survival, 
breast cancer still remains the leading cause of cancer death in women worldwide. 
This is due to our incomplete understanding of the biology and evolution of breast 
cancer, which results in the high rate of tumor relapse and metastatic dissemination. 
To improve breast cancer treatment, we must clearly elucidate the mechanism of 
mammary oncogenesis in order to develop targeted therapy that can specifically 
and completely eradicate tumor growth.  
 
1.1b. The physiology of the mammary gland 
 The mammary gland is an exocrine gland that produces and secretes milk 
during lactation. Alveoli are the most basic components of the mammary gland; they 
are hollow cavities that contain luminal cells, which produce and secrete milk into 
the lumen (Figure 1). These luminal cells are highly differentiated and the cells 
organize to form polarized acinar structure. Myoepithelial cells surround the luminal 
cells and provide basement support as well as to contract in response to oxytocin 
stimulation to excrete milk. Multiple alveoli combine to form mammary lobules, 
1
aveolus
(acinus)
lumen
adipocytes 
inflammatory cells
Figure 1: The structure of the mammary gland. The mammary gland is composed
of multiple lobules that are connected by ducts to form a hollow network for milk
production and secretion through the nipple during lactation. The lobule consists of
multiple aveoli (acini) which are the basic unit of the mammary gland. Each aveolus
is made up of luminal cells, which produce and secrete milk into to the lumen. The
myoepithelial cells surround the luminal cells and the aveolus is enclosed by a
basement membrane. Image obtained and modified from Tutorvista.com.
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which are connected by lactiferous duct to allow milk to flow to the nipple. The 
mammary extracellular matrix, which is composed of myoepithelial basement 
membrane and connective tissues, along with fibroblasts, adipocytes, and 
inflammatory cells, functions to maintain the morphology of the mammary gland and 
to provide signaling between mammary epithelial cells as well as signaling from 
other organs and tissues. The structure of the mammary gland is organized 
intricately to achieve efficient function. Therefore, tissue organization or 
morphogenesis in the mammary gland is critical to maintain the integrity of the 
tissue and prevent pathogenesis. Breast cancer most commonly arises from luminal 
cells, which are the cells that produce milk, and a smaller percentage of breast 
cancer arise from the lactiferous duct (Figure 1).   
 
1.1c. Treatment options for breast cancer  
 After a patient is diagnosed with breast cancer, treatment options include 
surgery, chemotherapy, radiation therapy, and systemic therapy. Most patients will 
undergo surgery (lumpectomy or mastectomy) to remove the cancer from the breast 
tissue, and this tumor mass is also used to assess the stage of the disease. Surgery 
is typically combined with other treatment options to enhance the chance of 
complete remission. In cases when the tumors are in excess of 1 cm, radiation or 
neoadjuvant therapy are performed to reduce the tumor size prior to surgery. Once 
all detectable tumor tissue has been removed by surgery, additional adjuvant 
therapy is given to women with breast tumors larger than 1 cm or have node 
positive disease. Adjuvant therapy administered systemically, is defined as the use 
of anti-cancer agents administered orally or intravenously and includes 
immunotherapy, endocrine therapy and chemotherapy.   
 Immunotherapy involves the manipulation of the patient’s immune system to 
fight cancer cells and thus renders less toxic side effects compared to traditional 
chemotherapy. The most commonly recognized agents used in immunotherapy are 
trastuzumab (Herceptin), lapatinib (Tykerb), and bevacizumab (Avastin). 
Trastuzumab, a monoclonal antibody to human epidermal growth factor receptor 2 
(HER2), has gained tremendous recognition due to the results of clinical trials 
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demonstrating that trastuzumab synergizes with standard chemotherapy to 
effectively lower the risk of recurrence and death (2). As a result, trastuzumab has 
been approved by the Food and Drug Administration to treat breast cancer patients 
with HER2 overexpression (3).  
 On the other hand, breast tumors with positive expression for estrogen 
receptor (ER) and/or progesterone receptor (PR) receive endocrine therapy. There 
are 3 major types of endocrine therapy: ovarian ablation, selective estrogen 
receptor modules (SERMs), and aromatase inhibitors. The ovaries are the main 
source of estrogen production in pre-menopausal women, and estrogen is 
mitogenic because it promotes growth of breast cancer cells that express ER. As a 
result, women with hormone receptor positive disease are given luteinizing 
hormone-releasing hormone (LHRH) to shut down estrogen production or subjected 
to ovarian removal by surgery. There are a total of 3 SERMs available in the clinic: 
tamoxifen, raloxifene, and toremifene, and they function by competitively inhibit the 
binding of estrogen to ER. While tamoxifen is the standard treatment for both pre- 
and postmenopausal patients positive for ER expression, aromatase inhibitors 
prove to be more effective in postmenopausal women (4, 5). Aromatase is an 
enzyme that is responsible for the aromatization of androgen to estrogen in the final 
step of estrogen synthesis. Irreversible steroidal aromatase inhibitor such as 
exemestane permanently binds to and inhibits aromatase activity while nonsteroidal 
inhibitors such as anastrozole and letrozole reversibly compete with the enzyme (6-
8). The major side effects of endocrine therapy include menopausal symptoms and 
increased risk of endometrial cancer.  
 Given that cancerous cells possess uncontrolled proliferation, 
chemotherapeutic agents are designed to target rapidly dividing cells. By doing so, 
chemotherapy tend to render toxic side effects because the cells in the bone 
marrow, digestive tracts and hair follicles are normal cells that also undergo rapid 
cell division. The mechanism of most chemotherapeutic agents is to inhibit cell cycle 
progression, particularly by inducing DNA damage. These drugs include alkylating 
agents, anthracyclines, topoisomerase inhibitors, antimetabolites, and plant 
alkaloids. Many studies have shown that the effectiveness of chemotherapy 
4
improves greatly when the agents are administered in combination regimen as 
opposed to single drug treatment (9).  
 
1.2. THE FIVE MOLECULAR SUBTYPES OF BREAST CANCER   
 Cancer is a heterogenous disease giving rise to dissimilar biology in different 
patients. Therefore, to achieve improved patient outcome, a better understanding of 
the molecular patterns of the tumors is necessary to identify clinical markers and 
design effective therapeutic agents. Using DNA microarray, Perou and colleagues 
first examined the gene expression signature of breast cancer tissues and applied 
hierarchical clustering analysis to divide the tumors into 5 groups based on the 
expression pattern of 8,102 human genes (Table 1) (10). The 5 molecular subtypes 
are: basal, luminal A, luminal B, ErbB2, and normal-like, and they all differ in clinical 
outcome but surprisingly not in lymph-node metastasis status (11). Significantly, the 
results from this and subsequent studies changed the way we study and treat 
breast cancer.  
 Based on its name, basal-like tumors are classified by high expression of 
cytokeratins, which are basal epithelial markers, and growth factor receptors, such 
as epidermal growth factor receptor (EGFR) and c-kit (12, 13). Indeed, cell culture 
studies demonstrate that the basal-like breast cancer cell lines are sensitive to 
EGFR inhibitors (14). The majority of basal-like tumor lacks ER, PR, and HER2 
expression and therefore is frequently associated with triple negative tumors. 
Consequently, patients diagnosed with basal-like tumors face with limited choices in 
molecular treatment and thereby explain their association with short overall- and 
disease-free survival. The genes represented in the luminal A subtype are mainly 
associated with steroid hormone-mediated signaling pathways and fatty acid 
metabolism. As a result, most luminal A tumors express high levels of ER and PR, 
display low Ki67 index, are histologically low-grade, and associate with favorable 
clinical outcome. Consequently, treatment for luminal A patients relies on endocrine 
therapy such as SERMs and aromatase inhibitors. Despite being positive for ER 
and PR expression, luminal B tumors are not sensitive to endocrine therapy and as 
a result, patients with luminal B tumors have high genomic grade and their 
5
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prognosis is poor.  
 Additionally, luminal B tumors display high Ki67 index, which is a marker for 
proliferation. Since gene expression of luminal B tumors is less strictly defined, the 
best treatment strategy for luminal B tumors appear to rely on chemotherapy to 
target the cell cycle. Tumors with HER2 amplification are categorized in the HER2+ 
subtype, and patients with this subtype present poor prognosis. Given the high 
HER2 protein levels, these patients are generally given trastuzumab or lapatinib. 
Interestingly, most of these tumors are negative for ER and PR making them poor 
candidates for endocrine therapy. Finally, normal-like tumors resemble normal 
breast tissues, contain less genomic alterations, and associate with good outcome.  
 Seven years after the five molecular subtypes were first described, Perou and 
colleagues identified an additional subtype of breast cancer termed claudin-low from 
analysis of 13 breast cancer samples (Table 1) (15). These tumors exhibit low 
expression for tight junction proteins such as E-cadherin, occludin, claudin 3, 4, and 
7 and this subtype was also observed mouse breast tumor samples. Furthermore, 
this gene expression profile is found in breast cancer stem cells (CSCs) that are 
enriched for the CD44hi/CD24lo cell surface marker as well as high aldehyde 
dehydrogenase (ALDH) expression, and these cells are insensitive to 
chemotherapy and hormone therapy (15-17). Compared to the other subtypes, 
claudin-low tumors express low levels of HER2, ER, and PR and are characterized 
by relatively slow proliferation as shown by low Ki67 transcription (15). Similar to the 
basal-like subtype, the prognosis of patients with claudin-low tumors is poor with a 
hazard ratio of 17.98 for overall survival (15). Although claudin-low tumors 
demonstrate response to chemotherapy, they are predicted to experience high 
probability of relapse due to the fact that the tumor is composed of CSCs that can 
reinitiate tumor growth once therapy is withdrawn and thus explain the poor clinical 
outcome (17). In conclusion, the vast difference in the genomic and transcriptional 
aberrations between the 6 subtypes of breast cancer suggests that perhaps each 
tumor subtype originated from different neoplastic cell type (18, 19). Undoubtedly, 
better understanding on the origin of tumor initiation will allow researchers to 
develop targeted therapeutic strategies to prevent and treat breast cancer. 
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 1.3. THE CELL CYCLE AND CANCER 
1.3a. Overview of the cell cycle 
 The cell cycle chronicles the events during which the cell undergoes DNA 
duplication followed by segregation of the copies of chromosomes to create two 
identical daughter cells (Figure 2). The cell cycle consists of two major stages: 1) 
interphase is the period of time to allow the cells to grow in size and duplicate DNA 
and 2) mitosis represents the division of the nuclei. Interphase includes G1, S and 
G2 phases. Cellular growth and preparation for DNA replication occurs during G1 
phase, which is followed by S phase when DNA synthesis occurs, and the cell again 
prepares for mitosis during G2 phase. The two gap phases are essential to provide 
the cell more time to grow in size and sufficiently prepare for the commitment to 
DNA synthesis during S phase and mitosis in M phase. Cells in G1 phase can enter 
G0, a quiescent state, if external conditions are not ideal for cell division such as 
lack of nutrients, contact inhibition, and loss of adhesion (20). However, once the 
cell has passed the G1 checkpoint, DNA replication is committed. 
 The engine of the cell cycle clock machinery is driven by different cyclins and 
cyclin dependent kinases (CDKs) (Table 2). There are 16 cyclins (A, B1, B2, C, D1, 
D2, D3, E1, E2, F, G1, G2, H, I, K, L) and 9 CDKs (CDK1-9) identified thus far; 
however, not all cyclins and CDKs carry out cell cycle-related functions (21-24). All 
cyclin proteins contain a “cyclin box,” a sequence of homology that binds to a 
conserved region, PSTAIRE, on CDKs to activate their kinase activity (25). As 
indicated by their name, the protein levels of most cyclins fluctuate at different 
phases of the cell cycle to ensure the correct spatial and temporal scheduling of cell 
proliferation. In contrast, CDKs belong to a family of serine/threonine protein 
kinases and their protein levels remain constant throughout the cell cycle. To 
achieve specific control of cell cycle progression, cyclins interact with their specific 
CDK partner and thus the cyclin protein level dictates the cell cycle activity of 
different cyclin/CDK complexes. To achieve full activation of the cyclin/CDK 
complexes, CDK-activating kinase (CAK) composed of cyclin H and CDK7 
phosphorylates CDKs at the T160 site that is adjacent to their active site (26). There 
8
Figure 2: Regulation of the cell cycle by cyclin/CDK complexes. The cell cycle
is defined by 5 major phases, which are G0, G1, S, G2, and M, and is designed to
achieve faithful cellular duplication to create 2 daughter cells. The progression of a
cell through the cell cycle is guided by the kinase activity of different cyclin/CDK
complexes, which function to prepare the cell for progression into the next stage of
the cell cycle.
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are 3 types of cyclin D proteins (D1, D2, and D3), and they associate with either 
CDK4 or CDK6 to promote G1 entry and progression (27). D-type cyclins carry out 
redundant functions as knockout of each individual cyclin D gene does not cause 
embryonic lethality while mice with loss of cyclin D2 and D3 and mice with all 3 D-
type cyclins knockout are not viable at birth (Table 2) (28-36). (Cyclin D1 will be 
discussed primarily in this thesis and referred to as cyclin D.) Cyclin D expression is 
predominately controlled by the presence of growth factor stimulation (37). 
Unphosphorylated retinoblastoma (pRb) tumor suppressor protein forms a complex 
with E2F and DP. When present in this complex, E2F and DP, which are 
transcription factors for genes necessary for S phase progression (including cyclin 
A, cyclin E and CDK1), cannot activate gene transcription (38-40). The cyclin 
D/CDK4/6 complex phosphorylates pRb, which contains multiple phosphorylation 
sites. Increasing phosphorylation of pRb displaces E2F and DP interaction, thereby 
resulting in increased transcription of cyclin E. There are 2 cyclin E genes (cyclin E1 
and cyclin E2) and they share approximately 47% sequence homology and 
functional activity (41-43). Similar to D-type cyclins, cyclin E1 and E2 also exhibit 
redundant functions since mice with loss of each cyclin E gene are viable but 
double knockout mice die before birth (Table 2) (44, 45). (Cyclin E1 will be 
discussed primarily in this thesis and referred to as cyclin E.) At the G1-S phase 
boundary when cyclin E protein level is highest, cyclin E associates with CDK2 and 
further phosphorylates pRb to completion thus creating a positive feedback loop on 
its own transcription. In cells lacking pRb, cyclin E/CDK2, but not cyclin D/CDK4/6, 
kinase activity is necessary for cell cycle progression suggesting that cyclin E/CDK2 
activity is critical to phosphorylate other key substrates in the cell cycle (46).  
 During S phase, cyclin A protein accumulates and replaces cyclin E as the 
partner of CDK2 to promote S phase progression (47, 48). Mice with cyclin A1 
knockout are viable while those with loss of cyclin A2 show embryonic lethality 
possibly due to the fact that cyclin A2 is expressed in most somatic cells and cyclin 
A1 is only expressed in zygotes and testis (Table 2) (49, 50). At the G2-M transition, 
cyclin A now interacts with CDK1 to prepare for entry into mitosis. Cyclin A 
negatively regulates E2F transcriptional activity by phosphorylating DP and 
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preventing E2F to bind to DNA and therefore shutting down S phase-related gene 
transcription. At this stage, CDK1 switches partner by associating with cyclin B to 
regulate mitosis by phosphorylating cytoskeleton proteins such as histone H1, 
lamins, and components of the mitotic spindle (24, 51). In fact, cyclin B1 colocalizes 
with microtubules and loss of this gene causes embryonic lethality in mice (Table 2) 
(52). In contrast, cyclin B2 is associated with the Golgi and mice lacking this gene 
are viable with no apparent abnormalities (52). Cyclin B/CDK1 kinase activity is 
negatively regulated via phosphorylation by the Wee1 and Myt1 protein kinases (53-
56). This inhibitory phosphorylation serves to prevent premature exposure of 
nuclear contents to the mitotic kinase in case the cell is not ready to enter mitosis. 
These phosphorylation sites are removed by the protein phosphatase cdc25C to 
activate the cyclin B/CDK1 complex when the cell is ready to divide (57, 58). During 
mitosis, which consists of prophase, metaphase, anaphase, and telophase, the 
duplicated chromosomes are segregated into opposing nuclei and cytokinesis 
follows to generate two identical daughter cells. The cell cycle now begins again at 
the entrance of G1 phase when the cell must make the decision to undergo another 
round of cell division or enter quiescence in G0 phase.  
 In addition to regulation by the cyclic trancription of cyclin proteins, the 
cyclin/CDK kinase activities are also controlled by 2 families of CDK inhibitors 
(CKIs), the INK4 (inhibitors of CDK4) and Cip/Kip families (59). The INK4 family 
includes p16INKa, p15INKb, p18INKc, and p19INKd whose function is to bind to CDK4 
and CDK6 to prevent cyclin D association and thereby suppress their kinase activity 
(60). The 4 members of the INK4 family share approximately 40% homology 
through the tandem ankyrin motifs. On the other hand, the Cip/Kip family includes 
p21Cip1, p27Kip1, and p57Kip2 and they are able to bind to and inhibit cyclin E/CDK2, 
cyclin A/CDK1, and cyclin B/CDK1 complexes (61). In addition to its inhibitory 
function on the cyclin/CDK complexes, p21Cip1 also binds to and inhibits proliferating 
cell nuclear antigen (PCNA) to halt DNA synthesis (62). The p21Cip1 gene is a 
transcriptional target of the tumor suppressor protein p53 (63). Upon detection of 
DNA damage, p53 protein is stabilized and upregulates p21Cip1 transcription 
causing cell cycle arrest to repair the damaged DNA. Paradoxically, p21Cip1 and 
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p27Kip1 have been reported to stabilize and thereby stimulating the activity of the 
cyclin D/CDK4/6 complex (64). In response to TGFß treatment, upregulated p15INKb 
proteins bind to CDK4/6 and as a result displace p27Kip1 from the cyclin D/CDK4/6 
complex (65, 66). The protein level of p27Kip1 accumulates leading to increased 
binding and inhibition of cyclin E/CDK2 kinase activity (67). Thus, arrest of cell cycle 
progression mediated by cyclin E/CDK2 is downstream of the growth inhibitory 
effect of TGFß.   
 To ensure that cell division results in a faithful duplication of the cell’s genetic 
information, there are a few checkpoints throughout the cell cycle in which cell cycle 
progression can be halted if the previous stages have not been completed. First, the 
restriction point (R) at the G1-S phase boundary is known as “the point of no return” 
because it marks the commitment of the progress through the cell cycle by initiating 
DNA synthesis. Prior to R, serum starvation causes the cell to enter G0 phase; 
however, once the cell has passed R, the cell cycle continues to mitosis even in the 
absence of serum (68). The G2 checkpoint occurs at the G2-M phase boundary 
when the cell checks for completion of DNA replication before entry into mitosis. 
During mitosis, detection of impaired chromosome alignment activates the spindle 
checkpoint and arrests the cells in metaphase. Additionally, DNA damage 
checkpoints are activated if the cell senses chromosome damage by radiation or 
chemicals, and this represents the major mechanism of action of most 
chemotherapeutic agents, which will be discussed in greater details in the last 
section of this chapter. The cell cycle resumes once these damages are 
successfully repaired.  
 
1.3b. Deregulation of the cell cycle in cancer  
 By definition, cancer results from uncontrolled proliferation of transformed 
cells. Therefore, in all aspects, deregulation of the cell cycle is the gateway to 
oncogenesis. Nearly all regulators of the cell cycle such as cyclins, CDKs, and CKIs 
have been demonstrated to participate in cancer development by altering their 
expression, function, and/or localization (Table 3). Tight regulation of cyclin 
expression leaves the cell cycle prone to oncogenic aberrations. Cyclin D 
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transcription is mainly controlled by mitogenic stimuli and its overexpression is 
reported in numerous types of human cancers, such as parathyroid adenoma, 
lymphoma, breast, lung and bladder cancer to name a few (Table 3) (69-71). The 
role of cyclin E in human cancer has been well documented and will be discussed in 
greater details in section 1.4. Meanwhile, cyclin A has been shown to be aberrantly 
high in lung carcinoma and correlate with poor survival (Table 3) (72). Since the 
expression of CDKs is unchanged and thus not tightly regulated throughout the cell 
cycle, deregulation of CDKs is not commonly observed in cancer. However, CDK4 
overexpression has been observed in glioma, melanoma, and sarcoma (73), while 
overexpression of CDK1 and 2 was reported in colon cancer (Table 3) (74, 75). 
Additionally, loss of CKI binding mutations in CDK4 and CDK6 have also been 
identified in neuroblastoma cell lines (76). 
 CKIs provide the braking mechanism in the progression of the cell cycle by 
inhibiting the kinase activity of cyclin/CDK complexes. Consequently, CKI 
deregulation is commonly documented in tumor development. As described 
previously, p16INKa, p15INKb, p18INKc, and p19INKd are CKIs that inhibit the cyclin 
D/CDK4/6 and their genes are encoded by the ARF-INK4 locus. This locus is 
deleted frequently resulting in downregulation of the transcription of these CKIs 
(Table 3) (77, 78). Particularly, inactivation or loss of p16INKa due to deletion, 
mutation, and hypermethylation occurs in most tumors (71). In the Cip/Kip family, 
p27Kip1 has been shown to be downregulated in lung, breast, and bladder due to 
elevated proteolysis by the proteasome, and low p27Kip1 is associated with 
increased tumor aggressiveness and poor outcome (79, 80). In addition, p21Cip1 is a 
gene target of p53 and given that p53 is the most frequently mutated gene in human 
cancer, p21Cip1 expression is downregulated in a number of human cancers (81). 
 Deregulated pRb function by gene deletion, inactivating mutations, viral 
inactivation, or overexpression of cyclin D and cyclin E is frequently observed in 
human cancer (Table 3). The pRb gene is mutated in retinoblastoma and lung 
cancer (82). Tumor virus proteins such as the human papillomavirus (HPV) E7, the 
adenovirus E1A, and the simian virus 40 (SV40) large T (tumor) antigen bind to and 
sequester pRb from its inhibitory, tumor suppressive, function in the cell cycle (83-
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85). In the absence of pRb, E2F is relieved from inhibition and is now able to 
activate transcription of S phase genes resulting in uncontrolled cellular proliferation 
(86). The pRb pathway is an important mechanism of the cell to suppress tumor 
growth since it is estimated that approximately 90% of human cancers possess 
abnormalities in the components of this pathway (71). Although the involvement of 
E2F gene alteration in human oncogenesis has not been observed, E2F 
overexpression has been reported to induce transformation and skin tumor 
development in cell culture and transgenic mouse models, respectively (Table 3) 
(87-89).  
 
1.4. THE ROLE OF CYCLIN E IN ONCOGENESIS 
1.4a. Cyclin E functions 
 Results from knockout animal studies further advanced our knowledge on the 
role of cyclin E and CDK2 in the cell cycle. Single cyclin E1 and cyclin E2 knockout 
mice are viable and develop normally with normal rates of proliferation in fibroblasts 
(Table 2) (44, 45). However, cyclin E1/E2 double knockout mice died during 
midgestation due to endoreduplication impairment. The giant trophoblast cells and 
megakaryocytes display defective endoreduplication in the cyclin E-null mice, which 
could be due to defects in MCM loading (90, 91). Cyclin E-null cells fail to enter S 
phase following serum stimulation and are resistant to oncogenic transformation by 
Ras (45, 92, 93). Given that cyclin E and CDK2 depend heavily on their interaction 
to exert their functions, one would expect CDK2-null mice to exhibit similar 
phenotypes to the cyclin E-null mice. Contrary to expectation, CDK2-null mice 
actually do not develop the phenotypes observed in cyclin E-null mice. That is, the 
CDK2-null mice carry out normal endoreduplication, are able to enter S phase upon 
serum stimulation and are susceptible to oncogenic transformation (94, 95). These 
findings suggest two possible scenarios to explain for the fact that lack of CDK2 
does not compromise the cell cycle functions of cyclin E. First, cyclin E is able to 
form active complex with another CDK that can compensate for CDK2 absence 
since cyclin E has been shown to interact with CDK1, 2, and 3 (96). The second, 
more intriguing theory is that perhaps cyclin E does not require association with 
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another kinase to exert its function. Indeed, evidences supporting this possibility 
include the fact that CDK2-kinase dead cyclin E mutants exhibit transforming 
capability in vitro and are still capable of entering S phase as long as the 
centrosomal localization signal is intact (97, 98). All in all, these results suggest that 
cyclin E does not require CDK2 to perform normal cell cycle activity as well as to 
mediate cellular transformation.  
   Cyclin E protein level and, consequently, its CDK2-associated kinase activity 
peak at the G1-S phase boundary making this complex the rate-limiting regulator of 
this checkpoint. Indeed, constitutive overexpression of cyclin E shortens G1 phase 
(46, 99, 100) and inhibition of the cyclin E/CDK2 activity prevents S phase entry 
(101, 102). Geng and colleagues demonstrated that cyclin E/CDK2 activity is 
sufficient to support S phase entry in the absence of cyclin D (103). That is, 
replacement of the cyclin D coding sequence with cyclin E cDNA in mice rescues 
the phenotypes associated with cyclin D knockout (103). Cyclin E is inactive 
unbound and requires interaction with its regulatory subunit, CDK2, to exert its 
kinase function. The cyclin E protein contains 2 motifs that regulate substrate 
binding. In the N-terminus, MRAIL at residues 130 to 134 mediates binding of 
substrates containing RXL motifs (104-106) while VDCLE at residues 274 to 278 in 
the C-terminus regulates binding of pocket proteins such as pRb, p107, and p130 
(107).  
 One critical function of cyclin E/CDK2 complex is to further phosphorylate 
and inactivate pRb to allow E2F-mediated transcription of S phase genes (Table 4) 
(91, 93). As mentioned previously, p27Kip1 is a CDK inhibitor that binds and inhibits 
the cyclin E/CDK2 complex. However, during S phase, cyclin E/CDK2 
phosphorylates p27Kip1 to mark it for ubiquitin-mediated proteasomal degradation by 
the Skp2 ubiquitin ligase (Table 4) (108, 109). At the G1-S phase checkpoint, cyclin 
E/CDK2 also phosphorylates p220NPAT (nuclear protein mapped to the ATM locus) 
to stimulate synthesis of 3 histone genes (H2B, H4, and H3) (Table 4) (110, 111). 
Particularly, the cyclin E/CDK2 complex colocalizes with p220NPAT at Cajal bodies, 
which are subcellular structures associated with histone gene clusters. CBP/p300, a 
histone acetyltransferase, is also a substrate of the cyclin E/CDK2 complex and 
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acts as a cofactor for multiple transcription factors (Table 4) (112). Additionally, 
histone H1 is a substrate for the cyclin E/CDK2 complex and phosphorylation of 
histone H1 is important for chromatin rearrangement, which is required for DNA 
synthesis (Table 4) (113).  
 Additionally, the role of cyclin E in facilitating the assembly of the pre-
replicative complex is important for proper DNA synthesis. At the origins of 
replication, origin replication complex (ORC) recruits Cdc6 and minichromosome 
maintenance complex (MCM) to the chromatin to prepare for DNA synthesis (114). 
DNA replication begins once cdc6 is removed from the origin of replication. 
Interestingly, cyclin E/CDK2 has been shown to bind to the chromatin via its 
interaction with cdc6 through and RXL motif, and these events are necessary for 
DNA replication to begin (Table 4) (115, 116). Cyclin E/CDK2 continues to bind to 
the chromatin as DNA replication progresses, and this interaction is critical to 
prevent re-replication of the DNA. In vitro studies demonstrated that once the cell is 
in mitosis and DNA synthesis is completed, cyclin E is phosphorylated by mitogen 
activated protein kinase (MAPK) and cyclin B/CDK1 causing its dissociation from 
the chromatin (115). 
 Another function of cyclin E is in its interaction with the components of the 
centrosome machinery. The centrosome is copied once per cell cycle and interacts 
with chromosomes to create the mitotic spindle. During mitosis, the centrosomes 
migrate to opposite poles of the cell and as a result segregate the duplicated 
chromosomes. The process of centrosomal duplication must be tightly controlled 
since aberrations of this event result in polyploidy and aneuploidy, which are known 
to cause genomic instability. Cyclin E plays a critical role during centrosomal 
duplication by phosphorylating nucleophosmin B23 (NPM/B23), CP110, and Mps1p-
like kinase (Table 4) (117-119). Specifically, phosphorylation of NPM/B23 by cyclin 
E/CDK2 causes NPM/B23 to dissociate from the centrosome to allow centriole 
orientation and splitting (118). Furthermore, Matsumoto and colleagues discovered 
a centrosomal localization signal in the cyclin E gene that facilitates cyclin E’s 
function during centrosomal duplication to support S phase entry (98). Tumor cells 
with p53 loss and cyclin E overexpression were observed to have elevated 
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frequency of centrosomal hyperamplification (120). Thus, hyperactive cyclin 
E/CDK2 complexes play a major role in inducing genomic instability that ultimately 
contribute to oncogenesis.  
 The kinase activity of the cyclin E/CDK2 complex is also important in 
regulating the function of the basic-helix-loop-helix (bHLH) transcription factors. The 
Id (Inhibitor of DNA binding) proteins, whose family consists of 4 members (Id1-4), 
are HLH proteins that form heterodimers with the bHLH transcription factors and 
prevent their binding to DNA to promote gene transcription (121). These bHLH 
factors regulate the gene transcription important for G1 progression, such as 
p21Cip1, as well as the differentiation pathway (122-124). The protein sequence of 
the Id2, 3, and 4 members contains a consensus CDK2 phosphorylation motif and 
is shown to be phosphorylated by cyclin E/CDK2 (Table 4) (125). This 
phosphorylation event alters the interaction of the heterodimer between Ids and the 
bHLH transcription factors thus releasing the inhibitory effect on bHLH-mediated 
gene transcription. Cells expressing mutant Id2 and Id3 that lack the CDK2 
phosphorylation site arrest in S phase possibly due to the repressed transcription of 
p21Cip1 (126). Thus, the function of cyclin E is involved in the intricate network of 
gene transcription regulation to promote a smooth G1 to S phase transition.  
 Cyclin E/CDK2 activity is also important in signal transduction pathways 
involving TGFß.  The TGFß signaling is known to induce paradoxical cellular effects 
and the participation of cyclin E in this pathway may explain this phenomenon. 
Under physiological condition, TGFß promotes anti-proliferative signaling by 
inducing G1 arrest and promoting differentiation and apoptosis. In contrast, TGFß 
promotes cancer progression and metastasis in malignant condition (127). At the 
cell surface, TGFß binds to its transmembrane receptor and activates the 
intracellular Smad signaling cascade (128). Upon phosphorylation by the receptor, 
Smad proteins translocate to the nucleus to activate p15INKb and p21Cip1 expression 
while repressing c-myc, Id1, Id2 and Id3 gene transcription (65, 129-131). In the 
nucleus, Smad2 and Smad3 are phosphorylated by cyclin D/CDK4, cyclin E/CDK2, 
and cyclin A/CDK2 complexes (Table 4) (132). This phosphorylation of the Smad 
proteins inactivates their transcriptional activity as mutations to the CDK 
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phosphorylation sites of Smads result in elevated p15INKb and p21Cip1 expression 
and c-myc repression leading to enhanced G1-S progression (132, 133). These 
findings are similarly observed with knockdown of CDK2 by siRNA or treatment of 
the cells with CDK2 inhibitor II (compound 3) (133). Therefore, the tumor-promoting 
role of TGFß is activated in cells with high CDK2 and CDK4 kinase activity, which 
can suppress the growth inhibitory signal mediated by Smad proteins while 
simultaneously upregulating the protein level of the oncoprotein c-myc.  
 
1.4b. Controlling the fluctuation of cyclin E protein levels  
 The G1-S phase checkpoint is vital for maintaining cellular differentiation and 
tissue integrity since it occurs prior to DNA synthesis. Cyclin E is a critical regulator 
of cell proliferation because it positively controls the transition of cells into S phase 
to signal the initiation of DNA replication. Cyclin E expression varies at different 
phases of the cell cycle and is highest at the G1-S phase boundary (134). The 
periodicity of cyclin E protein levels depends on transcriptional and post-
translational controls. Upregulation of cyclin E transcription during late G1 phase is 
due to hyper-phosphorylation of the pRb/E2F/DP complex by cyclin D/CDK4/6 
complex while removal of cyclin E proteins during S phase is achieved by ubiquitin-
mediated proteasomal degradation by Fbw7.  
 During G1 phase, cyclin D/CDK4/6 complex progressively phosphorylates 
pRb to release free E2F and DP to activate S phase genes, including cyclin E (38-
40). Since CDK2 expression is constant throughout the cell cycle, upregulation of 
cyclin E transcription results in elevated levels of active cyclin E/CDK2 complexes. 
Cyclin E/CDK2 complex continues to phosphorylate and completely inactivate pRb, 
thereby creating a positive feedback loop for cyclin E transcription. Cyclin E level 
gradually diminishes during S phase due to reduced gene transcription and 
increased proteasomal degradation.  
 The half-life of cyclin E in a normally cycling cell is less than 30 minutes, and 
inhibition of the proteasome can extend this to more than 2 hours. Unbound cyclin E 
proteins are susceptible to ubiquitin-mediated proteasomal degradation by Cul-3 
during early embryogenesis (135, 136). When cyclin E is bound to CDK2, auto-
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phosphorylation of cyclin E at the T380 site is recognized by the F-box protein Skp2 
to mark it for ubiquitin-mediated degradation (137). Complete knockout of Skp2 
leads to the accumulation of cyclin E and p27Kip1, which is also a substrate of Skp2 
(137-139). Inhibition of the cyclin E/CDK2 kinase activity by p27Kip1 prevents auto-
phosphorylation at T380 and thus allowing cyclin E to avoid degradation. In 
addition, the Fbw7 ubiquitin ligase also targets cyclin E bound to CDK2, and this 
degradation is dependent of the phosphorylation status of several sites on the cyclin 
E protein (140-142). In particular, T380 and T62 are the two auto-phosphorylation 
sites on cyclin E critical for Fbw7 binding to cyclin E to mediate ubiquitination. Cyclin 
E/CDK2 complexes that are bound to either p21Cip1 or p27Kip1 are inactive and thus 
cannot be degraded by Fbw7 because they lack the required phosphorylation (135, 
143). Taken together, the periodic rise and fall of cyclin E protein levels are fine-
tuned by tight regulation of the pRb pathway and redundant degradation 
mechanisms by the proteasome to ensure timely removal of this G1 cyclin.  
 
1.4c. Deregulation of cyclin E in human cancers 
 The function of cyclin E is to ensure proper progression of the cell into S 
phase; therefore, it is not surprising that deregulation of cyclin E contributes to 
oncogenesis. Indeed, cyclin E proves to be an important oncogene since its 
overexpression via gene amplification, upregulation of protein expression, or post-
translational deregulation occurs in multiple cancers, including breast, lung, 
colorectal, lymphoma, leukemia, gastric, and osteosarcoma to name a few (144-
153). Since repression of pRb from cyclin D/CDK4/6 phosphorylation positively 
controls cyclin E transcription through E2F activity, inactivation of pRb by the 
oncogene HPV16-E7 causes cyclin E overexpression in human foreskin fibroblasts 
(154). Additionally, multiple lines of evidence indicate Fbw7 is an important tumor 
suppressor and its loss of function mutations is thought to result in high cyclin E 
protein levels (141, 155, 156). Particularly, analysis of breast cancer cell lines 
reveals that the cyclin E gene is amplified and gene transcription is upregulated to 
as high as 64 folds resulting in elevated cyclin E activity throughout the cell cycle 
(144, 157, 158). In breast cancer patients, cyclin E gene amplification is rarely 
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observed in which only 14 of 1082 breast tumors were detected to show 
amplification (159). In contrast, the level of cyclin E protein expression is more 
frequently upregulated and our clinical study previously found that 127 of 268 breast 
tumor tissues demonstrated high cyclin E protein level (160). In fact, cyclin E 
overexpression was shown to be a stronger marker for predicting patient outcome 
than other traditionally used markers such as lymph node, ER and PR status or 
levels of HER2 (160). More specifically, high cyclin E expression was estimated with 
a hazard ratio of 13.3 for death from breast cancer, which is almost 8 folds higher 
than other established predictive factors such as positive nodes, late stage, and ER 
negative status. In the laboratory, approximately 10% of transgenic mice with 
human cyclin E overexpression in the mammary gland develop mammary gland 
hyperplasia and carcinomas at 8-13 months of age (161).  
 One mechanism of cyclin E-mediated oncogenesis is through inducing 
genomic instability (162-164). Initiation of DNA synthesis and centrosome 
duplication occurs almost concomitantly and cyclin E is intimately involved in these 
events.  Indeed, constitutive overexpression of cyclin E, but not cyclin D or cyclin A, 
in rat embryo fibroblasts and human mammary epithelial cells (hMECs) leads to 
chromosome instability (163). Given the critical role of cyclin E during DNA pre-
replication complex formation, high cyclin E activity may cause defects in MCM 
loading resulting in breakage of DNA at the replication forks, impaired chromosomal 
duplication, or incomplete chromosomal replication due to premature entrance into 
mitosis. Ensuring proper centrosome duplication is another cell cycle event that 
requires cyclin E function. Consequently, persistent cyclin E/CDK2 activity has been 
observed to lead to centrosome amplification, which predisposes the cell to 
genomic instability (120). More specifically, Skp2null mouse embryonic fibroblasts 
(MEFs) accumulate cyclin E and p27Kip1 proteins and exhibit chromosomal defects 
such as polyploidy and centrosome amplification (137). As a result, elevated cyclin 
E expression and activity leave the cell vulnerable to neoplastic transformation 
brought about by genetic aberrations. 
 
1.5. LMW-E IN BREAST CANCER 
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1.5a. The isoforms of cyclin E and their subcellular localization 
 The transcriptional regulation of cyclin E is complex and results in multiple 
cyclin E isoforms due to mainly post-translational modification as well as some 
splicing and alternative start site changes. In normal cells, the predominant cyclin E 
isoform is 50kD and is termed EL1, and the start codon is 15 amino acids upstream 
from the originally discovered cyclin E cDNA (46, 165). Although rare, an alternative 
translation site at methionine 46 gives rise to EL4. In addition to genomic and 
transcriptional amplification of the cyclin E gene in breast cancer cell lines, another 
mechanism of oncogenic transformation of cyclin E is post-translational modification 
of the protein. Full-length cyclin E is subjected to elastase-mediated cleavage (but 
not due to genomic rearrangements of the cyclin E gene) to generate 2 low 
molecular weight (LMW) isoforms in breast cancer (144, 165). This alteration of 
cyclin E occurs at 2 cleavage sites on the N-terminus of the full-length cyclin E (EL) 
giving rise to trunk 1 (T1) and trunk 2 (T2) isoforms. T1 and its phosphorylated 
isoform are named EL3 and EL2, respectively, while T2 and its phosphorylated 
isoform are called EL6 and EL5, respectively (166).  
 Similar to most nuclear proteins, cyclin E is translated in the cytoplasm where 
it forms a complex with CDK2, and then transported to the nucleus via the importin-
dependent pathway (167). The nuclear localization signal sequence is found at the 
N-terminus of the cyclin E gene, which is cleaved off in the LMW-E isoforms (168). 
In fact, fractionation and protein complementation assays demonstrate that the 
LMW-E/CDK2 complexes preferentially accumulate in the cytoplasm (169). Since 
the Fbw7 ubiquitin ligase is located in the nucleus, the altered subcellular 
localization of LMW-E renders it less susceptible to proteasomal degradation. This 
finding implicates many possibilities that can explain the particular oncogenic 
characteristics of LMW-E that is distinct from full-length cyclin E, and that these 
effects could be independent from cell cycle regulation.  
 
1.5b. LMW-E causes genomic instability 
 Since the function of cyclin E is critical during centrosome duplication and DNA 
replication, the presence of hyperactive LMW-E in the cell cycle undoubtedly results 
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in abnormal genetic content. Accordingly, LMW-E expression induces genomic 
instability by increasing the percentage of cells with polyploid and tetraploid DNA, 
subtelomeric chromatid breaks and multiple chromosomal fragments (170). Since 
cyclin E participates in MCM loading during DNA pre-replication complex assembly, 
elevated cyclin E activity exerted by LMW-E results in deregulation of DNA 
replication. In addition to deregulation of LMW-E during S-phase, LMW-E has been 
recently implicated in deregulating mitosis (171). As described previously, cdc25C is 
the phosphatase that removes the inhibitory phosphorylation sites on cyclin B to 
activate the cyclin B/CDK1 complex when the cell is ready for mitosis. In cells 
expressing LMW-E however, LMW-E phosphorylates and prematurely activates 
cdc25C causing faster mitotic exit and consequently cytokinesis failure and 
chromosomal instability (171). Furthermore, LMW-E expression in breast cancer 
patient samples also correlates with centrosome amplification, a process that leads 
to chromosome missegration and genetic instability (171). Examination of 331 
breast cancer patients revealed a significant correlation between high LMW-E 
expression and polyploidy (p = 0.0003) and these patients demonstrate significantly 
lower disease specific survival (p = 0.02).  
 
1.5c. LMW-E is oncogenic by adopting the 6 hallmarks of cancer  
 In 2000, Hanahan and Weinberg proposed that malignant growth requires 6 
specific alterations in cellular physiology collectively known as the 6 hallmarks of 
cancer: 1) self-sufficiency in growth signals, 2) insensitivity to anti-growth signals, 3) 
limitless replicative potential, 4) evading apoptosis, 5) sustained angiogenesis and 
6) tissue invasion and metastasis (172). That is, in order for a normal cell to 
successfully undergo neoplastic transformation, it must acquire most if not all of 
these capabilities. These hallmarks were argued to be present in all types of human 
cancer and thus explaining the relatively rare occurrence of cancer as well as the 
complexity and difficulty of developing effective anti-tumor therapy. Here we present 
research evidence accumulated from the last decade demonstrating that LMW-E 
does indeed drive malignant transformation by adopting these 6 hallmarks of cancer 
(Table 5).  
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 The decision to enter G1 phase is controlled by cyclin D, which requires the 
presence of growth factors. One mechanism acquired by cancer cells is to amplify 
growth factor signaling by upregulating the expression of growth factor receptors 
such as EGFR. Indeed, the oncogenic role of LMW-E is implicated in breast tumors 
with high HER2 expression. Retrospective study found that approximately 25% of 
395 breast cancer patient tissues examined had high LMW-E expression, which is 
associated with poor survival (p < 0.001) (160). Moreover, patients with 
overexpression of both HER2 and cyclin E, particularly LMW-E, were found to 
experience reduced 5-year disease-specific survival compared to patients with low 
cyclin E expression (173). Interestingly, knockdown of HER2 by siRNA reduces 
LMW-E expression and associated kinase activity and induces G1 arrest and 
apoptosis. Similarly, trastuzumab-treated xenografts created by MCF7-HER18 cells 
injection into nude mice showed reduced HER2 phosphorylation and LMW-E 
expression (173). Furthermore, cyclin E overexpression and amplification has been 
shown to play a direct role in mediating trastuzumab resistance in breast cancer, 
and treatment of these resistant cells with CDK2 inhibitor (CYC065), which is a 
2,6,9-trisubstituted purine derivative of roscovitine, induces apoptosis and inhibits 
xenograft tumor growth (174). Perhaps in tumors with high HER2 and LMW-E 
expression, constitutive growth signaling mediated by HER2 collaborates with the 
oncogenic functions of LMW-E to increase tumor aggressiveness and thus leads to 
poor patient outcome.  
 As described previously, cyclin/CDK complexes are the accelerators of the cell 
cycle while CKIs represent the brakes. Cyclin E/CDK2 kinase activity is critical for S 
phase entry and is subsequently inhibited by p21Cip1 and p27Kip1.  In vitro studies 
revealed that compared to EL, the LMW-E isoforms exhibit increased resistance to 
inhibition by p21Cip1 and p27Kip1 even though these CKIs demonstrated equal 
binding stoichiometry (175). These results suggest that the LMW-E isoforms are 
sequestering the CKIs from the full-length isoform and thereby causing an aberrant 
and prolonged cyclin E/CDK2 kinase activity beyond the G1-S phase boundary. 
Moreover, proteolytic processing of cyclin E into LMW-E renders tighter association 
with CDK2 resulting in elevated CDK2-associated kinase activity (175, 176). 
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Exogenous LMW-E expression in immortalized human mammary epithelial cells 
(hMECs) enhances S and G2/M phase entry thus increasing the rate of cellular 
proliferation (176).  
 In addition to insensitivity to CKI inhibition, LMW-E also mediates acquired 
resistance to pharmacological agents such as antiestrogen and aromatase inhibitor. 
MCF7 cells expressing exogenous LMW-E are less sensitive to growth inhibitory 
activity induced by fulvestrant treatment compared to EL-expressing cells, and this 
reduced sensitivity was demonstrated to be due to increased resistance of LMW-E 
to inhibition by p21Cip1 and p27Kip1 (170). These results were further confirmed using 
breast cancer patient data. More specifically, patients whose tumors are ER positive 
and express high cyclin E demonstrate no significant improvement in disease 
specific survival compared to patients not receiving antiestrogen (p = 0.083). 
Indeed, Pan and colleagues previously reported that cyclin E expression in breast 
cancer is a strong predictor of endocrine therapy failure (177). Additionally, 
aromatase inhibitors represent another form of endocrine therapy and have been 
reported to be more effective in the treatment of postmenopausal breast cancer 
patients compared to tamoxifen. Similar to fulvestrant, LMW-E expression also 
renders MCF7 cells resistant to inhibition by letrozole, an aromatase inhibitor, and 
breast cancer patients with LMW-E expression are predicted to be insensitive to 
aromatase inhibitor treatment (178). Interestingly, roscovitine, a CDK inhibitor, can 
reverse the letrozole-induced resistance mediated by LMW-E in breast cancer cells 
suggesting a potential therapeutic value of using roscovitine to treat 
postmenopausal breast cancer patients with high LMW-E levels. 
 Programmed cell death or apoptosis is a cellular event critical for the 
maintenance of tissue homeostasis and prevention of accumulation of damaged 
cells. Examination of xenografts generated from orthotopic injection of primary 
melanoma cells revealed that the LMW-E-expressing tumors showed reduced 
apoptotic cells visualized by TUNNEL staining compared to tumors with EL 
expression (179). More importantly, the LMW-E-induced melanoma tumors 
demonstrate higher microvessel density than tumors with EL expression indicating 
enhanced angiogenic potential, which is one of the hallmarks of cancer. Further 
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analysis of these melanoma cells using an experimental lung metastasis assay 
revealed that LMW-E expression induced greater metastasis potential than EL. 
Increased tumor and metastasis incidence due to LMW-E has been previously 
reported in breast cancer. Transgenic mice expressing LMW-E isoforms are 
themselves malignant since approximately 27% of LMW-E transgenic mice develop 
mammary adenocarcinomas compared to 10% of transgenic mice with EL 
expression (180). The frequency of tumor development in transgenic mice with full-
length cyclin E expression reported by Akli et al is similar to results reported 
previously by Bortner et al (161, 180). Furthermore, approximately 25% of the 
LMW-E tumors develop metastasis compared to 8% in the EL tumors (180). Taken 
together, the LMW-E isoforms are strong oncogenes that can successfully initiate 
and sustain tumor development through promotion of the 6 hallmarks of cancer.  
 
1.6. TARGETING THE CELL CYCLE  
1.6a. DNA damage-inducing agents 
 Given the idea that tumors arise from uncontrolled proliferation by altering the 
cell cycle, traditional chemotherapeutic agents were designed to target tumor cells 
by inducing DNA damage to arrest the cell cycle mainly in S or G2/M phases and 
subsequently induce apoptosis. Depending on the chemotherapeutic agent, tumor 
cells can be targeted in one of three ways: 1) chemically alter the DNA structure, 2) 
inhibit DNA synthesis, or 3) inhibit the mitotic process. For instance, cisplatin and 
nitrogen mustard function by cross-linking DNA resulting in chromosome breakage 
and causing the cell cycle to halt (181). As described previously, DNA damage 
induces p53 stabilization, p21Cip1 transcription, cell cycle arrest and/or apoptosis 
(182, 183). Topoisomerase is an enzyme that unwinds the DNA strands to aid 
during DNA replication, and inhibitors to this enzyme have been shown to be 
effective anti-tumor agents. More specifically, both camptothecin and etoposide are 
chemicals derived from natural compounds found in plants that inhibit 
topoisomerase activity by forming a ternary complex with the enzyme and DNA. As 
a result, the induced DNA damage causes the cell to arrest in G1 phase, upregulate 
p16INKa level and thereby inhibit the cyclin D/CDK4/6 kinase activity (184). 
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Doxorubicin is another potent topoisomerase inhibitor that has been used in the 
clinic, albeit dangerous heart toxicity at high dose. Doxorubicin is an anthracycline 
antibiotic that functions by intercalation into DNA helices and preventing 
topoisomerase from re-annealing the cut DNA during DNA replication (185). 
Microtubule inhibitors, on the other hand, disrupt mitotic spindle formation and 
arrest cells at the mitotic spindle assembly checkpoint, which is a radiosensitive 
period in the cell cycle (186). Similar to other agents mentioned, radiation therapy 
uses ionizing radiation to also inflict DNA damage, and is often combined with other 
chemotherapeutic agents to enhance tumor toxicity. Consequently, taxol and vinca 
alkyloids are two prominent microtubule inhibitors proven to be effective 
radiosensitizers in the clinic (187, 188).  
 
1.6b. CDK inhibitors 
 In the cell cycle, countless proteins are known to be involved in oncogenesis 
such as cyclin D, cyclin E, pRb, and p16INKa to name a few. Particularly, CDKs are 
the regulatory subunits of the cyclin/CDK complexes that exert kinase activity to 
control cell cycle progression. Consequently, CDKs proved to be ideal targets to 
halt cell cycle progression of tumor cells. To date, more than 50 CDK inhibitors have 
been reported, and most inhibitors are small molecule inhibitors that act by 
competitively binding to the ATP binding pockets of CDKs. For instance, 
olomoucine and its analog roscovitine are purine analogues that were shown to 
inhibit the kinase activity of CDK1 and CDK2 causing G1 and G2 cell cycle arrest 
and apoptosis (189, 190). Roscovitine demonstrates stronger anti-tumor effects 
compared to olomoucine and is currently under testing in clinical trials (191, 192). 
Further discussion on the use of roscovitine in cancer research will be discussed in 
more details below. Staurosporine and its analogue UCN-01 (7-
hydroxystaurosporine) are microbial alkaloids and were found to be non-specific 
inhibitors of CDK1 and PKC (193, 194). When combined with camptothecin and 
cisplatin, treatment of p53-deficient cells with UCN-01 induce DNA damage and 
apoptosis (195). Since most of these inhibitors rely on functional pRb and p53 to 
mediate cell cycle arrest and apoptosis, the status of these genes must be identified 
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prior to therapy to avoid unresponsiveness or resistance of the tumor to the 
therapeutic agents.  
 
1.6c. Targeting LMW-E/CDK2 kinase activity 
 Cyclin E is the regulatory subunit whose function requires interaction with 
CDK2 to phosphorylate target genes to allow transition from G1 to S phase of the 
cell cycle. In tumor cells, high cyclin E/CDK2 kinase activity persists throughout the 
cell cycle (157). Retrospective clinical evaluation of high-grade ovarian tumors 
identified cyclin E/CDK2 kinase activity as a significant predictive marker for 
response to platinum-based therapy (196). Moreover, CDK2 was recently reported 
to be required for LMW-E-mediated mammary oncogenesis in transgenic mice 
(197). Consequently, CDK2, which is a serine/threonine kinase, is and ideal anti-
tumor target to disrupt the cyclin E/CDK2 kinase activity. Indeed, roscovitine 
(Seliciclib) is a purine derivative that preferentially inhibits the kinase activity of 
CDK1 and 2 over other CDKs (191, 192). Recent study showed that roscovitine can 
reverse LMW-E-induced resistance to letrozole treatment in breast cancer cells 
(178). Moreover, when combined with doxorubicin or trastuzumab, roscovitine 
exerts synergistic effects in the combination treatment on sarcoma and breast 
cancer cells, respectively (173, 198). Roscovitine has entered phase I clinical trial 
where it demonstrated response in metastatic ovarian cancer and nasopharyngeal 
carcinoma while phase II trial which involves the combination of roscovitine with 
either gemcitabine/cisplatin or docetaxel showed partial response in patients (199, 
200). Perhaps the efficacy of roscovitine in these clinical studies can be improved if 
these patients were selected based on their LMW-E expression status given that 
CDK2-associated kinase activity is critical in inducing LMW-E-mediated tumor 
development. 
 
1.6d. Inhibition of LMW-E generation  
 Research in the last decade has moved towards a more mechanistic 
approach utilizing information from molecular profiling to achieve personalized 
treatment. Given the strong prognostic and predictive role of LMW-E in breast 
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cancer, the regulation of cyclin E expression and post-translational processing is a 
unique target for anti-cancer therapy. The generation of LMW-E isoforms is 
proposed to be a result of high elastase proteolytic activity, which is expected to 
result in enhanced cleavage of cyclin E into LMW isoforms and ultimately lead to 
tumor development (165). Indeed, treatment of a breast cancer cell line (MDA-MB-
157) with a neutrophil elastase inhibitor CE-2072 reduced the production of some 
LMW-E isoforms and also arrested the cells in G1 phase (201). In contrast, this 
inhibitor showed no effect in an immortalized hMEC line MCF-10A. Another potent 
and promising elastase inhibitor is ONO-5046, which has been demonstrated to 
inhibit the proliferation and metastatic development of non-small cell lung cancer 
cell line and tumor xenografts, respectively (202, 203). In addition, a recent study 
discovered the phytochemical indole-3-carbinol (I3C) found in most leafy vegetables 
as a neutrophil elastase inhibitor (204). Analysis of the proteolytic activity of 
elastase by zymography revealed that I3C effectively disrupts the cleavage of cyclin 
E into LMW isoforms and arrests MDA-MB-231 cells in G1 phase. These effects are 
similarly observed with knockdown of elastase protein expression by siRNA. 
Elastase expression is high in breast cancer and this is associated with poor patient 
outcome and high frequency of metastatic progression (205-209). Combined with 
the established oncogenic role of LMW-E in cancer, targeting elastase represents a 
unique therapy for cancers with high LMW-E expression and elastase activity. 
 Another mechanism of targeting the proteolytic processing of cyclin E is 
through the use of elafin, which is an endogenous elastase inhibitor that prevents 
the cleavage of cyclin E into LMW isoforms by elastase. C/EBPβ is a transcription 
factor that regulates elafin gene expression (210). In breast cancer cell lines and 
patient tissues, C/EBPβ is downregulated resulting in reduced elafin transcription. 
More specifically, elafin exerts its tumor suppressive role by inducing pRb-
dependent cell cycle arrest in breast cancer cells while triggering caspase-3-
dependent apoptosis in pRb-deficient cells (211). In immortalized hMECs with an 
intact G1-S checkpoint, elafin does not exert cytotoxic effect suggesting a valuable 
therapeutic utility of elafin in targeting tumor cells.  
 
34
1.7. GAP IN KNOWLEDGE 
 Cyclin E and more specifically, LMW-E, play critical role in the initiation, 
progression, and metastasis in human cancer. Clinical and molecular studies clearly 
identify the LMW-E isoforms as novel oncogenes and powerful predictors of patient 
survival. Consequently, mechanistic examination of the oncogenic functions elicited 
by LMW-E is necessary to better understand and target tumors with high LMW-E 
levels. Biological and molecular studies accumulated from the last decade lead us 
to the following questions:  
• Is LMW-E capable of initiating and maintaining tumor development?  
• What effect does LMW-E have on the proliferation and architecture of the 
mammary acini, and if so, can inhibition of LMW-E by pharmacological 
agents rectify these defects?  
• What signaling pathway(s) is/are deregulated in breast tumors with high 
LMW-E expression? 
• Does LMW-E induce tumor initiation, progression, and metastasis by 
altering gene expression to enhance invasiveness and self-renewal 
capability?  
• Are these phenotypes driven by previously unidentified substrate(s) of the 
LMW-E/CDK2 complex?  
 These are the main objectives of this dissertation, and the research data to 
address them are described in the following chapters. The overall hypothesis of this 
dissertation is that LMW-E initiate and maintain mammary tumor via 
deregulation of mammary acinar morphogenesis, induction of the EMT, and 
generation of cells with CSC properties. By examining these aspects of LMW-E 
in respect to the mammary gland and human pathophysiology, the results obtained 
will indeed move us closer to achieving personalized and molecularly targeted 
therapy for cancer treatment.   
 
 
 
 
35
CHAPTER 2: LMW-E REQUIRES CDK2-ASSOCIATED KINASE ACTIVITY TO 
INDUCE ABERRANT ACINAR MORPHOGENESIS AND MAMMARY 
TUMORIGENESIS  
 
2.1. INTRODUCTION 
2.1a. LMW-E in breast cancer 
 Prior to the G1-S phase boundary, cyclin E associates with CDK2 to further 
phosphorylate and inactivate the pRb-E2F complex to promote S phase entry (212-
214). Cyclin E overexpression by genomic and transcriptional amplification has 
been reported in multiple cancers, particularly in breast cancer (157, 161, 215-219). 
Additionally, posttranslational proteolytic cleavage of cyclin E mediated by serine 
protease generates two LMW-E isoforms in cancer cells (165, 220). Compared to 
full-length cyclin E, the LMW-E isoforms are hyperactive by forming tighter 
interaction with CDK2 and are more resistant to CKI inhibition resulting in higher 
rate of proliferation (175, 221). When subjected to antiestrogen treatment with 
fulvestrant and aromatase inhibitor with letrozole, LMW-E mediates resistance to 
the growth inhibitory effect of these agents (178, 201). Finally, retrospective 
examination of 395 breast cancer patient tissues identifies LMW-E as an 
independent and powerful prognostic and predictive marker of patient outcome 
(160).  
 
2.1b. The functional relationship between LMW-E and CDK2 
 There are a total of 16 cyclins and 9 CDKs identified to date, and most of them 
participate in regulating the cell cycle (Figure 2) (21-24). Although the primary 
structures of cyclins are different from each other, the tertiary structures are similar 
consisting of 2 compact domains of 5 alpha helices. Additionally, all cyclins share a 
homologous sequence of approximately 100 amino acids known as the cyclin box, 
which mediates their interaction with CDKs (25). Interestingly, results from knockout 
animal studies unveiled considerable functional redundancy and compensatory 
mechanisms between the different cyclin/CDK complexes in normal tissues. Since 
there are two cyclin E proteins (E1 and E2), mice with single cyclin E gene knockout 
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carry out normal development (44, 45). However, double cyclin E knockout mice die 
during gestation due to defects in endoreduplication of the giant trophoblast cells 
and megakaryocytes. Surprisingly, CDK2-null mice are viable and show no 
proliferation defects (94, 95).  
 In contrast to findings regarding cyclin E and CDK2 in normal development, 
the inter-dependency between LMW-E and CDK2 is different in malignant 
transformation. Transgenic mice expressing the LMW-E isoforms develop 
mammary adenocarcinomas at higher frequency (27%) compared to mice 
expressing full-length cyclin E (10%) (180). Furthermore, LMW-E overexpression 
does not induce mammary tumor development in CDK2-/- transgenic mice, and 
treatment of the mice with LMW-E-induced tumor using two different CDK inhibitors, 
meriolin and roscovitine, significantly delayed mammary tumor formation by 
approximately 6 weeks suggesting that the oncogenic potential of LMW-E requires 
CDK2-associated kinase activity (197). Interestingly, these mice succumb to 
salivary gland tumors indicating that perhaps LMW-E interacts with novel partner(s) 
specifically expressed in this tissue to cause neoplastic transformation. These 
findings suggest the tissue-specific requirement of CDK2 by LMW-E to induce 
tumor development.   
 
2.1c. Mammary acinar morphogenesis 
 The role of LMW-E in breast cancer is well established due to extensive 
molecular examination of this oncogene in the last decade. Biological processes are 
governed by the intimate relationship between form and function, which also helps 
explain how alteration of gene expression drives the development of malignant 
tumors. Perhaps by understanding the role of LMW-E in the context of the 
mammary acinus and how its expression affects form, then we will gain insights into 
its oncogenic function. Therefore, one of the objectives of this study is to examine 
the role of the LMW-E isoforms during acinar morphogenesis, which is an in vitro 
assay that closely recapitulates the mammary tissue.  
 Numerous studies have demonstrated that extracellular matrix interaction is 
very important for proper structure and function of normal tissues (222-224). When 
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cultured on 2-dimensional (2D) plates, both non-tumorigenic and tumorigenic 
epithelial cells form spindle-shaped structures. However, in 3-dimensional (3D) 
culture provided by a layer of laminin-rich basement membrane, non-tumorigenic 
hMECs arrest proliferation and undergo structural differentiation to form highly 
polarized acinar structures (Figure 1 & 3) (224). Meanwhile, tumorigenic cell lines 
grown in 3D culture do not arrest growth or polarize but instead form disorganized 
masses of cells. The acinus, or more commonly referred to as the alveolus, is the 
basic structure of the mammary gland. The basement membrane containing 
myoepithelial cells surrounds the single layer of luminal epithelial cells, which are 
highly differentiated and polarized, to provide structural and molecular support for 
the acinus (1, 225, 226). Towards the late stage of acinar morphogenesis, the cells 
in the center of the structure undergo apoptosis that results in luminal clearance and 
formation of a hollow lumen that serves to contain milk secretion during lactation 
(227, 228). Acinar morphogenesis involves 4 distinct stages of development: 
proliferation, polarization, luminal cell death, and continued proliferation along with 
luminal cell death (Figure 3). In essence, the mammary acinus can serve as an 
experimental “organism” to investigate mechanisms involved in tissue development 
and derailment in malignancy (1). In fact, recent studies have shown that the 
morphology of the acini is an accurate predictor for patient outcome. That is, human 
breast tumors that share a gene expression signature to the nontumorigenic 
HMECs in 3D culture are predicted to show significantly better prognosis (229). The 
morphological and functional relevance of this 3D culture system provides proof that 
this is a method of choice for studying form and function of the mammary gland in 
vitro.  
 
2.1d. Hypothesis and Specific Aims 
 Normal acinar morphogenesis is critical for maintaining homeostasis of the 
mammary gland, and cell cycle regulation plays a pivotal role in this process. 
Aberration from this control will undoubtedly result in uncontrollable proliferation and 
genomic instability. Therefore, we hypothesize that LMW-E disrupts normal 
mammary acinar development and serves as the initial route into breast tumor 
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Media containing 2% Matrigel
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Figure 3: In vitro acinar morphogenesis assay. (A) On day 0, cells in single
suspension are seeded on top of a 1 mm layer of solidified Matrigel. The cells are
covered with a layer of culture media containing 2% Matrigel and fresh media is
replaced every 4 days to provide continuous nourishment. After 15 days of culture,
these cells undergo proliferation and organization to form spherical acinar
structures. (B) Schematic of the progression of one cell seeded at day 0 into a fully-
formed acinus on day 15.
A
Acinus 
Adapted from Methods 2003;30(3):256-68
Day 0 Day 3 Day 5 Day 6-8 Day 15
B
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development. The oncogenicity of LMW-E depends on CDK2-associated kinase 
activity and thus represents an ideal target for developing therapy to treat breast 
cancer patients with high LMW-E expression. To address the hypothesis, we will 
closely examine the following specific aims:  
• Investigate the role of LMW-E in regulating acinar development 
• Examine the tumorigenicity of overexpression of LMW-E in vivo 
• Determine whether the deregulation by LMW-E is dependent on the CDK2-
associated kinase activity.  
• Elucidate a common signaling pathway present in 3D cultures and patient 
tissues that is deregulated by LMW-E 
 Briefly, the results presented in this chapter demonstrate that overexpression 
of LMW-E disrupts normal acinar morphogenesis in 3D in vitro culture and promotes 
tumorigenesis when expressed in non-transformed hMECs in vivo. CDK2-
associated kinase activity is necessary to induce these phenotypes, and roscovitine 
(a CDK inhibitor) treatment can rescue the aberrant morphologies induced by LMW-
E expression. Reverse-phase protein array assay of 276 breast tumor patient 
samples and cells cultured on monolayer and in 3D Matrigel demonstrated that in 
terms of protein expression profile, mammary epithelial cells cultured in Matrigel 
more closely resembled patient tissues than did cells cultured on monolayer. 
Additionally, the b-Raf-ERK1/2-mTOR pathway was activated in LMW-E expressing 
patient samples and activation of this pathway was associated with poor disease-
specific survival. Combination treatment with roscovitine plus either rapamycin 
(mTOR inhibitor) or sorafenib (b-Raf inhibitor) effectively prevented aberrant acinar 
formation in LMW-E-expressing cells by inducing G1/S cell cycle arrest. 
 
 
2.2. MATERIALS and METHODS 
2.2a. Constructs and cell culture 
 All immortalized cell lines were cultured in DFCI-1 medium as described 
previously (230). FLAG-tagged cyclin E gene constructs EL and LMW-E were 
cloned into the pcDNA 4.0 vector (Clontech, Mountain View, CA) and transfected 
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into 76NE6 hMECs. Transfected cells were selected with 80 µg/mL zeocin  
(Invitrogen, Carlsbad, CA), and stable transfectants were maintained in culture with 
10 µg/mL zeocin. 
 To generate 76NE6 cells with tetracycline-inducible cyclin E expression the 
cyclin E gene constructs were cloned into the pRetro-CMV/TO vector and 
transfected into 293T cells to produce retroviruses carrying the cyclin E constructs, 
and the pBMN-BSR-TetR vector to produce retroviruses carrying the Tet repressor. 
The 76NE6 cells were infected first with the retroviruses carrying the Tet repressor 
(TetR) gene fused with blasticidin-S resistance gene and then with the retroviruses 
carrying the cyclin E constructs. 76NE6 cells inducibly expressing TetR-vector, EL, 
LMW-E, ELR130A, and LMW-ER130A, were maintained in DFCI-1 medium with 20 
µg/ml blasticidin-S and 1 µg/ml puromycin (InvivoGen, San Diego, CA). Other cell 
lines used in this study (i.e. Hs578T and MDA-MB-231) were obtained from 
American Type Tissue Collection and cultured as described previously (231). 
 
2.2b. Tumorigenic assay and in vivo passaging 
 Nude mice were purchased from Charles River Laboratories (Wilmington, 
MA) and maintained in the Department of Veterinary Medicine at The University of 
Texas MD Anderson Cancer Center. The mice were injected subcutaneously in the 
mammary fat pad with 1x106 cells suspended in 100 µL of a 1:1 Matrigel:media mix 
(Matrigel from BD Biosciences, San Diego, CA). Doxycycline was added to drinking 
water containing 1% sucrose, and water was replaced twice weekly. Mice were 
sacrificed under an Animal Care and Use Committee (ACUF)-approved protocol 
when tumors reached approximately 12 mm in diameter or 10 weeks after injection, 
whichever came first. The tumors were harvested for histopathological analysis or 
for expansion of tumor cells in tissue culture for reinjection into mice for in vivo 
passaging. Tumors submitted for histopathology were fixed in 10% neutral buffered 
formalin, paraffin embedded, and serially sectioned at 5 µm thickness. 
 
2.2c. Staining of tumor sections 
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 Paraffin-embedded tumor sections were stained with hematoxylin and eosin 
and for cyclin E using a polyclonal anti-cyclin E antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA). The immunostaining was done as previously 
described (180) using a Vectastain ABC kit (per manufacturer’s web site) and a 
BCIP/NBT chromogen detection system (Vector Laboratories, Burlingame, CA). 
Briefly, the sections were incubated in 1% H2O2 to block endogenous peroxidase 
activity and then incubated for 20 min in 10 mmol/L sodium citrate buffer (pH 6.0) at 
90°C to retrieve nuclear antigens. Both primary and secondary antibody incubations 
were performed for 1 hr in blocking buffer (5% bovine serum albumin and 0.5% 
Tween-20 in 1x phosphate-buffered saline [PBS]) at room temperature. Nuclei were 
counterstained with hematoxylin. 
 
2.2d. Morphogenesis assay and drug treatment 
 3D culture on basement membrane was performed as described previously 
(232). Assay medium (DFCI-1 medium with 2% growth factor-reduced Matrigel) with 
or without drugs was replaced every 4 days, and cells were cultured for 15 days. 
 
2.2e. Indirect immunofluorescence analysis 
 Indirect immunofluorescence analysis of 3D cultures was performed as 
previously described with minor modifications (233). Cells cultured in 8-well 
chamber slides were fixed with 2% paraformaldehyde at room temperature for 20 
min, permeabilized with 1% Triton X-100 in PBS for 20 min, washed thrice with 
PBS/glycine buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, and 100 mM 
glycine), and blocked with IF buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM 
NaH2PO4, 7.7 mM NaN3, 0.1% bovine serum albumin, 0.2% Triton X-100, and 
0.05% Tween-20) plus 10% goat serum for 1 hr at room temperature. Primary 
antibodies (laminin V and α6-integrin [Chemicon, Billerica, MA], GM-130 & E-
cadherin [BD Pharmingen, San Diego, CA], and Ki67 [Abcam, Cambridge, MA]) 
were incubated in IF buffer at 1:200 dilution overnight at 4°C. The cells were 
incubated with Alexa fluor-conjugated rabbit (488), mouse (594), or rat (680) 
secondary antibodies (Molecular Probes, Carlsbad, CA), counterstained with 4,6-
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diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO) for 15 min at room 
temperature, and mounted with antifade solution (Molecular Probes, Carlsbad, CA). 
Confocal microscopy was performed at room temperature using an Olympus FV300 
laser scanning confocal microscope (Olympus America, Inc., Center Valley, PA) at 
40x magnification, and images were processed using Adobe Photoshop (Version 
11.0.2). For quantification, the diameter of each acinus was measured, and 
unpaired Student t test was used for statistical analysis. 
 
2.2f. Protein isolation for Western blot and kinase assay 
 Cell lysates were prepared and subjected to Western blot analysis as 
described previously (220). To obtain lysates from acini, acini were washed once 
with cold PBS, scraped, collected, and washed twice with cold PBS. Cell recovery 
solution (BD Biosciences) was added to the Matrigel/acini mixture at 1:1 volume, 
and cells were incubated on ice for 1 hr, washed with PBS, and lysed as described 
previously (165) The protein blots were incubated with primary antibodies (cyclin E, 
vinculin [Santa Cruz Biotechnology, Santa Cruz, CA], β-actin [Chemicon, Billerica, 
MA], BIM [Epitomics, Burlingame, CA], FAK, b-Raf, ERK1/2, pERK1/2 (T202/Y204), 
pMEK1/2 (S217/221), pS6 (S235/236), mTOR, eIF4E, Akt, pAkt(T308), and 
pRb(S807/811) [Cell Signaling Technology, Danvers, MA]) at 4°C with gentle 
shaking overnight. Kinase assay with histone H1 and GST-Rb as cyclin E 
substrates was performed as described previously (165). 
 
2.2g. Reverse-phase protein array (RPPA) analysis 
 The RPPA approach was performed as previously described (234). Cellular 
proteins were prepared as described for western blotting were denatured by boiling 
in 1% SDS (with beta-mercaptoethanol) and diluted in five 2-fold serial dilutions in 
dilution buffer (lysis buffer containing 1% SDS). Serial diluted lysates were arrayed 
on nitrocellulose-coated slides (Grace Biolab) using Aushon 2470 Arrayer (Aushon 
BioSystems). Each sample was robotically printed in 5 fold serial dilutions on 
multiple slide including positive and negative controls prepared from mixed cell 
lysates or dilution buffer, respectively as well as multiple cell lines incubated with 
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and without growth factors to provide dynamic range. 
 Each slide was probed with a validated primary antibody plus a biotin-
conjugated secondary antibody. Antibody targets were selected as being relevant to 
breast cancer through a literature review. Antibodies where then obtained and 
validated against each potential target. Only antibodies with a Pearson correlation 
coefficient between RPPA and western blotting of greater than 0.7 were used in 
reverse phase protein array study. Antibodies with a single or dominant band on 
western blotting were further assessed by direct comparison to RPPA using cell 
lines with differential protein expression or modulated with ligands/inhibitors or 
siRNA for phospho- or structural proteins, respectively. 
 The signal obtained was amplified using a Dako Cytomation–catalyzed 
system (Dako) and visualized by DAB colorimetric reaction. The slides were 
scanned, analyzed, and quantified using a customerized-software Microvigene 
(VigeneTech Inc.) to generate spot intensity. 
 Each dilution curve was fitted with a logistic model (“Supercurve Fitting” 
developed by the Department of Bioinformatics and Computational Biology in MD 
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). This fits 
a single curve using all the samples (i.e., dilution series) on a slide with the signal 
intensity as the response variable and the dilution steps are independent variable. 
The fitted curve is plotted with the signal intensities – both observed and fitted - on 
the y-axis and the log2-concentration of proteins on the x-axis for diagnostic 
purposes. The protein concentrations of each set of slides were then normalized by 
median polish, which was corrected across samples by the linear expression values 
using the median expression levels of all antibody experiments to calculate a 
loading correction factor for each sample. 
 
2.2h. Breast cancer patient samples and clinical data 
 The clinical data from 267 breast cancer patients used in this study were 
reported previously (160).  Each patient had received a diagnosis of breast cancer 
between 1990 and 1995 at 1 of 12 hospitals in the Chicago area. The study was 
approved by the institutional review board of the Wadsworth Center (Albany, NY). In 
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the study reported herein, we used tissue samples from a portion of these for RPPA 
analysis to investigate large-scale protein expression pattern. 
 
2.2i. Statistical analysis 
 Each cell culture experiment was performed at least three times. Continuous 
outcomes were summarized with means and standard deviations. Comparisons 
among groups were analyzed by two-sided t test and Wilcoxon rank-sum test. 
Analyses were performed using SPSS software, version 12.0. For analysis of the 
RPPA results, the data for each protein were median-centered, and then the 
medians of each sample were subtracted from the raw data for the sample. For the 
71 proteins common between the 2D culture, 3D culture and patient data sets, the 
data for each protein in each data set were standardized (subtraction of mean then 
divided by standard deviation), and then the standardized data were combined. The 
combined data set contains 93 cell line samples from 2D and 3D each, with three 
technical replicates for each of the 31 unique samples, and 276 breast tumor patient 
samples. 
 Disease-specific survival (DSS) was calculated from the date of surgical 
resection of the primary tumor to the date of death or last follow-up. Data for 
patients who died from causes other than breast cancer were censored at the time 
of death. DSS curves were computed by the Kaplan-Meier method (235). Bivariate 
analyses of DSS in patients with high LMW-E expression according to levels of 
FAK, BIM, total Akt, and pAkt(T308) were performed with the use of a two-sided 
log-rank test (236). 
 
2.3. RESULTS 
2.3a. Breast cancer cells fail to undergo acinar morphogenesis in 3D culture 
 Cellular context provided by the extracellular matrix plays a critical role in 
defining the morphological development of the cell. Therefore, the acinar 
morphogenesis assay was performed to determine if the 3D culture system can 
distinguish acinar morphology between normal and breast cancer cells. This assay 
involves culturing cells on top of a layer of Matrigel, a laminin-rich basement 
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membrane, and a single cell seeded on day 0 is capable of forming a highly 
polarized acinus that is fully differentiated by day 15 in culture (224, 233) (Figure 
4A). The 76N cell line is a mortal hMEC line isolated from a reduction mammoplasty 
specimen, and these cells senesce at passages 18-20 in tissue culture (230). The 
76NE6 cell line was generated by infection of the 76N cells with the HPV E6 virus, 
which binds and degrades p53 (237). As a result, the 76NE6 cells lack functional 
p53, are immortalized, but remain nontumorigenic. MCF-10A is also a 
nontumorigenic hMEC line that was immortalized spontaneously by extended 
culture (238). The 2 breast cancer cell lines used were Hs 578T and MDA-MB-231, 
which are p53+/mut and express endogenous LMW-E. These cells were cultured on 
Matrigel surface for 15 days and then subjected to immunofluorescence (IF) 
staining. The staining markers were GM-130 and α6-integrin, which stain the apical 
and basal surfaces of the acinus, respectively (239). Figure 4A clearly shows that 
the immortalized hMECs arrested proliferation and formed differentiated, polarized 
acinar structures. More specifically, these acini were spherical in structure and 
showed distinct α6-integrin staining on the outer surface (basal) and GM-130 
staining on the inner surface (apical) of the acini. In contrast, the 2 breast cancer 
cell lines maintained single-cell morphology in 3D culture. That is, these cells failed 
to form coherent, round structures with unorganized α6-integrin and GM-130 
staining.  
 To examine the effect of Matrigel culture on proliferation, a growth curve 
assay was performed on these cells cultured on 2D and 3D culture conditions for a 
total of 20 days. Both hMECs exhibited faster proliferation in 2D culture than in 3D 
culture with the 76NE6 cells growing much faster than the MCF-10A cells in both 
culture contexts (Figure 4B and C). Additionally, both hMECs demonstrated growth 
arrest on day 20 with a total of approximately 300,000 cells. On the contrary, both 
breast cancer cell lines displayed faster proliferation in 3D cultures as compared to 
normal cells. (Figure 4D & E). Particularly, the breast cancer cells cultured on 2D 
culture appeared to plateau at day 10 whereas those cultured in 3D culture seemed 
to continue to proliferate until day 20. Perhaps in addition to having aberrant cell 
cycle arrest machinery, the 3D culture environment provides more nutrients for the 
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Figure 4: Breast cancer cells fail to undergo acinar morphogenesis in 3D
culture. (A) MCF-10A, 76NE6, Hs 578T and MDA-MB-231 cells were seeded at 70
cells/mm2 density on 1 mm Matrigel thickness. After 15 days in 3D culture, the cells
were fixed and immuno-stained with anti-GM-130 and anti-a6-integrin antibodies.
Nuclei were counter-stained with DAPI. Scale bar = 50 um. (B-E) On day 0, 5000
cells were seeded on 8 chamber slides for monolayer or coated with Matrigel as in
A and harvested every 2 days until day 20 for cell count using the automatic cell
culture counter.
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Hs 578T and MDA-MB-231 cells to continue to proliferate. Taken together, these 
observations suggest that breast cancer cells lose the ability to respond to 
environmental cues provided by the basement membrane to undergo 
morphogenetic differentiation and growth arrest. Additionally, these results further 
confirm the unique ability of this 3D culture system to morphologically distinguish 
normal from cancer cells.  
 
2.3b. hMECs but not breast cancer cells demonstrate cell cycle arrest in 3D 
culture  
 Since the initial stage of acinar morphogenesis involves extensive cell 
division, is cell cycle regulation responsible for the aberrant phenotypes observed? 
To address this question, cell lysates of MCF-10A, 76NE6, Hs 578T, and MDA-MB-
231 cells from day 0 (2D) and day 15 of morphogenesis (3D) were subjected to 
Western blot analysis for proteins that regulate cell cycle progression. Overall, the 
protein expression profiles of the 4 cell lines examined were largely different from 
2D to 3D culture condition. Both hMEC lines demonstrate cell cycle arrest by 
reducing the expression levels of cyclin B, D, E, CDK1, 2 and upregulating p27Kip1. 
In contrast, the breast cancer cells express high levels of cyclin D and CDK4 
suggesting that perhaps G1 phase progression is active (Figure 5A). Matrigel is 
composed of a protein mixture secreted from the Engelbreth-Holm-Swarm (EHS) 
mouse sarcoma cells that also contains high growth factor level thus explaining the 
elevated cyclin D and CDK4 proteins. In addition, all 4 cell lines express high levels 
of pAkt (S473) in 3D culture, and phosphorylation of Akt activates both p21Cip1 and 
p27Kip1, which in turn inhibit cyclin E/CDK2 activity. Cyclin E protein level is lower in 
3D culture suggesting reduced G1-S phase transition. Moreover, a previous study 
has shown that Akt is selectively activated in the matrix-attached cells and not in the 
centrally located cells in the luminal space (239). Perhaps the presence of 
extracellular matrix signaling enables these matrix-attached cells to survive by 
activating the Akt pathway. This finding also explains the high levels of pAkt (S473) 
in both the Hs 578T and MDA-MB-231 cell lines in 3D culture since these breast 
cancer cells maintain single cell morphology and thus every cell is in contact with 
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AFigure 5: hMECs but not breast cancer cells
demonstrate cell cycle arrest in 3D culture. (A)
Lysates from 76NE6, MCF-10A, Hs 578T and
MDA-MB-231 cells were isolated at day 0 (2D)
and day 15 (3D) of acinar morphogenesis and
subjected to Western blot analysis with the
indicated antibodies. β-actin was used as a
loading control. (B-E) Cells were cultured as in A
and harvested at the indicated day during acinar
morphogenesis for FACS analysis. Cells were
fixed in ethanol overnight and stained with
propidium iodide for cell cycle analysis.
            D15
         D12
      D6
   D3
D0
PI
76NE6
co
un
ts
B
           D15
         D12
      D9
    D6
  D3
D0
co
un
ts
C
           D15
         D9
      D6
   D5
D0
PI
MDA-MB-231
co
un
ts
E
PI
MCF-10A
            D15
          D12
       D9
     D6
   D3
D0
co
un
ts
D
PI
Hs 578T
cyclin E
 
p53 
cyclin A
cyclin B
cyclin D
CDK1
CDK2
CDK4
p21Cip1
p27Kip1
elafin
Akt
pAkt (S473)
β-actin
D0   D15    D0     D15   D0   D15    D0    D15
 76NE6   MCF-10A  Hs-578T  MDA-MB-231
49
the basement membrane. In addition, elafin is an endogenous inhibitor of elastase, 
which is responsible for LMW-E cleavage. Elafin has been reported to be 
downregulated in many breast cancer cell lines, and both the Hs 578T and MDA-
MB-231 cell lines completely lack elafin protein expression. Meanwhile, the hMECs 
dramatically upregulate elafin expression in 3D culture suggesting that these cells 
are entering cellular quiescence since elafin upregulation has been demonstrated to 
induce cell cycle exit.  
  Fluorescence activated cell sorting (FACS) analysis with propidium iodide 
(PI) staining was used to directly assess the cell cycle distribution of normal and 
cancer cells grown on 3D culture from day 0 to day 15. As expected, the control 
MCF-10A cells were mostly in G1 phase during the entire morphogenetic process 
(Figure 5C). The 76NE6 cells also became G1 arrested and showed very low S 
phase population (<5%) after 6 days in 3D culture (Figure 5B). Interestingly, the 2 
breast cancer cell lines also showed decreasing S phase (but not until day 15 in the 
MDA-MB-231 cells) and a slight increase in G1 phase from day 0 to day 15 in 3D 
culture (Figure 5D & E). Collectively, the 76NE6 and MCF-10A cell lines showed 
growth arrest and polarity organization in 3D culture, whereas the Hs 578T and 
MDA-MB-231 cells, to some extent, failed to show these behaviors. These findings 
suggest that cell cycle regulation is important for proper acinar morphogenesis, but 
does not entirely account for the aberrant morphologies observed in the breast 
cancer cells.  
 
2.3c. LMW-E expression leads to aberrant acinar morphogenesis  
 We speculate that LMW-E is a critical initiator of oncogenesis and one of its 
early roles during this process is to deregulate mammary acinar morphogenesis. 
Similar to the parental 76NE6 cells, the 76NE6-vector cells formed perfectly 
spherical acinar structures (Figure 6A). Interestingly, the acini developed from the 
76NE6-EL cells are larger compared to those of vector control cells, but the 
structures remained spherical in shape. In contrast, the 76NE6-LMW-E cells formed 
very large, irregularly shaped structures with a few multi-acinar complexes. We 
quantified the size of the acini by measuring the longest diameter of the structures 
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Figure 6: LMW-E expression leads to aberrant acinar morphogenesis. (A)
76NF2V, and 76NE6 cells with stable expression of V, EL, and LMW-E(T1) were
seeded at 70 cells/mm2 density on 1 mm Matrigel thickness. After 15 days in 3D
culture, the cells were fixed and immuno-stained with anti-GM-130 and anti-a6-
integrin. Nuclei were counter-stained with DAPI. Scale bar = 50 um. (B) The diameter
of the acini were measured and averaged from 3 independent experiments. Error
bars = SEM (Student’s t test, *p<0.05). (C-F) On day 0, 5000 cells were seeded on 8
chamber slides for monolayer or coated with Matrigel as in A and harvested every 2
days until day 20 for cell count.
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and found that ectopic LMW-E expression in the 76NE6 cells does lead to 
approximately 28% larger acini compared to vector control cells (p < 0.0001) 
(Figure 6B). These results signify that, in the mammary gland, LMW-E is an 
important regulator of the early onset of oncogenesis by perhaps causing 
enlargement of mammary lobules.  
 As established previously, the morphology and growth patterns of human 
mammary epithelial cells are dramatically different from 2D to 3D culture. Normal 
hMECs grown in 3D culture provided by laminin rich basement membrane arrest 
proliferation and form fully differentiated acinar structures. The 76NE6-vector, 
76NE6-EL, LMW-E, and 76NF2V cells had almost identical doubling times in 2D 
culture at approximately 45 hours (Figure 6C-F). In contrast, when cultured in 3D 
medium, these cells exhibited fast rate of proliferation up to day 5 and begin to 
plateau at day 10, which is consistent with previous observations (239).  The 
difference in growth behavior between the EL and LMW-E clone was not apparent 
in 3D culture except that the total cell number of the EL clone was larger than the 
LMW-E clone after 20 days of culture. Furthermore, the 76NF2V cell line showed 
growth arrest at the latest time point, but the cell number declined noticeably after 
reaching the peak. This is due to the control of the cell cycle by an intact p53. In 
addition, these results also suggest that the 3D culture system is more sensitive at 
distinguishing the differences between EL and LMW-E in the cells than the 2D 
counterpart.  
 
2.3d. Deregulation of the cell cycle progression by LMW-E during acinar 
morphogenesis 
 Protein expression relies on different cellular context, depending what 
environment the cell is in contact with. Since expression of key cell cycle regulators 
could be modulated by signals received from the 3D environment, we questioned if 
the addition of Matrigel was sufficient to mediate changes in expression levels of 
these proteins.  To address this question we subjected cells cultured in 2D and 3D 
conditions to western blot analysis). The results from this experiment demonstrated 
that in all cell lines examined (76NF2V, 76NE6-V, EL, and LMW-E), the activity of 
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the cell cycle is greatly repressed in 3D context as evidenced by reduced 
expression of many of the cyclins and CDK expression (Figure 7A). This suggests 
that cells cultured on monolayer plates do not experience growth-inhibiting effects 
from the extracellular matrix and exhibit high cell cycle activity continuously. 
However, the cells in 3D culture showed dramatic proliferation arrest behavior after 
15 days in culture with the protein levels of cyclin A, B, D, CDK1, 2, 4, and pAkt 
(S473) significantly downregulated. In contrast, both the 76NE6-EL and 76NE6- 
LMW-E cells upregulate cyclin E expression in 3D culture. Contrary to our 
expectation, overexpression of LMW-E did not affect the expression of these cell 
cycle proteins in 3D culture as the expression profile of the LMW-E cells is similar to 
that of the vector control cells. Interestingly, the 76NE6-LMW-E cells express much 
higher elafin proteins in 3D culture compared to the 76NE6-EL cells. Elafin is an 
endogenous inhibitor of elastase and therefore can prevent the cleavage of cyclin E 
into LMW isoforms (240). Maybe this induction of elafin expression can compensate 
for the oncogenic effects of LMW-E in these cells by preventing further LMW-E 
generation.  
 To determine the effect of overexpression of EL and LMW-E on the cell cycle 
profile of hMECs during acinar morphogenesis, the cells were cultured on Matrigel 
and subjected to FACS analysis with PI staining every 3 days post seeding on 
matrigel. As observed previously with the 76NE6 cell cycle profile (Figure 5B), the 
76NE6-V, EL and 76NF2V cells arrest in G1 phase by reducing the S and G2/M 
population from day 6 to day 15 of acinar development (Figure 7B-D). In contrast, 
the 76NE6- LMW-E cells demonstrate a dramatically different cell cycle distribution 
during acinar morphogenesis (Figure 7E). On day 0, the cell cycle distribution of the 
76NE6- LMW-E cells is similar to the parental cells with approximately 60% in G1, 
15% in S, and 25% G2/M phase. After 6 days in 3D culture, these cells appear to 
lack S and G2/M population as the DNA content represents mainly G1 phase. This 
population then shifts gradually to S and then G2/M population from days 9 to 15 of 
acinar morphogenesis. On day 15, approximately 90% of the population is in G2/M 
phase while about 10% are in G1 phase. This unusual pattern of cell cycle 
distribution suggests that the LMW-E overexpressing cells are able to traverse the 
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Figure 7: Deregulation of the cell cycle
progression by LMW-E during acinar
morphogenesis. (A) Lysates from 76NF2V and
76NE6 cells with stable expression for V, EL,
LMW-E were isolated at day 0 (2D) and day 15
(3D) of acinar morphogenesis and subjected to
Western blot analysis with the indicated antibodies.
β-actin was used as a loading control.(B-E) Cells
were cultured as in A and harvested at the
indicated day during acinar morphogenesis for
FACS analysis. Cells were fixed in ethanol
overnight and stained with propidium iodide for cell
cycle analysis.
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G1-S phase transition but arrest in S and G2/M phase due to increasing DNA 
damage that LMW-E overexpression can induce in these cells (176). Taken 
together, these results suggest that LMW-E expression induces formation of large 
and irregular acini, which could be explained by the aberrant cell cycle machinery 
during the progression through the different developmental stages of acinar 
morphogenesis.    
 
2.3e. Elafin overexpression fails to completely revert breast cancer cells 
during acinar morphogenesis  
 LMW-E expression is unique in cancer cells due to the action of elastase, 
and their expression leads to more aggressive proliferative phenotype (165). Elafin 
is a potent endogenous inhibitor specific for elastase and proteinase-3 (241). We 
recently reported that elafin is transcriptionally down regulated in most tumor cell 
lines and thus explaining the generation of LMW-E in tumor but not in normal cells 
(210). Previous studies have shown that exogenous elafin expression can inhibit the 
proliferation of MDA-MB-468, which express high levels of LMW-E, in vitro and in 
xenograft mouse model suggesting that perhaps elafin is an effective candidate to 
negate the growth advantage given by LMW-E expression. Therefore, we aim to 
determine whether inhibition of elastase by overexpression of elafin in breast cancer 
cells would cause reversion of these cells into highly organized acinar structures. 
Adenovirus containing elafin DNA were infected into the 76NE6, MCF-10A, Hs 
578T, and MDA-MB-231 cell lines and then cultured on Matrigel (Figure 8A). On 
day 15 of morphogenesis, the cells were fixed and stained with GM-130 and a6-
integrin antibodies. The results obtained indicated that overexpression of elafin was 
not toxic to immortalized cells (Figure 8B). That is, the 76NE6 and MCF-10A cells 
still formed correct acinar structures in the presence of high levels of elafin. 
However, the Ad-luciferase and Ad-elafin conditions generated larger acini perhaps 
due to the presence of adenovirus in general. As for the breast cancer cells, the Hs 
578T cells remained single-cell phenotype in contrast to the MDA-MB-231 cells, 
which formed adherent round structures in the presence of both Ad-luciferase and 
Ad-elafin. Western blot analysis confirmed that overexpression of elafin reduced 
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AFigure 8: Elafin overexpression fails to completely revert breast cancer cells
during acinar morphogenesis. Cells were treated with PBS and adenovirus
carrying luciferase and elafin DNA on 2D plates. Three days later, the cells were
extracted for (A) Western blot analysis with the indicated antibodies and (B) acinar
morphogenesis assay. On day 15 of morphogenesis, all cells were fixed and
immunostained with GM-130 and a6-integrin antibodies, and nuclei were
counterstained with DAPI.
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LMW-E expression and this is correlated with increased pAkt (S473) expression. 
The pAkt pathway leads to many different downstream effects, one of which is 
activation of p27Kip1, which then can act to inhibit the cyclinE/CDK2 complex. 
Perhaps this pathway is activated to keep the cell cycle in check when elafin is 
expressed.  
 
2.3f. Loss of p53 control cooperates with LMW-E to drive aberrant acinar 
formation  
 Cyclin E and p53 are both critical regulators of the cell cycle. Numerous 
studies have shown that overexpression of cyclin E and its LMW isoforms lead to 
high proliferation, aberrant expression of other cell cycle regulators, and 
chromosomal instability. Furthermore, p53 is a tumor suppressor and was found to 
have high frequency of mutation in breast tumors with high cyclin E protein content 
(242). The association between cyclin E expression and p53 gene status plays 
important role in maintaining the integrity of the cell cycle machinery in normal 
mammary cells. Since previous experiments demonstrated that stable LMW-E 
expression leads to formation of larger and irregularly shaped acini compared to the 
76NE6 parental cells, we next aim to investigate whether p53 collaborates with 
LMW-E to induce these phenotypes. Adenovirus containing the LMW-E DNA was 
infected into the 76NE6 (degraded p53) and 76NF2V (wt p53) cells, and these cells 
were cultured on Matrigel for 15 days to analyze acinar formation (Figure 9A). The 
76NF2V cells infected with the LMW-E construct still maintain the spherical acinar 
structure with the size of the acini slightly larger than those of the PBS and Ad-
luciferase control cells (Figure 9B). However, the size of these acini is in similar 
range to those of the 76NE6 parental cells. Meanwhile, the 76NE6 cells induced 
with LMW-E expression via adenoviral infection lead to formation of acini with 
misshapen structures that are about 2 times larger than the parental control cells. 
The results obtained suggest that loss of p53 control cooperates with LMW-E 
expression to drive aberrant acinar formation. This deregulation by p53 and LMW-E 
appears to affect the size and shape of the acini only but not on the polarity and 
lumen formation as even parental 76NF2V acini contain filled lumen.  
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AB
Figure 9: Loss of p53 control cooperates with LMW-E to drive aberrant
acinar formation. Cells were treated with PBS and adenovirus carrying
luciferase and LMW-E DNA on 2D plates. Three days later, the cells were
extracted for (A) Western blot analysis and (B) acinar morphogenesis assay.
On day 15 of morphogenesis, all cells were fixed and immunostained with
GM-130 and a6-integrin antibodies, and nuclei were counterstained with
DAPI.
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 2.3g. Coculture with breast cancer cells cause formation of larger hMEC acini  
 The microenvironment provides physical support as well as molecular 
crosstalk to nearby cells and thus creating a niche for these cells to grow and 
differentiate into specific tissue. This experiment was designed to address the 
question of whether signals released from normal cells can overcome those of 
tumor cells or can tumor cells recruit normal cells to become more abnormal? The 
cell lines examined were: 76NE6, MCF-10A, 76NF2V, Hs 578T, and MDA-MB-231. 
These cells were cultured on Matrigel and brightfield images were taken at days 6, 
10 and 15 of acinar morphogenesis. Figure 10A shows that the breast cancer cells 
do not form coherent acinar structures but instead their morphologies are similar to 
those observed on monolayer culture, which are single-celled and spindle-shaped 
phenotypes. The MCF-10A, 76NF2V and 76NE6 cells were grown in 3 different 3D 
culture conditions: 1) alone, 2) mixed with Hs 578T or MDA-MB-231 cells at 1:1 
ratio, and 3) on the top layer (insert) of a transwell plate with the Hs 578T or MDA-
MB-231 cells on the bottom well (Figure 10B-D). Contrary to our expectation that 
coculture could rescue the morphology of breast cancer cells, the results revealed 
that it actually causes increase in acinar size of all 3 immortalized hMEC lines. The 
results demonstrated that the morphology of breast cancer cells did not change 
when cultured together with normal breast cells in 3D culture. However, the acinar 
structures of the normal cells are slightly larger when cultured with breast cancer 
cells. It is possible that breast cancer cells release certain growth factors or 
cytokines to stimulate enhanced proliferation of the normal cells thus implicating 
that tumor cells can recruit normal cells to become abnormal.  
 
2.3h. LMW-E is tumorigenic 
 Previous experiments using cultured cells have demonstrated that the LMW-
E isoforms are both biochemically and biologically hyperactive and exhibit strong 
oncogenic potentials (175). In addition, LMW-E is found in breast cancer cell lines 
and patient samples but not in normal tissues suggesting that perhaps LMW-E 
partakes unique oncogenic role in malignancy. To investigate whether ectopic 
59
Figure 10
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LMW-E expression in a non-tumorigenic hMEC line, 76NE6, induces cellular 
transformation in vivo, we injected these cells stably expressing vector, EL, and 
LMW-E subcutaneously into nude mice and observe for xenograft development 
(Table 6). The MDA-MB-468 breast cancer cell line was injected as a positive 
control. While injection of the vector control cell did not yield tumor development, 
7% of the injection of the 76NE6-EL cells formed tumors. More importantly, the 
76NE6-LMW-E is significantly more tumorigenic as their injection led to 74% tumor 
incidence (p<0.0001). The significant difference in the tumorigenic potential 
between EL and LMW-E led us to believe that the proteolytic cleavage of cyclin E 
into LMW-E renders novel physical and molecular interactions with other proteins to 
support tumor growth in mice.  
 Now that we have established that LMW-E is tumorigenic, the next question 
to address is: does LMW-E function to sustain tumor maintenance and reinitiate 
tumor development? Consequently, we subjected the LMW-E-expressing tumor 
cells to serial in vivo passaging in the mouse mammary fat pad. The 76NE6-LMW-E 
tumors were removed and prepared for culture in vitro (T1G2 clones) (see Figure 
11A for schematic of in vivo passaging). Two clones from this generation were 
injected back into the mice (T1G2.2 and T1G2.7) and all 10 of the injections 
rendered tumor growth (Table 6). We repeated the passaging for two additional 
rounds generating the T1G3 and T1G4 clones, and the injections also resulted in 
100% tumor formation. We selected 3 clones from each generation for further 
studies in vitro (T1G2.2, 5, 7; T1G3.1, 5, 8; and T1G4.2, 7, 8), and they are 
collectively named tumor-derived cells (TDCs). Taken together, these results 
strongly indicate that LMW-E expression by itself is capable of promoting tumor 
development and enhancing tumorigenicity with in vivo passaging.  
 
2.3i. In vivo passaging selects for increasing LMW-E and decreasing elafin 
expression 
 To further investigate the mechanism of LMW-E-mediated tumorigenesis, the 
TDCs were subjected to western blot analysis for cyclin E and elafin expression. 
Most of the TDC clones show dramatic increase in LMW-E protein levels compared 
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Figure 11: In vivo passaging
selects for increasing LMW-E and
decreasing elafin expression. (A)
Schematic of the generation of in vivo
passaged clones with 3 successive
injections (T1G2-G4). (B) Tumors
were removed from the fat pad of
76NE6-LMW-E mice, minced, and
cultured on monolayer plates.
Lysates were extracted and subjected
to Western blot analysis with
antibodies against cyclin E, elafin and
β-actin. EL (C), LMW-E(D), and elafin
(F) protein levels were quantified by
densitometry and compared between
different generations of in vivo
passaged cells (Student t test,
G
T1G2
   T1G4
elafin   DAPI     merge
Elafin; DAPI
Normal
(human breast tissue)
*p<0.05). (E) Paraffin-
embedded slides of
the 4 representative
tumors were stained
with hematoxylin and
eosin (top panel) and
cyclin E antibody
(bottom panel). (G)
Parafin-embedded
tumor sections from
normal human breast
tissue, T1G2, and
T1G4 tumors were
subjected to
immunofluorescent
staining with elafin
antibody and nuclei
were counterstained
with DAPI. Scale bar
= 100um.65
to the 76NE6-LMW-E cells (Figure 11B). Furthermore, quantification of the cyclin E 
protein levels by densitometric analysis suggested that in vivo passaging resulted in 
the reduction of the full-length (EL) cyclin E level (Figure 11C) while the LMW-E 
isoform level was increasing with each generation of passaging (Figure 11D). 
Analysis of the tumor tissues by immunohistochemistry staining revealed strong 
cyclin E expression (Figure 11E). Pathological analysis was performed by Dr. 
Caroline Van Pelt and the results suggested that the tumors formed by the 76NE6-
LMW-E were characterized as adenosquamous carcinoma, adenocarcinoma with 
pillar differentiation, and squamous cell carcinoma. The morphology of the tumors 
also appear less organized, diffuse and lack obvious glandular structures.  
 In contrast to cyclin E, elafin is thought to play anti-tumor promoting role 
since elafin prevents the cleavage of cyclin E by inhibiting elastase and its 
expression is downregulated in most breast cancer cell lines (210). We speculate 
that since the levels of LMW-E is augmented with in vivo passaging, this 
phenomenon could be due to loss of elafin expression during growth selection in the 
mouse fat pad. Most of the in vivo passaged clones demonstrated near complete 
loss of elafin expression while the 76NE6-LMW-E parental cells express very high 
elafin (Figure 11B). Densitometric analysis also showed that the expression level of 
elafin (an endogenous inhibitor of serine protease (210) diminished with increasing 
passaging in vivo indicated that cyclin E was subjected to elevated proteolytic 
processing in the mouse microenvironment (Figure 11F). In addition, 
immunofluorescence staining was performed using paraffin section of normal 
human mammary tissue and the xenograft tumors from the T1G2 and T1G4 
generations to examine elafin expression pattern in these tissues. The normal 
human breast tissues contain numerous acini with a clear hollow lumen and contain 
1 to 2 layers of luminal cells (Figure 11G, top panel white arrow). These luminal 
cells and the cells in the interstitial region express relatively high elafin. In contrast, 
the T1G2 tumor contains acini with filled lumen with noticeably reduced elafin 
expression, especially in the cells that make up the acinar structures. More 
convincingly, the T1G4 tumor shows even more disorganized acinar structures that 
are less defined and elafin expression is almost completely lost. These observations 
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suggest that with in vivo passaging, the LMW-E-expressing cells lose control of the 
regulation of acinar morphogenesis, and elafin downregulation could be either the 
cause or effect of this deregulation. These findings suggest that not only LMW-E is 
tumorigenic, but also the fact that LMW-E expression was enhanced in most of the 
TDCs implies that perhaps LMW-E expression is advantageous and selects for 
growth and survival of these cells in the mice.  
 
2.3j. The tumorigenicity of LMW-E requires CDK2-associated kinase activity 
 To eliminate potential false positive and effects from clonal variation, we 
generated a more stringent model system in the 76NE6 cell line in which the 
expression of FLAG-tagged vector, EL, and LMW-E can be induced with varying 
doxycycline concentrations (Figure 12A). At the G1-S phase boundary, cyclin E 
binds to CDK2 to form an active complex that phosphorylates multiple proteins to 
induce S-phase entry. Immunoprecipitation using FLAG antibody followed by 
incubation with 32P-γ-ATP and histone H1 confirms that inducible EL and LMW-E 
have functional cyclin E-associated kinase activity (Figure 12A). The inducible 
76NE6 cells expressing V, EL, and LMW-E and were injected subcutaneously into 
the mammary fat pad of nude mice and cyclin E expression was induced by 
doxycycline administration in drinking water 24 hours after the injection. Induction of 
LMW-E expression with 500 µg/ml doxycycline led to significantly more tumor 
formation at 95% for LMW-E and 90% for compared to uninduced cells at 11% as 
assessed by the Fisher’s Exact test (p<0.0001) (Table 7). Similar to our previous 
observation, induction of EL expression with doxycycline led to tumor formation at 
17% compared to 11% uninduced cells.  
 Given that cyclin E requires interaction with CDK2 to exert its kinase activity, 
we next aimed to investigate whether the oncogenicity of LMW-E requires CDK2-
associated kinase activity. Previous study reported that the R130 site on the cyclin 
E protein is important for mediating the interaction between cyclin E and CDK2 
(135). As a result, the point mutation R130A was introduced into the different 
isoforms of cyclin E. Results shown in Figure 12A confirm that the cyclin E/CDK2 
kinase activity of these cyclin E mutants is abolished by immunoprecipitating cyclin 
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Figure 12: LMW-E deregulation of acinar morphogenesis is dependent on
CDK2-associated kinase activity. (A) 76NE6-TetR cells were cultured with or
without doxycycline induction, and the lysates were extracted and subjected to
Western blot analysis with antibodies against cyclin E and β-actin. In vitro kinase
assay was performed by immunoprecipitation with FLAG antibody and histone H1
and GST-Rb were added as substrates. Doxycycline was administered to achieve
approximately 1x and 2x cyclin E protein levels. (The doxycycline concentrations
for the 76NE6-TetR-V and wild-type EL and LMW-E cells were 0, 0.2, and 0.4
ng/ml, and the doxycycline concentrations for the ELR130Aand LMW-E R130Acells
were 0, 1, and 2 ng/ml.) (B) 76NE6-TetR cells were cultured on Matrigel for 15
days with or without doxycycline induction. Bright-field images were taken at day
15. Values underneath each figure represent mean diameter (µm) ± SEM. (C)
The diameters of at least 100 acini from 3 different experiments were measured.
Error bars = SEM (Wilcoxon rank-sum test, *p<0.05). (D) Multi-acinar complexes
were counted. Error bars = SEM (Wilcoxon rank-sum test, *p<0.05). Multi-acinar
complexes were defined as complexes with more than 2 acini growing on top of
each other. Logistic regression models were used to compare the rate of
formation of multi-acinar complexes between/among groups (*p<0.05).
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E FLAG-tagged proteins and measure the extent of histone H1 phosphorylation 
(Figure 12A). Injection of the 76NE6 cells with inducible expression for ELR130A and 
LMW-ER130A and into the mammary fat pad of nude mice revealed that LMW-E does 
require CDK2-associated kinase activity to induce tumor formation (Table 7). In 
other words, the tumor incidence caused by ELR130A and LMW-ER130A and compared 
with vector control is not statistically significant. These data suggest that LMW-E 
demonstrates stronger tumorigenic potential than EL, and this ability to induce 
tumor formation requires the kinase activity exerted from interaction with CDK2.  
 
2.3k. LMW-E deregulation of acinar morphogenesis is dependent on CDK2-
associated kinase activity  
 As CDK2-associated kinase activity is required for mammary tumor 
development, we speculate that this same requirement is critical for LMW-E-
mediated acinar deregulation. Bright field images of 76NE6 cells with inducible 
expression for different cyclin E constructs during acinar morphogenesis confirm 
previous data that induction of EL led to generation of larger acini with the 
structures remaining spherical (Figure 12B). In contrast, induction of the LMW-E 
isoforms generated acini with very irregular shapes and multi-acinar aggregations. 
The diameter of at least 100 acini were measured and the quantification revealed 
that cyclin E expression lead to large acini formation in a dose dependent manner 
(Figure 12C). On the contrary, we observed that induction of ELR130A and LMW-
ER130A did not result in enlargement of acinar size (Figure 12C). In addition, LMW-E 
expression tend to form multiacinar complexes in which at least 2 acini are 
overlapping or fused into one aggregate (Figure 12B). Quantification revealed that 
this phenotype was only observed in wild type LMW-E-expressing cells but not in 
the cells expressing EL or the R130A mutant cyclin E variants (Figure 12D). These 
results suggest that the LMW-E/CDK2-associated kinase activity is responsible for 
driving mammary tumorigenesis by generating deregulated acinar structures in the 
mammary gland. Previous clinical examination of breast cancer patient samples 
revealed that high LMW-E protein levels significantly correlate with poor patient 
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survival, and the data presented here further confirms that the level of LMW-E 
expression positively correlates with aberrant acinar development. 
 
2.3l. LMW-E generates enlarged acini by reducing apoptosis and enhancing 
proliferation  
 To determine the mechanism of LMW-E-mediated tumorigenesis, the 9 TDC 
clones were also subjected to acinar morphogenesis. Similar to our observation with 
the stable and inducible model systems, all TDCs form large and non-spherical acini 
that are approximately 28% larger than the 76NE6 parental acini (p < 0.05) (Figure 
13A and B). The acinar morphogenesis process includes several distinctive stages. 
During the first 8 days of culture on Matrigel, the cells undergo high rates of 
proliferation, which continues to occur while the cells in the interior of the structure 
undergo apoptosis due to anoikis or detachment from the basement membrane to 
generate a hollow lumen (239). The luminal cell layer is highly polarized which is 
important for milk secretion into the luminal space. Cell proliferation subsides 
towards the late stage of morphogenesis from day 10 to day 15 to form a mature 
acinus that is approximately 120 um in diameter. As expected, the levels of cyclin E 
protein in the parental 76NE6 cells is lower in 3D culture compared to 2D culture 
since these cells have arrested proliferation by downregulating the G1-S phase 
cyclin (Figure 5A). However, the 76NE6-LMW-E and TDCs express dramatically 
high cyclin E protein levels during acinar morphogenesis compared to the parental, 
vector and 76NE6-EL cells (Figure 13C). In vitro kinase assay demonstrates that 
the TDCs exhibit high cyclin E/CDK2 kinase activity indicating that these cells are 
not arresting cell cycle progression but instead are actively traversing through the 
G1-S phase transition (Figure 13C). Perhaps LMW-E expression generates an 
aberrant positive feedback loop during acinar morphogenesis that leads to further 
upregulation of cyclin E expression in the acini.  
 BIM is a Bcl2 pro-apoptotic protein that is upregulated during acinar 
morphogenesis to induce cell death in the matrix-detached cells to create a hollow 
lumen (243). Interestingly, the acini expressing cyclin E downregulate BIM 
expression suggesting that there is reduced apoptosis in these acini (Figure 13C). 
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Figure 13: LMW-E generates enlarged acini by reducing apoptosis and
enhancing proliferation. (A&B) 76NE6 cells stably transfected with vector, EL, and
LMW-E and tumor-derived cells (TDCs) were seeded at a density of 70 cells/mm2
on 1-mm-thick Matrigel. After 15 days in 3D culture, cells were fixed and
immunostained with GM-130 and α6-integrin antibodies. Nuclei were counterstained
with DAPI. Scale bar = 50 µm. The diameters of the acini were measured and
averaged from 3 independent experiments. Values underneath each figure
represents mean (µm) ± SEM. Error bars = SEM (Student t test, *p<0.05). (C)
Lysates from these cells were isolated at day 15 and subjected to Western blot
analysis with the indicated antibodies. In vitro kinase assay was performed by
immunoprecipitation of lysates from 3D culture using polyclonal cyclin E antibody
and incubation with (γP32)ATP and GST-Rb. (D&E) Cells cultured on Matrigel for 15
days were fixed and immunostained with E-cadherin and Ki67 antibodies. Nuclei
were counterstained with DAPI. Scale bar = 50 µm. The number of Ki67-positive
cells per acinus was counted and averaged from 3 independent experiments. Error
bars = SEM (Student t test, *p<0.05). (F) Linear regression of the correlation
between acinar diameter and percentage of Ki67-positive cells.
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To determine whether LMW-E expression was sufficient to prevent growth arrest of 
cells in mature acini, we fixed acini at 15 days and stained them for Ki67. While 
Ki67 expression was not detectable in the 76NE6-vector acini, LMW-E-expressing 
acini displayed high Ki67 staining, particularly in cells that were in contact with the 
basement membrane (Figure 13D & E). Furthermore, we determined a strong 
positive correlation between the acinar diameter and the percentage of Ki67-
positive acini, indicating that the formation of large acini may be due to increased 
proliferation (Figure 13F). Taken together, we demonstrate here that LMW-E 
causes generation of large and misshapen acini by enhancing cell proliferation and 
inhibiting apoptosis. These phenotypes share similarity with early-staged tumors 
and those with HER2 overexpression (232). Therefore, we believe that this 
deregulation of the mammary acinar morphogenesis by LMW-E occurs in vivo thus 
explaining the tumorigenicity of LMW-E and its advantageous selection with 
increasing in vivo passaging. 
 
2.3m. Roscovitine rescues LMW-E-induced aberrant acinar development  
 Given that LMW-E-mediated tumorigenesis and aberrant acinar 
morphologies depend on intact CDK2-associated kinase activity, we next aim to 
determine whether inhibition of this kinase activity can reverse these phenotypes. 
Roscovitine was the pharmacological agent of choice since it has demonstrated 
high CDK1 and 2 specificity and potent anti-tumor effectiveness. The 76NE6 and 
T1G2.2 cells were seeded on Matrigel culture and treated with roscovitine 24 hours 
after seeding every 4 days until day 15 in culture. The results showed that the 
treatment of the T1G2.2 cells during acinar morphogenesis with roscovitine led to 
formation of smaller and spherical acini while showing no effects on the 76NE6 
parental cells (Figure 14A & B). These data suggest that roscovitine is effective in 
reversing the aberrant acinar phenotypes caused by LMW-E expression and is non-
toxic to normal cells.  
 Further treatment of the TDCs with 3 different roscovitine concentrations 
demonstrated significant reduction of acinar diameter (Figure 14C). Similar to the 
76NE6 parental cells, the 76NE6-vector and EL acini show no significant effects in 
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response to roscovitine treatment. We also observed that roscovitine treatment 
significantly reduces the multi-acinar complex formation by the LMW-E-expressing 
cells (p < 0.05) (Figure 14D). Perhaps roscovitine induces a G1 arrest since cyclin E 
and pRb protein levels are downregulated in the roscovitine-treated acini (Figure 
14E). We speculate that inhibition of LMW-E/CDK2 complex by roscovitine allows 
the acini to arrest proliferation and thereby suppressing the aberrant positive loop 
that drives cyclin E protein overexpression. Growth arrest towards the end of 
morphogenesis (days 12-15) also allows cells to properly organize into correct and 
spherical acinar structures. Thus, our data suggest that roscovitine is an effective 
pharmacological agent that can reverse the phenotypes mediated by LMW-E/CDK2 
complex and sheds light into our effort to develop therapeutic strategy for breast 
cancer patients with high LMW-E expression levels. 
 
2.3n. High LMW-E expression is associated with activated b-Raf-ERK1/2-
mTOR pathway in vitro and in human tumor tissues 
 While it is widely accepted that the 3D culture system serves as a more 
physiologically relevant model for the investigation of cell behavior compared to 2D 
plastic surface (223, 228), no direct comparison between cells cultured on this 3D 
model and human samples has been performed. To provide such a comparison, we 
analyzed the protein expression of the TDCs grown on monolayer and Matrigel 
cultures as well as 276 breast cancer patient tissues by performing Reverse Phase 
Protein Array (RPPA) analysis (234). The RPPA method is a proteomic protein 
expression analysis that has been shown to be highly reproducible in analyzing the 
expression patterns of proteins involved in cell signaling (16, 234, 244). Hierarchical 
clustering was performed using Euclidean distance and Ward’s minimum variance 
for agglomeration (Figure 15A). The resulting heat map demonstrated that the cells 
from 2D and 3D cultures had strikingly different protein expression patterns and that 
the protein expression pattern of the cells from 3D cultures (mammary epithelial 
cells cultured in Matrigel) more closely resembled that of patient tissues than did the 
protein expression pattern of cells grown on monolayer. These results were 
expected since it is has been established that the 3D culture system is a more 
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FD Figure 15: High LMW-E expression is
associated with
activated b-Raf-
ERK1/2-mTOR
pathway in vitro and
in patient tissues. (A)
Hierarchal cluster
analysis of protein
expression in 76NE6,
76NE6-LMW-E and all
of the TDC clones
grown on 2D (red) and
3D (green) cultures
and 276 breast cancer
patient samples (blue).
Unsupervised
clustering of the top 50
proteins separated by
low versus high EL (B)
and LMW-E (C)
expression. (Red:
patients with low cyclin
E expression; blue:
patients with
E
prognosis. (E) The lysates from 3D
culture were subjected to Western blot
analysis to validate the RPPA data. The
cell lines are 76NE6-parental (P) and
with stable expression of vector (V), EL,
and LMW-E and the tumor-derived cells
(TDCs). (F) Linear regression analysis
between the RPPA data and the
densitometry values from Western blot
analysis of the proteins from (E).
associated with high
LMW-E levels. Red
indicates that high LMW-
E along with high protein
expression was
associated with poor
prognosis; grey indicates
that high LMW-E along
with low protein
expression was
associated with poor
high cyclin E
expression.) (D)
Proteins whose
expression was
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physiologically relevant model than cell culture on a 2D plastic surface for the 
investigation of cell behavior (223, 228). Furthermore, in an unsupervised analysis 
of the patient RPPA data, we observed separate clustering between the low and 
high LMW-E-expressing breast tumors but not between low and high full-length 
cyclin E (Figure 15B & C). 
 We next identified the proteins whose expression was significantly 
associated with LMW-E levels as well as patient survival in the tumor database. Our 
analysis revealed that in the breast cancer patient samples with high LMW-E 
expression, the b-Raf-ERK1/2-mTOR pathway was also activated (Figure 15D). 
Furthermore, Western blot analysis of the lysates from the TDCs grown on Matrigel 
showed high concordance with the RPPA data and also validated the activation of 
this signaling axis in vitro: (Figure 15E & F). Additionally, breast cancer patient 
tumors with high LMW-E expression also expressed high levels of b-Raf, pMEK1/2 
(S217), ERK2, mTOR, and eIF4E and a low level of pAkt (T308) while those with 
high EL expression only showed significant difference in the expression of b-Raf, 
mTOR, and eIF4E (Table 8). Collectively, these data suggested that in terms of 
proteomic expression patterns, breast cancer cells grown in 3D culture more closely 
resemble human tumors than do breast cancer cells grown in 2D culture and that 
3D culture thereby facilitates the identification of signaling events that correlate with 
LMW-E levels. 
 
2.3o. Combination drug treatment prevents induction of aberrant acinar 
development by LMW-E 
 Having established the importance of CDK2-associated kinase activity in 
aberrant acinar morphogenesis in 3D culture and given that the b-Raf-ERK1/2-
mTOR signaling axis was deregulated in tumor cells and patient samples with high 
LMW-E expression, we hypothesized that combination treatment with roscovitine (a 
CDK inhibitor) plus either rapamycin (an mTOR inhibitor) or sorafenib (a pan kinase 
inhibitor that has activity against b-Raf) normalizes acinar morphology. Combination 
treatments of cells cultured in Matrigel using these agents resulted in a larger 
reduction of the levels of pS6 (S235/236), pERK1/2 (T202/Y204), and pRb 
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Table 8. Pa$ent protein expression based on low and high LMW‐E and 
EL levels by RPPA analysis 
* Wilcoxon ranksum test 
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(S807/811) than no treatment or treatment with single agents (Figure 16A). 
Moreover, the combination treatments upregulated the expression of the CDK 
inhibitors p21 and p27, consistent with a cell cycle arrest at the G1/S phase (data 
not shown). Examination of the acinar formation as a result of the combination drug 
treatments revealed that the TDCs displayed a significant reduction in acinar size 
and Ki67 levels compared to the untreated cells and cells treated with single agents 
(p < 0.05) (Figure 16B-D). More specifically, both combination drug treatment 
conditions led to a 2-fold reduction in both acinar size and the number of Ki67-
positive acini compared to the single agent conditions (Figure 16C & D). In contrast, 
the 76NE6-vector and 76NE6-EL cells displayed no change in these phenotypes in 
response to the drug treatments, suggesting that the absence of LMW-E expression 
may protect these cells from the toxic effects of the drugs. Thus, roscovitine in 
combination with either rapamycin or sorafenib can prevent the development of the 
aberrant acinar phenotypes caused by LMW-E expression, confirming a role for 
LMW-E/CDK2 kinase activity in causing formation of large, multilobular acini and 
demonstrating a potential therapeutic approach to treat cancer patients with high 
LMW-E expression. 
 
2.3p. Activated b-Raf-ERK1/2-mTOR signaling pathway and high LMW-E 
expression predict poor survival 
 In a large retrospective clinical study, we previously found that breast cancer 
patients whose tumors had high levels of LMW-E expression, as determined by 
Western blot analysis, have significantly worse DSS than patients whose tumors 
had low LMW-E expression (160). In the study reported herein, we used tissue 
samples from a portion of this patient cohort for RPPA analysis to investigate large-
scale protein expression pattern. Similar to our previous observation, we found that 
patients with high LMW-E protein levels had significantly worse DSS than patients 
with low LMW-E expression (p<0.0001) (Figure 17A). More specifically, patients 
with high LMW-E and low full-length cyclin E expression demonstrated significantly 
worse DSS compared to patients with high LMW-E and also high full-length cyclin E 
(p=0.004). Bivariate analysis of LMW-E along with key nodes in the b-Raf-ERK1/2-
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Figure 16: Combination drug treatment prevents induction of aberrant acinar
development by LMW-E. (A) Cells were seeded on Matrigel for 24 hours and then
treated with rapamycin, sorafenib, and roscovitine as indicated. Medium containing
drugs was replaced every 4 days, and lysates were collected on day 15 for
Western blot analysis with the indicated antibodies. (B) On day 15 of Matrigel
culture, cells grown as in (A) were fixed and stained with E-cadherin (red) and Ki67
(green), and nuclei were counterstained with DAPI (blue). Scale bar = 50 µm. (C)
The diameters of the acini were measured and averaged from three independent
experiments. Error bars = SEM (Student t test, *p<0.05). (D) The number of Ki67-
positive cells per acinus was counted and averaged from three independent
experiments. Error bars = SEM (Student t test, *p<0.05).
86
Figure 17
0.
00
0.
25
0.
50
0.
75
1.
00
0 24 48 72 96 120
Low LMW/high full length (E/N =0/22)
Low LMW/low full length (E/N=5/92)
High LMW/high full length (E/N=10/33)
High LMW/low full length (E/N=81/129)
P<0.0001
A
p=0.3
p=0.007
p=0.004
Survival time (months)
D
is
ea
se
-s
pe
ci
fic
 s
ur
vi
va
l (
%
)
87
Figure 17
Su
rv
iv
al
 ti
m
e 
(m
on
th
s)
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 F
AK
 (E
/N
 =
4/
36
)
H
ig
h 
FA
K 
(E
/N
=6
/1
9)
P=
0.
01
9
H
ig
h 
fu
ll l
en
gt
h
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 F
AK
 (E
/N
 =
41
/8
6)
H
ig
h 
FA
K 
(E
/N
=5
0/
76
)
P=
0.
00
4
H
ig
h 
LM
W
-E
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 B
IM
 (E
/N
 =
5/
24
)
H
ig
h 
BI
M
 (E
/N
=5
/3
1)
P=
0.
6H
ig
h 
fu
ll l
en
gt
h
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 B
IM
 (E
/N
 =
45
/6
8)
H
ig
h 
BI
M
 (E
/N
=4
6/
94
)
P=
0.
01H
ig
h 
LM
W
-E
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 A
KT
 (E
/N
 =
4/
16
)
H
ig
h 
AK
T 
(E
/N
=6
/3
9)
P=
0.
5
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 A
KT
 (E
/N
 =
56
/7
9)
H
ig
h 
AK
T 
(E
/N
=3
5/
83
)
P=
0.
00
02
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 A
KT
(p
T3
08
) (
E/
N
 =
7/
27
)
H
ig
h 
AK
T(
pT
30
8 
(E
/N
=3
/2
8)
P=
0.
2
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 A
KT
(p
T3
08
) (
E/
N
 =
57
/9
0)
H
ig
h 
AK
T(
pT
30
8 
(E
/N
=3
4/
72
)
P=
0.
09
B
88
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 B
IM
/lo
w
 A
KT
 (E
/N
 =
3/
9)
Lo
w
 B
IM
/h
ig
h 
AK
T 
 (E
/N
 =
2/
15
)
H
ig
h 
BI
M
/lo
w
 A
KT
 (E
/N
 =
1/
7)
H
ig
h 
BI
M
/h
ig
h 
AK
T 
 (E
/N
 =
4/
24
)
P=
0.
6
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 F
AK
/lo
w
 A
KT
 (E
/N
 =
1/
8)
Lo
w
 F
AK
/h
ig
h 
AK
T 
(E
/N
 =
3/
28
)
H
ig
h 
FA
K/
lo
w
 A
KT
 (E
/N
 =
3/
8)
H
ig
h 
FA
K/
hi
gh
 A
KT
 (E
/N
 =
3/
11
)
P=
0.
1
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 F
AK
/lo
w
 A
KT
(p
T3
08
) (
E/
N
 =
3/
17
)
Lo
w
 F
AK
/h
ig
h 
AK
T(
pT
30
8)
 (E
/N
 =
4/
10
)
H
ig
h 
FA
K/
lo
w
 A
KT
(p
T3
08
) (
E/
N
 =
1/
19
)
H
ig
h 
FA
K/
hi
gh
 A
KT
(p
T3
08
) (
E/
N
 =
2/
9)
P=
0.
05
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 B
IM
/lo
w
 A
KT
 (E
/N
 =
3/
9)
Lo
w
 B
IM
/h
ig
h 
AK
T 
 (E
/N
 =
2/
15
)
H
ig
h 
BI
M
/lo
w
 A
KT
 (E
/N
 =
1/
7)
H
ig
h 
BI
M
/h
ig
h 
AK
T 
 (E
/N
 =
4/
24
)
P=
0.
6
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 B
IM
/lo
w
 A
KT
(p
T3
08
) (
E/
N
 =
3/
8)
Lo
w
 B
IM
/h
ig
h 
AK
T(
pT
30
8)
 (E
/N
 =
2/
16
)
H
ig
h 
BI
M
/lo
w
 A
KT
(p
T3
08
) (
E/
N
 =
4/
19
)
H
ig
h 
BI
M
/h
ig
h 
AK
T(
pT
30
8)
 (E
/N
 =
1/
12
)
P=
0.
4
0.000.250.500.751.00
0
24
48
72
96
12
0
Lo
w
 A
KT
/lo
w
 A
KT
(p
T3
08
) (
E/
N
 =
3/
7)
Lo
w
 A
KT
/h
ig
h 
AK
T(
pT
30
8)
 (E
/N
 =
4/
20
)
H
ig
h 
AK
T/
lo
w
 A
KT
(p
T3
08
) (
E/
N
 =
1/
9)
H
ig
h 
AK
T/
hi
gh
 A
KT
(p
T3
08
) (
E/
N
 =
2/
19
)
P=
0.
3
H
ig
h 
EL
Su
rv
iv
al
 ti
m
e 
(m
on
th
s)
C
Figure 17
89
lo
w
 F
A
K
; l
ow
 B
IM
 (E
/N
 =
 1
9/
32
)
lo
w
 F
A
K
; h
ig
h 
B
IM
 (E
/N
 =
 2
2/
54
)
hi
gh
 F
A
K
; l
ow
 B
IM
 (E
/N
 =
 2
6/
36
)
hi
gh
 F
A
K
; h
ig
h 
B
IM
 (E
/N
 =
 2
4/
40
)
p 
= 
0.
00
36
lo
w
 F
A
K
; l
ow
 A
K
T 
(E
/N
 =
 2
1/
31
)
lo
w
 F
A
K
; h
ig
h 
A
K
T 
(E
/N
 =
 2
0/
55
)
hi
gh
 F
A
K
; l
ow
 A
K
T 
(E
/N
 =
 3
5/
48
)
hi
gh
 F
A
K
; h
ig
h 
A
K
T 
(E
/N
 =
 1
5/
28
)
p 
= 
4e
-0
4
lo
w
 F
A
K
; l
ow
 A
K
T 
(p
T3
08
) (
E
/N
 =
 2
2/
41
)
lo
w
 F
A
K
; h
ig
h 
A
K
T 
(p
T3
08
) (
E
/N
 =
 1
9/
45
)
hi
gh
 F
A
K
; l
ow
 A
K
T 
(p
T3
08
) (
E
/N
 =
 3
5/
49
)
hi
gh
 F
A
K
; h
ig
h 
A
K
T 
(p
T3
08
) (
E
/N
 =
 1
5/
27
)
p 
= 
0.
01
09
lo
w
 B
IM
; l
ow
 A
K
T 
(E
/N
 =
 2
6/
34
)
lo
w
 B
IM
; h
ig
h 
A
K
T 
(E
/N
 =
 1
9/
34
)
hi
gh
 B
IM
; l
ow
 A
K
T 
(E
/N
 =
 3
0/
45
)
hi
gh
 B
IM
; h
ig
h 
A
K
T 
(E
/N
 =
 1
6/
49
)
p 
= 
1e
-0
4
lo
w
 B
IM
; l
ow
 A
K
T 
(p
T3
08
) (
E
/N
 =
 2
4/
33
)
lo
w
 B
IM
; h
ig
h 
A
K
T 
(p
T3
08
) (
E
/N
 =
 2
1/
35
)
hi
gh
 B
IM
; l
ow
 A
K
T 
(p
T3
08
) (
E
/N
 =
 3
3/
57
)
hi
gh
 B
IM
; h
ig
h 
A
K
T 
(p
T3
08
) (
E
/N
 =
 1
3/
37
)
p 
= 
0.
01
61
lo
w
 A
K
T;
 lo
w
 A
K
T 
(p
T3
08
) (
E
/N
 =
 3
6/
46
)
lo
w
 A
K
T;
 h
ig
h 
A
K
T 
(p
T3
08
) (
E
/N
 =
 2
0/
33
)
hi
gh
 A
K
T;
 lo
w
 A
K
T 
(p
T3
08
) (
E
/N
 =
 2
1/
44
)
hi
gh
 A
K
T;
 h
ig
h 
A
K
T 
(p
T3
08
) (
E
/N
 =
 1
4/
39
)
p 
= 
4e
-0
4
Su
rv
iv
al
 ti
m
e 
(m
on
th
s)
Disease-specific survival (%)
H
ig
h 
LM
W
-E
D
Fi
gu
re
 1
7:
 A
ct
iv
at
ed
 b
-R
af
-
ER
K
1/
2-
m
TO
R
 s
ig
na
lin
g
pa
th
w
ay
 a
nd
 h
ig
h 
LM
W
-E
ex
pr
es
si
on
 p
re
di
ct
 p
oo
r
su
rv
iv
al
 in
 b
re
as
t c
an
ce
r
pa
tie
nt
s.
 (A
) K
ap
la
n-
M
ei
er
es
tim
at
es
 o
f d
is
ea
se
-s
pe
ci
fic
su
rv
iv
al
 b
as
ed
 o
n 
th
e
ex
pr
es
si
on
 o
f l
ow
 a
nd
 h
ig
h 
E
L
an
d 
LM
W
-E
 m
ea
su
re
d 
by
W
es
te
rn
 b
lo
t a
na
ly
si
s 
of
 2
76
br
ea
st
 c
an
ce
r p
at
ie
nt
 s
am
pl
es
.
(B
) B
iv
ar
ia
te
 a
na
ly
si
s 
of
 c
yc
lin
E
 p
ro
te
in
 le
ve
ls
 in
 a
ss
oc
ia
tio
n
w
ith
 F
A
K
, B
IM
, A
kt
 a
nd
 p
A
kt
(T
30
8)
 p
ro
te
in
 le
ve
ls
 o
bt
ai
ne
d
fro
m
 R
P
P
A
 a
na
ly
si
s.
 T
he
ex
pr
es
si
on
 le
ve
ls
 o
f F
A
K
, B
IM
,
A
kt
 a
nd
 p
A
kt
 (T
30
8)
 w
er
e
di
ch
ot
om
iz
ed
 u
si
ng
 th
ei
r
m
ed
ia
n 
va
lu
es
 fr
om
 a
ll 
27
6
pa
tie
nt
 s
am
pl
es
. (
C
 &
 D
)
M
ul
tiv
ar
ia
te
 a
na
ly
si
s 
w
as
pe
rfo
rm
ed
 b
y 
in
cl
ud
in
g 
on
ly
th
os
e 
pa
tie
nt
s 
w
ith
 h
ig
h 
E
L 
(C
)
an
d 
LM
W
-E
 (D
) e
xp
re
ss
io
n 
an
d
ex
am
in
in
g 
LM
W
-E
 e
xp
re
ss
io
n
al
on
g 
w
ith
 th
e 
ex
pr
es
si
on
 o
f
FA
K
, B
IM
, A
kt
, a
nd
 p
A
kt
 (T
30
8)
le
ve
ls
.  
A
ll 
p 
va
lu
es
 a
re
 b
as
ed
on
 lo
g-
ra
nk
 te
st
.
90
mTOR pathway revealed that among breast cancer patients with high LMW-E 
expression, those with high FAK levels had significantly worse DSS than those with 
low FAK levels (p=0.0042) (Figure 17B). In contrast, among patients with high 
LMW-E expression, low BIM or low total Akt levels was associated with worse 
survival. Additionally, the overall DSS of patients with high LMW-E combined with 
these proteins in the b-Raf-ERK1/2-mTOR pathway was dramatically worse than in 
the patients with high full-length cyclin E expression (Figure 17B). 
To determine whether these individual proteins collaborate to reduce patient 
survival, we performed multivariate analysis by analyzing patients with high LMW-E 
expression and combining 2 additional proteins. We found that patients with high 
LMW-E, high FAK, and low BIM, Akt, or pAkt (T308) experienced significantly worse 
DSS than the other groups (p<0.05) (Figure 17D). In addition, patients with high 
LMW-E, low BIM, and low Akt or pAkt (T308) experienced significantly worse DSS 
(p<0.05). Interestingly, we were not able to find statistical significance between full-
length cyclin E expression in the same multivariate analysis with these proteins 
(Figure 17C). Essentially, our statistical analysis suggests that it is likely that LMW-
E, FAK, BIM, Akt, and pAkt (T308) function in the same pathway to adversely affect 
patient survival in breast cancer. 
 
2.4. CONCLUSIONS  
 The extracellular matrix provides environmental cues that induce differentiation 
and senescence of normal epithelial cells, and this response is lost when a cell 
transforms into a cancer cell. The acinar morphogenesis assay is an in vitro model 
system that can clearly distinguish the difference in growth behavior between 
normal epithelial cells and tumor cells (224, 232). The results from this study 
demonstrate that immortalized hMECs growth arrest and form differentiated and 
polarized acinar structures in laminin rich basement membrane while breast cancer 
cell lines fail to exhibit these behaviors. The morphological difference between 
normal and cancer cells displayed on Matrigel culture is because signaling from the 
extracellular matrix greatly influences the progression of the cell cycle intracellularly. 
Previous studies have demonstrated that malignant breast cancer cells express 
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high levels of β1-integrin receptor and exhibit disorganized distribution of the 
receptor in the acinar structures (245). Treatment of these structures with a blocking 
b1-integrin antibody reverts the aberrant morphologies, downregulates cyclin D 
expression while upregulating p21Cip1 levels (245). Therefore, cell cycle regulation is 
critical for the maintenance of the integrity of the differentiation state of the cells and 
tissue. Without this regulation, the cells ignore the signals provided from the 
surrounding and become highly proliferative and cancerous. The difference in 
cellular proliferation is observed in cells cultured on monolayer and 3D matrix. 
Immortalized hMECs (76NE6, 76NF2V, and MCF-10A) exhibited growth arrest 
when cultured on 3D Matrigel compared with those cultured on monolayer.  
 High rate of proliferation resulting from deregulated G1-S phase transition 
mediated by overactive LMW-E/CDK2 complex is morphologically distinguishable 
during acinar morphogenesis. This uncontrolled proliferation is apparent by high 
Ki67 staining in the matrix-attached cells of the LMW-E-expressing acini but not in 
EL and vector control acini. The highly proliferative luminal cells may also explain 
the large and non-spherical acinar structures since coordination of cellular arrest 
and differentiation is lost. In addition to hyperactive proliferation, the LMW-E-
expressing acini also downregulate bim indicating failure of the central cells to 
undergo apoptosis thus leaving a filled lumen (243). Elevated proliferation and 
reduced apoptosis observed in the acinar structures may explain the ability of LMW-
E to induce tumor growth in the mouse mammary fat pad.  
 While the cyclin E/CDK2 complex is the accelerator of the G1-S checkpoint, 
p53 is the brake. Acting as a tumor suppressor, one of the major functions of p53 is 
to activate p21Cip1 transcription in response to DNA damage, which in turn inhibits 
the cyclin E/CDK2 complex (246). The molecular link between cyclin E 
overexpression and loss of p53 control in breast cancer has been suggested in a 
number of reports. In one study, 56% of breast cancer patients with high cyclin E 
content were found to also possess p53 gene mutations (242). Furthermore, in our 
transgenic mouse model, overexpression of LMW-E is sufficient to induce 
mammary adenocarcinomas with 25% of the tumors advancing to metastasis (180). 
Moreover, these mice were found to select for loss of heterozygosity (LOH) of p53 
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and spontaneous inactivation of the ARF-p53 pathway. The aberrant acinar 
phenotypes induced by LMW-E worsen with loss of p53 expression. Therefore, the 
counterbalance between LMW-E and p53 has biochemical and functional 
implications in normal mammary acinar development, and deregulation of this 
process could act as the first step of derailment into malignancy. 
 Elafin is an elastase inhibitor and thus can prevent the generation of LMW-E. 
We recently reported that elafin is transcriptionally down regulated in most tumor 
cell lines, rendering the generation of LMW-E in tumor but not in normal cells (210). 
Ectopic elafin expression is able to some extent induce MDA-MB-231 cells to form 
spherical structure from single cell morphology. Furthermore, results from the 
xenograft study suggest that perhaps LMW-E-mediated tumorigenesis is due to 
elafin downregulation since the in vivo passaged tumors exhibit high LMW-E 
expression and suppressed elafin protein level. Research from our lab indicate that 
elafin is upregulated upon growth factor starvation or basement membrane 
detachment to elicit cell cycle arrest and or apoptosis, depending on the cell’s pRb 
status. While the mechanism of elafin transcriptional downregulation remains to be 
elucidated, it is possible that loss of elastase inhibition mediated by elafin is 
responsible for the high levels of LMW-E in the xenograft tumors.  
 LMW-E is necessary and sufficient for growth of cancer cells in vivo. Xenograft 
transplantation experiment indicates that 74% of injection of hMECs expressing 
LMW-E led to tumor development whereas the percentage of tumor formation with 
injection of EL-expressing hMECs was 10 folds lower. This observation is consistent 
with previous study using transgenic mouse model to illustrate that LMW-E is a 
stronger oncogene than EL (180). Moreover, LMW-E expression is selected with 
increasing passaging of the tumor cells through the mice suggesting that LMW-E 
provides advantageous growth and survival for the tumor. With each generation of 
passaging, the LMW-E-expressing tumors developed at higher efficiency compared 
to the first generation. The microenvironment can exert selective pressure to induce 
genetic and epigenetic changes to favor progression of the tumor (247). 
 Our previous studies showed that LMW-E isoforms form tighter complexes 
with CDK2 compared to EL isoform and thereby exhibit higher kinase activity (175, 
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221). Furthermore, the LMW-E/CDK2 complexes are significantly more resistant to 
inhibition by p21 and p27 over EL/CDK2 complexes (175). Alteration in the 
interaction with CDK2 and inhibitory response to CKIs explains the difference in the 
oncogenicity between EL and LMW-E isoforms described in this report. 
Interestingly, the oncogenicity of LMW-E and formation of multiacinar complexes 
are strictly dependent on CDK2 kinase activity suggesting that perhaps unbound 
LMW-E exhibits no oncogenic activity. Therefore, CDK2 kinase activity presents as 
an ideal target to treat patients with high LMW-E expression. Roscovitine treatment 
can rescue the formation of large and multi-acinar complexes induced by LMW-E 
while showing no toxic effects on parental control acini. In the literature, roscovitine 
has proven to be an effective therapeutic agent in targeting numerous types of 
tumor cells including breast cancer, non-small cell lung cancer, sarcoma, multiple 
myeloma and lymphoma (173, 178, 198, 248, 249). Since the tumorigenic activity of 
LMW-E strongly depends on CDK-associated kinase activity, roscovitine becomes 
an apparent choice for designing therapeutic strategies for cancer patients with high 
LMW-E expression. The fact that LMW-E requires CDK2 kinase activity to drive 
multiacinar complexes and promote tumor-initiating activity of hMECs in mice 
suggests that LMW-E itself has no intrinsic oncogenic activity. Therefore, treatment 
of tumors with high LMW-E protein levels can be achieved by inhibiting CDK2 
kinase activity. Our data demonstrate that combination treatment using roscovitine 
together with rapamycin or sorafenib of LMW-E-expressing acini efficiently prevents 
the aberrant morphogenetic phenotypes without toxic effects on hMECs lacking 
LMW-E expression. 
 The results from proteomic analysis demonstrated a marked contrast in the 
protein expression profiles of cells grown on monolayer and cells grown in 3D 
culture and illustrated a high similarity between cells in 3D culture and human tumor 
tissues, thus establishing a bridge between the 3D culture system and human 
tissues and further supporting the use of this culture system for biological study 
(250). In fact, gene expression signatures of mammary cells extracted from this 3D 
culture system can be reliably used to predict patient outcome in which the 
signature of growth-arrested and well-organized hMECs predicts favorable clinical 
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outcome (229, 251). Data from this analysis also allowed for the delineation of a 
signaling pathway that is deregulated in breast cancer patients who express high 
LMW-E levels. We demonstrated that tumors and cell lines with high LMW-E 
expression have upregulated b-Raf-ERK1/2-mTOR signaling, which has been 
reported to result in enhanced cell survival and reduced apoptosis (252-254). 
 In this chapter, multiple experimental systems were employed to explore the 
role of LMW-E with CDK2 in tumorigenesis. The results obtained indicate that LMW-
E induces aberrant acinar morphologies and is clearly a much stronger oncogene 
compared to EL. More importantly, these oncogenic phenotypes mediated by LMW-
E are dependent on its ability to interact with CDK2 to exert its kinase activity. 
Furthermore, proteomic analysis also identifies a signaling pathway involving raf-
ERK1/2-mTOR that is activated in tumor cells with high LMW-E expression and 
associate with poor patient outcome. Clinically, there is a high percentage of breast 
cancer patients whose expression of LMW-E significantly predicts poor prognosis 
and adverse clinical outcomes (160). Our data suggest that the combination of 
roscovitine with either rapamycin or sorafenib should be evaluated as a therapeutic 
strategy to treat breast cancer patients with high LMW-E expression. 
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CHAPTER 3: LMW-E INDUCES THE EMT AND ENRICHES FOR CELLS WITH 
CSC PROPERTIES  
 
3.1. INTRODUCTION 
3.1a. The cancer stem cell (CSC) theory 
 Cancer is a multi-step heterogeneous disease caused by accumulation of 
genetic and epigenetic alterations that lead to uncontrolled growth of normal cells. 
This theory is supported by epidemiological data demonstrating that breast cancer 
development occurs many years after the actual oncogenic event (255, 256). 
Indeed, stem cells or progenitor cells are believed to be more susceptible to these 
alterations since they endure longer lifespan and thus are able to gain sufficient 
mutations to initiate and sustain tumor development (257). However, recent 
research in this field suggests that CSCs can in fact arise from a differentiated cell 
of origin.  
 The CSC theory states that there is a small population of cells within the 
tumor mass that possess unique properties shared by stem cells such as self-
renewal capacity, multi-potency, and unlimited proliferation (257, 258). More 
specifically, CSCs have the ability to proliferate extensively and give rise to diverse 
cell types with reduced development or proliferation potential. Recent research 
presents vast evidence supporting the existence of CSCs in both hematological 
cancers as well as solid tumors (259-269). The Hierarchy stem cell model states 
that there are different subpopulations of cells within the tumor mass that possess 
different capabilities of self-renewal and differentiation (Figure 18A) (257, 260). This 
model emphasizes that only a small definable subset of tumor cells has the 
potential to initiate tumor growth and reproduce the hierarchy of cells that comprise 
the tumor. Indeed, numerous studies reported that many tumors are heterogeneous 
and contain many cell types thus suggesting that the few CSCs are multi-potent 
(270-274). In contrast, the Stochastic model predicts that the process of each 
individual cell within a tumor to self-renew and differentiate occurs randomly and 
can be predicted by statistics (Figure 18B) (257, 258, 275). This model maintains 
that the tumor is composed of a homogeneous population of cells and every cell 
96
CSC
CSC
CSC
CSC
HIERARCHY MODEL
STOCHASTIC MODEL
A
B
Figure 18: CSC models. (A) In the Hierarchy model, only a small subset of cells
termed CSCs (red cells) are capable of self-renewal and form new tumors. The
more differentiated cells do not possess self-renewal capability (blue cells), cannot
form new tumors, and eventually reach terminal differentiation. (B) The Stochastic
model argues that the tumor is composed of a homogenous population and every
cell in the tumor has an equal but small chance to self-renew and form new tumors.
Adapted from Nature 2001;414(6859):105-11.
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has a low but equal chance of acquiring tumorigenic potential. Clonal outgrowth of 
an individual cell due to genetic/epigenetic insult leads to selection and 
accumulation of this dominant population that then forms the bulk of the tumor 
(276). Currently there is no clear evidence that is sufficient to distinguish between 
these two models suggesting that they are not mutually exclusive. While the 
discussion on the origin of tumor cells and how to appropriately define these cells is 
ongoing, research in the last few years have further strengthen the fact that these 
CSCs are important in tumor initiation, maintenance, metastasis, and resistance to 
therapy.   
 
3.1b. Molecular markers of mammary CSCs 
 CSCs are not only present in hematological cancers but are also identified in 
numerous solid tumors, most notably in breast cancer (263). Accumulating evidence 
from a number of publications indicate that mammary CSCs can be identified and 
isolated based on their expression for the CD44hi/CD24lo surface markers, aldehyde 
dehydrogenase (ALDH) enzymatic activity, and the ability to form tumors at low cell 
numbers and mammospheres in low attachment and non-differentiating culture 
conditions (263, 277, 278). Early work by Al-Hajj and colleagues demonstrated that 
as few as 100 primary breast cancer cells that are defined by the CD44hi/CD24lo cell 
surface expression pattern can form tumors when injected into the mammary fat 
pad of nude mice and also can be serially passaged while tens of thousands of cells 
with the CD44hi/CD24hi phenotype cannot (263). Particularly, the in vivo passaged 
tumors from the second and third generations display similar population distribution 
as the original tumor suggesting that the CD44hi/CD24lo population possess self-
renewal capability as well as the ability to differentiate into non-CSCs.  
 Although, as of yet, there are no functions associated with this cell surface 
marker, CD44hi/CD24lo cells are able to form mammosphere structures under non-
adherent and non-differentiating culture condition, which is a functional test that has 
been reliably employed to investigate the self-renewal and differentiation capability 
of neuronal stem cells (279). While epithelial cells require basement attachment for 
survival and proliferation, Dontu and colleagues demonstrated that a single 
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mammary progenitor cell is able to proliferate and differentiate to form a floating 
mammosphere when cultured on non-adhesive substratum (277). Furthermore, 
mammospheres contain undifferentiated cells that are able to give rise to the 3 
types of cells in the mammary gland, which are myoepithelial, ductal, and alveolar 
(luminal) epithelial cells (Figure1). Breast cancer cells grown in mammosphere 
culture condition exhibit increased tumorigenicity and downregulate CD24 
expression, and these phenotypes can be reversed with passage in monolayer 
culture (280, 281).  
 Another functional marker identified to be associated with CSC is ALDH, 
which is a detoxifying enzyme that has been shown to be involved in early 
differentiation of stem cells by oxidizing retinol to retinoic acid (282) and is believed 
to mediate self-protection against some alkylating chemotherapeutic agents (283). 
Similar to the CD44hi/CD24lo cells, sorted ALDHhi cells injected into xenograft 
mouse model are capable of recapitulating the phenotypic distribution of the original 
tumor (278). Although there is a small percentage of CD44hi/CD24lo cells that are 
also ALDHhi (approximately 1% of the tumor population), as few as 20 cells with the 
CD44hi/CD24lo/ALDHhi phenotype are able to generate tumors in mice, which are 5 
folds more tumorigenic compared to the CD44hi/CD24lo population alone (278). 
Clinically, breast cancer patients whose tumors contain high ALDH expression are 
predicted to have poor clinical outcome (278, 284). Overall, the identification of 
these CSC markers have greatly facilitated our understanding of mammary tumor 
biology and allowed for examination into the mechanism of drug resistance and 
tumor relapse. 
 
3.1c. The EMT connection to CSCs 
 The cells defined by the CD44hi/CD24lo antigenic phenotype are enriched in 
tumor-initiating cells, exhibit enhanced tumor invasiveness, and can be generated 
through induction of the EMT (263, 285, 286). Mani and colleagues first reported 
that induction of the EMT by ectopic expression of twist, TGFβ1 or snail results in 
an enrichment of the CD44hi/CD24lo population, mammosphere formation, and 
tumorigenicity in hMECs (285). EMT is a developmental process in which epithelial 
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cells gain mesenchymal phenotypes and behaviors such as increased motility and 
invasion to allow formation of new tissues and organs (287). However, aberrant 
induction of the EMT in tumor cells is known to enhance proliferation and invasion 
(288). Indeed, acquisition of the EMT traits is thought to aid tumor cells to invade 
and migrate to form metastasis at distant organ and the reverse process termed 
mesenchymal-epithelial transition (MET) is necessary for successful colonization at 
the new tumor location.  
 
3.1d. LMW-E associates with basal-like breast cancer 
 Analysis of the breast cancer subtypes indicated that the CD44hi/CD24lo cell 
population is enriched in the basal-like breast tumors, which are clinically 
associated with poor prognosis (289, 290). The basal-like subtype of breast cancer 
was first defined by gene expression microarrays to be negative for ER, PR, and 
HER2, and positive for cytokeratin 5/6 and EGFR (10). Interestingly, the mammary 
tumors formed from overexpression of LMW-E also assume the basal-like 
phenotypes and resemble the morphological characteristics of the tumors caused 
by deregulation of the Wnt pathway, which are acinar, glandular, papillary, solid, 
and adenosquamous (180, 291). Rosner and colleagues demonstrated that the 
phenotypes of the tumors often predict the genotypes signifying that tumors that 
share the same morphological characteristics are predicted to exhibit deregulation 
to the same pathway (292). Recent analysis of our breast cancer patient samples 
further indicated that of the LMW-E-expressing tumors, triple negative (TN) tumors 
(negative receptor status for ER, PR, and HER2) expressed dramatically higher 
levels of LMW-E than other tumors with at least one positive receptor, and these TN 
patients are significantly more likely to experience tumor recurrence (p = 0.045). 
Given that the mammary tumors formed from ectopic expression of LMW-E assume 
the basal-like phenotypes and LMW-E expression is high in TN breast cancer 
patients, we speculate that the mechanism that specifically allows LMW-E to initiate 
and maintain breast cancer is through activation of the EMT as well as acquisition of 
mammary CSC characteristics.  
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3.1e. Anti-CSC therapy 
 Most chemotherapeutic agents are designed to target highly proliferative 
cells, which typically form the bulk of the tumor. CSCs however exhibit low 
proliferation index, and consequently they are resistant to many current cancer 
treatments including chemo- and radiation therapy (293, 294). More specifically, the 
CD44hi/CD24lo population was reported to be enriched in the tumor mass after 
chemotherapy and these cells demonstrate enhanced mammosphere formation 
efficiency (295). The CSCs that remain after therapy are capable of regenerating a 
new tumor thereby leading to tumor relapse. In addition, CSCs express high levels 
of the multi-drug resistance proteins and the ATP-binding cassette (ABC) 
transporter family, which function by pumping chemotherapeutic agents out of the 
cell (296).  
 The overwhelming evidence supporting the existence of CSCs suggests that 
our conventional therapeutic approaches would only target the non-CSCs that make 
up the bulk of the tumor but spare the CSCs that are capable of regenerating the 
tumor post-treatment. As a result, we need to improve our therapeutic strategy by 
specifically targeting these CSCs in addition to eradicating the non-CSCs. A rational 
strategy to overcome this challenge is to combine agents that can target both the 
CSC and non-CSC populations. Recently, a large screen for small compounds that 
can specifically target the CSC population revealed that salinomycin, an 
antibacterial drug, exerts highly specific toxicity against CD44hi/CD24lo cells 
compared to paclitaxel (297). Therefore, combination of this agent with a general 
chemotherapeutic agent such as doxorubicin, which can kill proliferating non-CSCs, 
will likely to result in complete remission. 
 
3.1f. Hypothesis and Specific Aims 
 Initiation and maintenance of cancer depends on a strong oncogene that can 
elicit multiple downstream effects to convert a normal cell to a tumor cell. We 
believe that the tumorigenicity of LMW-E is mediated through induction of the EMT 
that leads to enrichment of the CSC population, and these tumor cells can be 
effectively targeted with combination treatment using doxorubicin and salinomycin. 
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Additionally, the ProtoArray microarray analysis, which will be discussed in greater 
details in the Results section, will be used to identify novel substrate(s) of the LMW-
E/CDK2 complex that will allow for elucidation into the mechanism of LMW-E-
mediated mammary tumorigenesis. The following specific aims are designed to 
address this hypothesis:  
1. Understand the role of LMW-E in the induction of the EMT 
2. Analyze the CSC properties of cells induced with LMW-E expression  
3. Identify a therapeutic regimen to target the LMW-E-induced CSCs 
4. Identify novel LMW-E/CDK2-associated substrates and/or interacting 
proteins 
 Briefly, the tumor-derived cells (TDCs) isolated from in vivo passaging 
exhibited phenotypes characteristic of the EMT, which are reduced cell-cell contact 
by downregulation of E-cadherin, upregulated gene expression profile associated 
with the EMT, and enhanced basement membrane invasion. Moreover, the LMW-E-
expressing tumor cells demonstrated an increase in the CD44hi/CD24lo population, 
and examination of patient tumor samples indicated that cytoplasmic cyclin E IHC 
staining significantly associate with high CD44hi/CD24lo score compared to nuclear 
cyclin E staining (p = 0.0435). Further analysis for the CSC characteristics revealed 
that the TDCs possess self-renewal capability by forming mammosphere structures 
and also upregulated ALDH expression and enzymatic activity. Combination drug 
treatment with doxorubicin and salinomycin reduced the CSC population and 
synergistically killed the CSCs while sparing normal cells that do not express LMW-
E. Finally, ProtoArray analysis revealed that LMW-E/CDK2 phosphorylates Hbo1 in 
the N-terminal domain, which demonstrated no effects on the in vitro histone 
acetyltransferase activity of Hbo1. Co-expression of LMW-E/CDK2 with Hbo1 in 
HEK293T resulted in an enrichment of cells with CSC properties and knockdown of 
Hbo1 in the TDCs reduced these properties. Taken together, these data suggest 
that Hbo1 is downstream of LMW-E/CDK2 overactive kinase activity, and increased 
Hbo1’s HAT activity may be critical for the CSC phenotypes observed. 
 
3.2. MATERIALS and METHODS 
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3.2a. General reagents 
 Antibodies used for western blot analysis are: E-cadherin and ALDH (BD 
Bioscienes, Sparks, MD), CDK2 and CD24 (Santa Cruz Biotechnology Santa Cruz, 
CA), CD44 (Cambridge, MA), Hbo1 (Proteintech Group, Chicago, IL), FLAG-tag 
(Sigma, St. Louis, MO), Myc-tag (Cell Signaling Technology, Boston, MA).  
 
3.2b. Brightfield and indirect immunofluorescence analysis 
 Cells grown on tissue culture dish were photographed using the Leica DM 
4000M microscope (Buffalo Grove, IL) at 5X objective with an attached digital 
camera, and images were processed with the Photoshop software (Version 11.0.2). 
Indirect immunofluorescence analysis was performed as described in chapter II with 
minor modifications. Cells were grown directly on the 8-chamber slides for 
monolayer culture and the E-cadherin primary antibody (BD) was incubated in IF 
buffer at 1:200 dilution overnight at 4°C. The cells were incubated with Alexa fluor-
conjugated mouse secondary antibodies (Molecular Probes, Carlsbad, California), 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO) for 
15 min at RT, and mounted with antifade solution (Molecular Probes). Confocal 
analyses were performed using the Olympus FV300 laser scanning confocal 
microscope (Olympus America, Inc., Center Valley, PA) using the exact same 
setting for all samples.  
 
3.2c. Transwell invasion assay 
 For each sample, 100 µl of 1 mg/ml Matrigel in serum free-cold MEM media 
was aliquoted into the upper chamber of 24-well transwell plate (Corning, Corning, 
NY) and incubated at 37oC for at least 4-5 hours for adequate gelling. The cells 
were washed and suspended in serum free medium at a 1x106 cells/ml 
concentration. One hundred µl of cell suspension was transferred onto the upper 
chamber containing the Matrigel layer. The lower chamber of the transwell was filled 
with 600 µl of complete media containing 10 µg/ml fibronectin as an adhesive 
substrate. After 24 hours, the cells were fixed with 4% formaldehyde for 15 minutes, 
rinsed with PBS, and stained with 0.2% crystal violet for 10 minutes. The crystal 
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violet was rinsed with excess ddH2O and the top chamber containing the Matrigel 
was thoroughly cleansed with Q-tips and the invaded cells were photographed with 
a light microscope. For quantification, the cells on the top and bottom of the 
chamber are collected using trypsin and counted using the culture counter. Each 
sample was counted 3 times and each experiment was repeated independently 3 
times.  
 
3.2d. Quantitative RT-PCR analysis 
 Total RNA was isolated from cell culture with TRIzol reagent according to the 
manufacture's protocol (Invitrogen). After treatment with DNase I (NEB, Ipswich, 
MA), 1 µg of the RNA samples was reverse-transcribed using Transcriptor First 
Strand cDNA Synthesis Kit (Roche, Branford, CT) with the control reactions 
excluding reverse transcriptase. Realtime PCR was done with aliquots of the cDNA 
samples mixed with SYBR Green Master Mix (Sigma). The primer sequences were: 
cyclin E forward 5'-TGTGTCCTGGATGTTGACTG-3', reverse 5'-
CAAGCTGTCTCTGTGGGTCT-3’; E-cadherin forward 5’-
TGCCCAGAAAATGAAAAAGG, reverse 3’-GTGTATGTGGCAATGCGTTC; N-
cadherin forward 5’-ACAGTGGCCACCTACAAAGG, reverse 3’-
CCGAGATGGGGTTGATAATG; Twist forward 5’-GGAGTCCGCAGTCTTACGAG, 
reverse 3’-TCTGGAGGACCTGGTAGAGG; Slug forward 5’-
GGGGAGAAGCCTTTTTCTTG, reverse 3’-TCCTCATGTTTGTGCAGGAG; 
Vimentin forward 5’-GAGAACTTTGCCGTTGAAGC, reverse 3’-
GCTTCCTGTAGGTGGCAATC; and GAPDH forward 5’-
ACCCAGAAGACTGTGGATGG-3’, reverse 5’-CTGGACTGGACGGCAGATCT-3’; 
 
3.2e. CD24/CD44 FACS analysis 
 To perform doublestaining of the cell surface markers, 500,000 cells were 
washed 3 times with PBS containing 1% horse serum and resuspended with 10 µl 
PE anti-mouse CD24, 10 µl APC anti-mouse CD44 (BD Pharmingen, San Jose, CA, 
USA) and 30 µl of the 1% serum PBS buffer. The samples were incubated for 20 
minutes on ice, washed with 1% serum PBS buffer, analyzed with the FACS 
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Calibur, and the data was analyzed by the Flowjo software (version 8.8.6) (Tree 
Star, Inc., Ashland, OR). Cells only and single antibody label were used to set up 
the gates for analysis. For cell sorting experiments, antibody staining was 
performed similarly but under sterile condition and sorted using the FACSAria cell 
sorter (BD, Franklin Lakes, NJ). 
 
3.2f. Study patients, Western blot analysis, and immunohistochemical 
staining 
 The target population for the study is women with a diagnosis of invasive 
breast cancer stages I, II and III who are scheduled for surgery to remove the breast 
cancer with axillary lymph node dissection or sentinel lymph node dissection. IHC 
analyses of Cyclin E and CDK2 will be performed using available paraffin-
embedded tumor specimens from residual tissue prepared and archived by the 
MDACC Institutional Tissue Bank per the standard procedure for surgical cases. 
Results of the IHC analyses compared with results previously obtained by Western 
Blot analysis of freshly resected surgical tissue. 
 Lysates were prepared from freshly resected surgical tissues as described 
previously (165,228) and subjected to Western blot analysis using cyclin E 
monoclonal antibody HE12 from Santa Cruz Biotechnology (Santa Cruz, CA). 
Densitometry of the Western blots were measured using the IP-Lab Gel software 
(Scanalytics) and normalized to β-actin protein levels. Full-length, LMW-E, and total 
cyclin E densitometric values were separated into low (less than or equal to normal 
tissues) and high groups (higher than the levels found in normal tissues). 
 Tumor tissues from 118 breast cancer patients were subjected to double IHC 
staining with antibodies to CD24 (Clone SN3b, 1:400) and CD44 (Clone 156-3C11, 
1:800) from Neomarkers (Thermo Fisher, Fremont, CA). Briefly, sections were 
deparaffinized in xylene, rehydrated in ethanol, antigen retrieval in Tris-
ethylenediamine tetraacetic acid buffer (pH 9.0) at 125oC for 5 minutes. The DAKO 
EnVision G2 Doublestain System Rabbit/Mouse (diaminobenzidene 
(DAB+)/Permanent Red) kit was used for detection of CD44 and CD24. CD44 was 
detected with Permanent Red and CD24 was detected using DAB. In general, 
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CD24 staining was detected mainly in the cytoplasm and CD44 staining was mainly 
in the membrane as noted previously (289). Scoring was done blindly by 2 
investigators blinded to patient annotation and the percentage of CD44hi/CD24lo 
tumor cells were scored as follows: 0 (0%), 1 (1-10%), 2 (11-25%), 3 (26-50%), 4 
(51-75%), 5 (76-100%).  
 Cyclin E IHC was accomplished using C-terminal cyclin E (C-19) antibody 
detecting both EL and LMW-E forms (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA), diluted at 1:2000 in normal goat serum. Cyclin E staining intensity and percent 
positivity were evaluated both in the nucleus and cytoplasm of cancer cells. We 
identify four different phenotypes of cyclin E distinguished with respect to 
predominant nuclear or cytoplasmic localization of staining. Breast tumors were 
considered negative when no staining was detected either in the nucleus or in the 
cytoplasm (score = 1). Among the cases evaluated as cyclin E positive, if the score 
assigned to the nucleus exceeded the score assigned to the cytoplasm, cyclin E 
expression was considered predominantly nuclear (score = 2). When the nucleus 
and the cytoplasm received equal scores, cyclin E expression was considered both 
nuclear and cytoplasmic (score = 3). If cytoplasmic staining was graded higher than 
nuclear staining, cyclin E expression was considered predominantly cytoplasmic 
(score = 4).  
 
3.2g. Soft agar transformation and mammosphere formation assays 
 For soft agar transformation assay, the base agar was made by mixing 90 ml 
10% FBS MEM with 22.5 ml 2.4% Noble agar (DIFCO, Lawrence, KS). The solution 
was heated to melt the agar and then aliquot to 6-well plates with 1 ml per well and 
allowed to solidify at RT. For the top agar, 2000 cells were mixed with 850 µl 10% 
FBS MEM and 125 µl 2.4% agar and transferred to the base agar for each well of 6-
well plate. The cells were cultured for 15 days, stained with 0.005% crystal violet in 
25% methanol for 1.5 hours, washed with ddH20 and counted using the GelCount 
(Oxford Optronix Ltd., Oxford, UK). For mammosphere culture, cells were plated at 
40,000 cells/ml in ultra-low attachment plates (Corning, Corning, NY) in MEM media 
(Media Tech, Manassas, VA) containing 1% methylcellulose (Sigma, St. Louis, MO) 
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and supplemented with 20 ng/mL EGF and B27 (Invitrogen, Carlsbad, CA). For 
quantification, 10% v/v 5 mg/ml MTT solution was added to each well after 7 days in 
culture, incubated for 1 hour at 37oC and counted using the GelCount software.  
 
3.2i. ALDEFLUOR assay 
All contents of the ALDEFLUOR assay are included in the kit from Stem Cell 
Technologies (Durham, NC). To measure the ALDH enzymatic activity, 1 million 
cells were washed in assay buffer. For each sample, ALDH substrate (1 µmol/l 
BAAA) and ALDH inhibitor (50 mmol/l DEAB) were added to 500,000 cells in 
separate tubes and incubated at 37oC for 1 hour. The cells were washed in assay 
buffer and analyzed with FACS Calibur. The DEAB sample was used to gate each 
individual sample to achieve less than 2% positive. 
 
3.2h. Drug treatment & high-throughput survival assay (HTSA) 
 For CD24/CD44 FACS analysis, cells were seed at 20,000 cells/cm2 density 
on 6-well plates 24 hours before drug treatment (day 0) (Figure 19A). On day 1, 
medium containing varying doxorubicin or salinomycin concentrations was added to 
the cells and replaced every 2 days for a total of 4 days. On day 5, the cells were 
allowed to recover for 3 days in drug-free medium before FACS analysis. For 
HTSA, cells were seeded at 3,000 cells/cm2 density for 24 hours in 96-well plates 
and medium containing doxorubicin or salinomycin were added on days 1 and 3 
(Figure 19B). The cells were allowed to recover for 5 days in drug-free media before 
analysis. On day 10, 50 µl of 2.5 mg/ml MTT solution (Sigma) was added to each 
well and incubated at 37°C for 4 hours in the dark. The media were removed and 
100 µl of solubilization solution (0.04 N HCl, 1% SDS, in isopropyl alcohol) was 
added per well and gently rocked for 1 hour. After solubilization, cell viability was 
measured at 590 nm absorbance using the Wallac-Victor3 multilabel plate reader 
(PerkinElmer, Waltham, MA). At least 3 independent experiments were performed 
for each analysis. 
 
3.2i. ProtoArray Human Protein Microarray analysis 
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Figure 19: Schematic of the doxorubicin and salinomycin combination
treatment. (A) For CD24/CD44 FACS analysis, the cells were seeded at
20,000 cells/cm2 density on 6-well plates on day 0. On days 1 and 3,
medium containing doxorubicin or salinomycin was added to the cells. On
days 5 and 7, the cells were fed with drug-free medium and harvested for
FACS analysis on day 8. (B) For the HTSA, the cells were seeded at 3,000
cells/cm2 density on 96-well plates on day 0. On days 5, 7, and 9, the cells
were fed with drug-free medium and subjected to the MTT assay on day 10.
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 The ProtoArray human protein microarrays (Invitrogen, Carlsbad, CA) 
contain more than 6,100 kinase substrates expressed as N-terminus GST fusion 
(www.invitrogen.com⁄protoarray). Purified FLAG-EL/CDK2 and FLAG-LMW-E/CDK2 
complexes were produced in sf9 insect cells, purified by IP with FLAG-tagged 
antibody and eluted with 3X FLAG peptide (Sigma, St. Louis, MO). Arrays were 
incubated either with recombinant active EL/CDK2 or LMW-E/CDK2 at a 
concentration of 50 nM in the presence of 33P-γ-ATP for 1 hour at 30°C. After 
washing and drying, arrays were exposed to X-ray film overnight. Imaging and data 
analysis were performed as recommended by the manufacturer. Briefly, the films 
were scanned to obtain 50 µm resolution and the arrays were aligned using the 
ProtoArray(R) Prospector Imager. The radioactive spots were quantified and 
analyzed using the ProtoArray(R) Prospector Analyzer, and the EL/CDK2 and 
LMW-E/CDK2 arrays were compared directly.  
 
3.2i. Cyclin E/CDK2 substrate screening using ATP analog 
 pVL1392-hCDK2 F80G mutant was generated using the QuikChange XL 
site-directed mutagenesis (Qiagen) per instruction provided by the manufacturer. 
CDK2 (wild type and F80G), EL and LMW-E were expressed, purified from sf9 
insect cells, and incubated with GST-Rb, ATP or PE- ATP-γ-S (BioSite, Täby, 
Sweden) at 30°C for 30 minutes. The samples were boiled with 2x sample buffer 
and separated by SDS-PAGE. The gel was fixed in 50% (v/v) ethanol in water with 
10% (v/v) acetic acid and stained with 0.1% (w/v) Coomassie blue R350.  
 The ATP analog (PE-ATP-γS) can fit into the ATP pocket of the F80G CDK2 
but not the wild-type CDK2 kinase. The replacement of the γ-phosphoryl oxygen 
with sulfur allows for specific tagging of the substrates with the thiophosphate 
group. Thio-containing groups can react with iodoacetyl-agarose to form covalent 
bond while unbound peptides are washed away. Thiophosphopeptides are 
specifically liberated by oxidation-promoted hydrolysis of the sulfur-phosphorus 
bond and recovered peptides can be analyzed by nanoscale liquid chromatography 
coupled to a Q TRAP tandem mass spectrometer. 
 
109
3.2j. HAT activity colorimetric assay 
 To obtain purified proteins, pEXP-N-Myc-Hbo1 (wt, T88A, T88D), pEXP-N-
SFB-(EL, LMW-E, CDK2) were transfected into HEK293T cells using LipoD293 
transfection reagents (SignaGen, Rockville, MD) and lysates were harvested 24 
hours later. The proteins were purified by IP using Myc-tag or FLAG-tag antibodies 
and purified Myc-tagged proteins were left on beads in 1x wash buffer, while 
purified FLAG-tagged proteins were eluted using 3X FLAG peptides (Sigma, St. 
Louis, MO). The HAT activity colorimetric assay kit was purchased from MBL 
International (Woburn, MA) and performed according to manufacturer’s instructions. 
Briefly, purified proteins or 25 µg of HeLa nuclear extract (positive control supplied 
with the kit) were diluted in 40 µl water per well of 96-well plates. The samples were 
mixed with the assay mix, which contains 50 µl of 2X HAT assay buffer, 5 µl HAT 
substrate I, 5 µl HAT substrate II, and 5 µl NADH generating enzyme. The plates 
were incubated at 37°C for 2 hours and the samples were read at 440 nm using the 
Wallac-Victor3 multilabel plate reader (PerkinElmer, Waltham, MA).  
 
3.2k. Lentiviral packaging and infection of shRNAs 
 All shRNA constructs were purchased from Thermo Scientific (Open 
Biosystem, Huntsville, AL). To generate lentivirus expressing shRNAs, HEK293T 
cells were co-transfected with pCMVdeltaR8.2, pMD2.G, and pGIPZ-(empty, 
shGAPDH, or shHbo1) using LipoD293 transfection reagents (SignaGen, 
Gaithersburg, MD). The supernatants containing the virus were filtered through 0.45 
µm filter and directly added to cells for infection. GFP expression was confirmed 
prior to selection with 0.5 µg/ml puromycin. 
 
3.3. RESULTS 
3.3a. LMW-E-expressing tumor cells exhibit reduced cell-cell contact and 
enhanced invasion  
 One unique feature of mammary epithelial cells is that they tend to form 
isolated islands when cultured as a monolayer by forming tight junctions with nearby 
cells. In the previous chapter, we have extensively described the tumorigenic 
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phenotypes of hMECs with exogenous LMW-E expression through 3 serial in vivo 
passaging generations. In addition to deregulating mammary acinar 
morphogenesis, we observed that the TDCs display reduced cell-cell contact by 
growing further away from neighbor cells. To examine cell-cell adhesion, the TDCs 
were immunostained with E-cadherin, a transmembrane protein that maintains cell 
adhesion by ensuring that the cells within a tissue are bound together. Figure 20A 
clearly shows that the LMW-E-expressing cells demonstrate dramatically reduced 
E-cadherin expression, particularly at the membrane junction, while the parental 
76NE6 cells display strong membranous E-cadherin staining (white arrows). 
Downregulation of E-cadherin protein levels are confirmed by Western blot analysis 
demonstrating that cells with LMW-E expression have reduced E-cadherin protein 
levels (Figure 20B & C).  
 Cellular invasion is one of the critical events leading to successful metastasis 
and requires migration of the tumor cells through the basement membrane to 
invade the surrounding tissues (298). Given that E-cadherin regulates cellular 
adhesion, downregulation of E-cadherin is known to be associated with tumor 
progression and metastasis. Cells with E-cadherin knockdown are more motile 
resulting in their enhanced ability to penetrate the basement membrane and thus 
invade into surrounding tissues to form metastasis (299, 300). The Boyden chamber 
invasion assay was performed to investigate whether LMW-E expression enhances 
cellular invasiveness. The cells were seeded on a microporous transwell insert on 
top of a thin layer of Matrigel with fibronectin on the other side of the membrane to 
act as a chemo-attractant. After 24 hours, the cells that have invaded to the bottom 
side of the membrane were stained with crystal violet for visualization. Figure 20D 
shows that while the vector control cells were unable to invade through the Matrigel 
basement membrane, cells with cyclin E expression were highly invasive. More 
specifically, quantification of the invaded cells demonstrate that while all cells with 
cyclin E expression invade significantly more than vector control cells, the 76NE6-
LMW-E and TDCs combined invade significantly more than the 76NE6-EL cells (p < 
0.05) (Figure 20E). Collectively, we provide evidence suggesting that 
overexpression of LMW-E downregulates E-cadherin expression and thereby 
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Figure 20: LMW-E-expressing tumor cells exhibit reduced cell-cell contact
and enhanced invasion. (A) Cells were fixed and immunostained with E-cadherin
antibody and nuclei were counterstained with DAPI (scale bar = 100 µm). (B)
Lysates were extracted and subjected to Western blot analysis with antibodies
against cyclin E, E-cadherin, and β-actin. (C) Densitometric values of the Western
blot analysis. (D) Cells were seeded on Matrigel-coated transwell chamber and
incubated on top of fibronectin-containing media for 24 hours. The cells on top of
the membrane were removed and the cells remaining on the bottom were stained
with crystal violet and images were taken with a light microscope. (E) After 24
hours incubation, the cells on the bottom of the transwell were collected and
counted. Statistical analysis used was unpaired student’s t-test.
113
enhance the invasiveness of hMECs. 
 
3.3b. LMW-E activates gene expression associated with the EMT 
 Loss of cell-cell contact and reduced E-cadherin expression typically signify 
that the cells have undergone the morphogenetic reprogramming from epithelial to 
mesenchymal phenotype, which is commonly known as the epithelial-mesenchymal 
transition or EMT. The EMT is an epigenetic process that involves modulation of 
numerous transcription factors to transform the cells from epithelial to mesenchymal 
characteristic to allow them to migrate and invade through the basement 
membrane. The transcriptional levels of genes known to be involved in the EMT 
were analyzed by realtime qRT-PCR. Firstly, analysis of cyclin E mRNA level 
confirmed high expression in the 76NE6-LMW-E and the TDCs and these cells 
exhibited downregulation of E-cadherin (Figure 21A & B). Furthermore, in the cells 
that show high cyclin E expression, they also upregulate N-cadherin, twist, slug, and 
vimentin mRNA levels, which are the genes associated with the EMT (Figure 21C-
F). Interestingly, we observed that the levels of cyclin E protein as well as mRNA 
transcript were much higher in the 76NE6-LMW-E cells compared to the 76NE6-EL 
cells (Figure 20B, 20C & 21A), which is a phenomenon that was also observed in 
the transgenic mouse model with overexpression of LMW-E. We speculate that high 
LMW-E protein levels may lead to hyperactive G1-S transition causing a positive 
feedback loop through activation of E2F, and increased E2F activity has been 
shown to stabilize cyclin E by reducing conjugation with ubiquitin (301). Additionally, 
cyclin E transcription has been reported to be positively regulated by the E2F 
transcription factor, and in fact, the cyclin E promoter does contains several E2F 
binding sites (302). Taken together, exogenous LMW-E expression in the 76NE6 
cells resulted in reduced cell-cell adhesion and induced transcriptional changes that 
are featured as the EMT.  
 
3.3c. LMW-E expression enriches for the CD44hi/CD24lo population  
 As the connection between induction of the EMT and generation of cells with 
CSC properties was recently demonstrated, we suspect that the tumorigenicity of 
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Figure 21: LMW-E activates gene expression associated with the EMT. (A –
F) Cells were grown in monolayer culture to 70% confluency and RNA were
extracted and subjected to qRT-PCR analysis for the mRNA levels of cyclin E (A),
E-cadherin (B), twist (C), vimentin (D), N-cadherin (E), and slug (F). These values
were normalized against GAPDH mRNA levels and statistical analysis used was
unpaired student’s t-test.
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LMW-E could be due to its ability to induce the EMT and enrich for CSCs. To date, 
many surface markers have been demonstrated to be unique CSC markers, and 
CD44hi/CD24lo is the best well-established markers for mammary CSCs. We aim to 
investigate whether ectopic expression of EL or LMW-E in the 76NE6 cells and 
whether in vivo passaging of these cells would enrich for this population. The cells 
were stained using antibodies to the surface markers CD24 and CD44 that are 
conjugated to different fluorophores, and their relative expression levels were 
measured by FACS analysis (Figure 22).  
 The majority of the 76NE6-vector cells were CD44hi/CD24hi with only 1.5% of 
the population was CD44hi/CD24lo (Figure 22A & B). While stable expression of EL 
increased the CD44hi/CD24lo population to approximately 10%, the 76NE6-LMW-E 
cells have significantly more CD44hi/CD24lo population compared to the 76NE6-EL 
cells (p = 0.001) (Figure 22A & B). The difference was more remarkable in the 
TDCs, in which most of the clones contained approximately 10 folds higher of this 
CSC population. Furthermore, Western blot analysis using CD24 and CD44 
antibodies confirmed that indeed LMW-E-expressing cells downregulated CD24 and 
upregulated CD44 protein levels (Figure 22C). Since in vivo passaging led to 
enhancement of LMW-E expression as well as enrichment for the CD44hi/CD24lo 
population, we believe that cyclin E may be involved in selecting for this CSC 
population. In fact, correlation analysis revealed that cyclin E expression level 
positively correlate with the CD44hi/CD24lo population with R2 = 0.853 (p < 0.0001) 
indicating that cells with high cyclin E expression are also statistically likely to be 
CD44hi/CD24lo (Figure 22D).  
 
3.3d. Cytoplasmic cyclin E expression correlates with high CD44hi/CD24lo 
population in breast cancer patient tissue 
 Given that cyclin E expression positively associates with the CD44hi/CD24lo 
population in hMECs, we now aim to determine whether this correlation also exists 
in breast cancer patient samples. A total of 118 breast cancer patient tissues were 
analyzed for the CD24 and CD44 expression by double IHC staining on the tissue 
sections and visualized with 3,3'-Diaminobenzidine (DAB) and permanent red, 
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Figure 22: LMW-E expression
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respectively (Figure 23A). The slides were given a score of 0 to 5 that correspond to 
a range of the percentage of the CD44hi/CD24lo population as follows: 0 (0%), 1 (1-
10%), 2 (11-25%), 3 (26-50%), 4 (51-75%), 5 (76-100%). In addition, these same 
tissue slides were also subjected to IHC staining using antibody to cyclin E (Figure 
23B). We scored the cyclin E staining based on its intensity as well as localization. 
Breast tumors were considered negative when no staining was detected either in 
the nucleus or in the cytoplasm (score = 1). Among the cases evaluated as cyclin E 
positive, if the score assigned to the nucleus exceeded the score assigned to the 
cytoplasm, cyclin E expression was considered predominantly nuclear (score = 2). 
When the nucleus and the cytoplasm received equal scores, cyclin E expression 
was considered both nuclear and cytoplasmic (score = 3). If cytoplasmic staining 
was graded higher than nuclear staining, cyclin E expression was considered 
predominantly cytoplasmic (score = 4). Lastly, lysates prepared from these patient 
samples were also analyzed for the protein levels of EL and LMW-E by Western 
blot followed by densitometric analysis (Figure 23C). Statistical analysis was applied 
to data obtained from 1) CD24/CD44 double IHC staining, 2) cyclin E IHC staining, 
and 3) EL versus LMW-E protein levels from Western blot analysis. 
 Statistical analysis revealed that more than 60% of the patient tissues 
contain less than 10% of the CD44hi/CD24lo population, and this patient distribution 
was similar to that previously reported (Table 9) (289). More specifically, we found 
that cytoplasmic staining of cyclin E significantly correlated with high percentage of 
the CD44hi/CD24lo population (p = 0.0435), and the fact that the patient sample was 
relatively small further demonstrates the strength of the relationship between these 
two factors (Figure 24A). In fact, when cytoplasmic versus nuclear cyclin E IHC 
scores were compared with the densitometry values from Western blot analysis of 
the patient tissues, we found that high LMW-E expression levels significantly 
associated with cytoplasmic cyclin E staining (p = 0.0194) while full-length and total 
cyclin E expression levels did not (Figure 24B-D). Since LMW-E lacks an N-terminal 
nuclear signal sequence, previous report has shown that LMW-E preferentially 
accumulates in the cytoplasm, and these results further support this observation 
(169). In conclusion, similar to our cell line data, breast cancer patients who have 
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Figure 23: IHC analysis for CD24, CD44 and cyclin E expression in breast
cancer patient samples. (A) A total of 118 breast cancer patient tissue slides
were subjected to IHC double staining with CD24 and CD44 antibodies and
scored for %CD44hi/CD24lo. (B) IHC single staining using cyclin E antibody and
scored with respect to intensity as well as cytoplasmic versus nuclear
localization (1: no staining, 2: nuclear > cytoplasmic, 3: nuclear = cytoplasmic, 4:
nuclear < cytoplasmic). The slides were scored blindly by 2 independent
investigators. (C) Cyclin E EL and LMW-E protein levels were measured by
Western blot analysis from breast cancer patient tissues and quantified by
densitometry. Shown here are representative samples to illustrate the IHC
staining that reflect the scoring assigned and the LMW-E protein levels by
densitometry.
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Figure 24: Cytoplasmic cyclin E expression correlates with high
CD44hi/CD24lo score in breast cancer patient tissue. (A Patient tissues were
subjected to IHC analysis using CD24, CD44, and cyclin E antibodies. The
CD44hi/CD24lo scores were correlated to the nuclear versus cytoplasmic cyclin E
staining scores. Statistical analysis used was unpaired student’s t-test. The
cyclin E nuclear and cytoplasmic staining scores were correlated with total cyclin
E (B), EL (C), and LMW-E (D) protein levels from densitometry of Western blot
analysis. Statistical analysis used was Pearson’s chi-square test.
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high CD44hi/CD24lo population significantly correlate with cytoplasmic cyclin E, and 
we have demonstrated that cytoplasmic cyclin E protein represents the LMW 
isoforms.  
 
3.3e. LMW-E-expressing cells exhibit enhanced anchorage-independent 
growth, self-renewal capability, and ALDH activity 
 LMW-E expression increased with in vivo passaging suggesting that perhaps 
LMW-E provided oncogenic advantage to tumor-initiating cells that will continue to 
select for those cells possessing tumorigenic phenotypes such as transformation. 
Anchorage independent growth is one of the characteristics of neoplastic cellular 
transformation and is traditionally tested by culturing cells on soft agar medium. The 
cells were embedded in between 2 layers of soft agar at 200 cells/cm2 density. After 
15 days in culture, the plates were stained with crystal violet and automatically 
counted using the GelCount software. As expected, the LMW-E-expressing cells 
formed more transformed colonies compared to cells with vector and EL expression 
(Figure 25A). To confirm that the CD44hi/CD24lo cells have higher tumorigenic 
potential than the CD44hi/CD24hi cells, these cells were sorted into these 2 
respective populations and subjected to soft agar transformation assay. The results 
obtained clearly demonstrated that the sorted CD44hi/CD24lo population was able to 
form much more colonies than unsorted cells, and the CD44hi/CD24hi population 
was unable to sustain growth on soft agar (Figure 25A). These observations may 
explain the ability of LMW-E-expressing cells to form tumor in vivo due to the high 
CD44hi/CD24lo population that allow them to grow in the absence of a basement 
membrane compared to EL-expressing cells. 
 In addition to the CD44hi/CD24lo population, mammary CSCs also possess 
self-renewal capability and thus a single cell can give rise to multiple lineages of 
more differentiated cell types to form a mammosphere (277). Although similar to the 
soft agar transformation assay in some aspects, the mammosphere formation assay 
specifically tests the ability of cells to grow in an ultra-low attachment dish in the 
presence of high EGF and no serum, which is a non-differentiating culture condition. 
CSCs are able to undergo proliferation and self-renewal to form a floating colony 
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Figure 25: LMW-E-expressing cells exhibit enhanced anchorage-
independent growth, self-renewal capability, and ALDH activity. (A)
Anchorage-independent growth was tested by culturing cells in soft agar
medium. Unsorted cells and cells stained with CD24 and CD44
conjugated antibodies and sorted for the CD44hi/CD24hi and
CD44hi/CD24lo populations were seeded in soft agar culture. After 15
days in culture, the colonies were stained with crystal violet and counted
using the GelCount program. (B) Representative brightfield images of
cells cultured on ultra-low attachment plates for 7 days (scale bar =100
µm). The vector control cells undergo apoptosis as apparent by extensive
membrane blebbing (white arrows). (C) MTT solution was added to the
mammosphere cultures at 500 µg/ml concentration and incubated at 37oC
for 1 hour. Number of mammospheres were quantified using the
automated GelCount program and statistical analysis used was unpaired
student’s t-test. (D) Lysates from mammosphere cultures were extracted
and subjected to Western blot analysis with antibodies to cyclin E, ALDH,
and β-actin. (E & F) ALDELUOR assay was performed on cells grown on
monolayer. For each sample, 500,000 cells were incubated with the
ALDH substrate alone or with the ALDH inhibitor (DEAB) and subjected to
FACS analysis. The ALDH activity is obtained by subtracting the DEAB
inhibitor value and the statistical analysis used was unpaired student’s t-
test.
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while differentiated epithelial cells undergo anoikis, which is apoptosis due to lack of 
basement membrane attachment (277). As expected, the 76NE6-vector control 
cells underwent apoptosis as apparent by extensive membrane blebbing (Figure 
25B). In contrast, the 76NE6-LMW-E and the TDCs were able to form larger and 
more mammospheres compared to those formed by the 76NE6-EL cells (Figure 
25B). Sum159 is a breast cancer cell line that has been shown to contain very high 
percentage of the CD44hi/CD24lo population and form very robust and reliable 
mammospheres and therefore are used in this experiment as a positive control 
(303). To quantify the number of mammospheres formed and confirm the viability of 
the cells in these structures, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was added to the cells after 7 days in culture and the 
viable colonies were automatically counted using the GelCount software. Statistical 
analysis revealed that cells with LMW-E expression formed significantly more 
mammospheres than cells with full-length cyclin E expression (p < 0.05) (Figure 
25C).  
 High ALDH protein and enzymatic levels are found to be associated with 
CSC phenotypes such as high CD44hi/CD24lo population and mammosphere 
formation (278). Western blot analysis of the mammosphere cultures showed that 
the 76NE6-LMW-E cells and the TDCs indeed express high LMW-E and ALDH 
protein levels compared to the 76NE6-EL and vector control cells (Figure 25D). 
Therefore, we subjected the cells to the ALDEFLUOR assay to measure the ALDH 
enzymatic activity by FACS analysis. Briefly, the cells were incubated with Bodipy-
aminoacetaldehyde (BAAA), an ALDH substrate that can freely diffuse across the 
plasma membrane (304). The presence of ALDH inside the cell catalyzes the 
substrate into Bodipy-aminoacetate (BAA), which is fluorescent and can be 
detected with flow cytometry. Diethylamino-benzaldehyde (DEAB) is an inhibitor of 
ALDH and is used to normalize the ALDH activity. The results obtained showed that 
the 76NE6-LMW-E cells and the TDCs exhibit high ALDH activity compared to the 
76NE6-EL and vector control cells (Figure 25E). Statistical analysis demonstrated 
that the LMW-E-expressing cells have higher ALDH enzymatic activity compared to 
cells expressing EL (p < 0.05) (Figure 25F). Collectively, the evidences presented 
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here suggest that LMW-E enriches for cells with CSC properties by upregulating the 
ALDH activity level and enabling hMECs to survive and undergo self-renewal in the 
absence of basement membrane attachment thus explaining the enhanced 
tumorigenicity of LMW-E over full-length cyclin E.  
 
3.3f. Doxorubicin synergizes with salinomycin to kill LMW-E-expressing tumor 
cells  
 Salinomycin is a pharmacological agent recently identified from a large 
screen of small molecule inhibitors to specifically kill CSCs (297). Particularly, 
breast cancer cells treated with salinomycin demonstrated a decrease in the 
CD44hi/CD24lo population, reduction in their ability to form mammospheres, and the 
4T1 xenograft tumors formed less metastasis compared to parallel paclitaxel 
treatment (297). Therefore, we aim to determine whether salinomycin can 
specifically target the CD44hi/CD24lo population in the tumor cells with LMW-E 
expression. The cells were treated with salinomycin for 4 days and then allowed to 
recover in drug-free medium for 3 days (Figure 19A). The cells were then harvested 
and stained with PE-CD24 and APC-CD44 conjugated antibodies, and the 
CD44hi/CD24lo population was measured by FACS analysis. The results showed 
that salinomycin treatment reduced the CD44hi/CD24lo population in a dose 
dependent manner (Figure 26A). More specifically, the TDCs contain approximately 
80% of the CD44hi/CD24lo population in which only 10% of these cells remained 
after treatment with 8 µM salinomycin. Additionally, salinomycin treatment also 
effectively disrupted their ability to form mammospheres (Figure 26B). Similar to the 
results previously published, we also showed that salinomycin demonstrated high 
effectiveness in targeting the phenotypes associated with CSCs that are induced 
with LMW-E expression (297). 
 Most highly proliferative cancer cells are sensitive to conventional 
chemotherapies drugs while CSCs are believed to be more resistant to them thus 
resulting in high frequency of tumor relapse (293). Doxorubicin, a common 
chemotherapeutic agent, is an anthracycline antibiotic, which functions by 
intercalating DNA and thereby inhibits DNA replication. As anticipated, doxorubicin 
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Figure 26: Doxorubicin synergizes with salinomycin to kill LMW-E-
expressing tumor cells. (A) Cells were seeded on monolayer for 24 hours and
treated with salinomycin for 4 days with the drug-containing media replaced every
48 hours. After 3 days of recovery in drug-free medium, the cells were trypsinized
and stained for PE-CD24 and APC-CD44 antibodies and analyzed by FACS
analysis. (B) Cells were seeded on ultra-low attachment plates on day 0 and then
treated with salinomycin on days 1 and 3. On day 7, MTT solution was added to
the mammosphere cultures and incubated at  37oC for 1 hour.  Number of
mammospheres were quantified using the automated GelCount program. (C)
Cells were seeded on monolayer for 24 hours and treated with doxorubicin and
analyzed by FACS as in (A). (D) HTSA was performed to examine the toxicity of
combining doxorubicin and salinomycin. Cells were seeded at 3000 cells/cm2
density in 96-well plates on day 0, treated with doxorubicin on day 1 and then with
salinomycin on day 3, and allowed to recover for 5 days in drug-free medium. On
day 11, MTT solution was added to the cells and cell viability was measured at
590nm absorbance using a spectrophotometer. (E) An isobologram illustrates the
effects of the combined drugs calculated from the Calcusyn software. The
combination indices calculated that lay above the line of additivity represent
antagonistic, on the line are additive and underneath the line are synergistic effect.
(F) The results obtained from A were subjected to calculation using the Calcusyn
software. The isobolograms shown are representative from 3 independent
experiments. (G) The combination indices were averaged from 3 independent
experiments and the statistical analysis used was unpaired student’s t-test.
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treatment with increasing drug concentration did not affect the distribution of the 
CD44hi/CD24lo population of any of the cell line tested (Figure 26C). These 
observations led us to develop a combination treatment regimen in which the LMW-
E tumor cells will be first treated with doxorubicin to eliminate the non-CSC 
population and then followed by salinomycin to target the CSC population. One 
advantage of combining drug treatment is that it allows for administration of the 
drugs at low concentration and therefore lessens the toxic side effects. To achieve 
this goal, the combined drugs must exert a synergistic effect in which the outcome 
is greater than the sum of the single agent alone. To examine the toxicity of 
combining doxorubicin and salinomycin, we utilized the high-throughput survival 
assay (HTSA). After seeding at 3000 cells/cm2 density for 24 hours in 96-well 
plates, the cells were first treated with doxorubicin for 48 hours, followed by 
salinomycin for 48 hours, and then allowed to recover for 5 days in drug-free 
medium (Figure 19B). On the 10th day, MTT solution was added to the cells and cell 
viability was measured at 590 nm absorbance using a spectrophotometer. While the 
IC50 of doxorubicin and salinomycin alone were approximately 7.5 nM and 3 µM, 
respectively, the combination of these drugs resulted in higher fraction of cell death 
(Figure 26D).  
 The Calcusyn software was used to calculate the combined drug effects on 
the viability of the cells. This program analyzes the effects from the 2 drugs and 
generates an isobologram, a graph that displays the effects of the combined drugs: 
synergistic, additive, or antagonistic (Figure 26E). The Calcusyn program calculates 
a combination index based on the fractions of cell death due to doxorubicin and 
salinomycin treatments, and a line of additivity is placed at a value of 1 on each 
axis. A combination index of 1 represents additive effect, greater than 1 represents 
antagonistic effect, and less than 1 represents synergistic effect. The isobolograms 
of the 76NE6-V and 76NE6-EL cells indicated that the combined drug treatment 
resulted in additive to antagonistic effects (Figure 26F). In contrast, the drug 
treatment demonstrated a clear synergistic effect in the LMW-E-expressing cells 
(76NE6-LMW-E, T1G2.2, T1G3.1, and T1G4.2). An average of the combination 
indices revealed that the doxorubicin and salinomycin combination resulted in 
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additive/antagonistic effects in the 76NE6-V and 76NE6-EL cells but synergistic 
effects in the 76NE6-LMW-E and the TDCs (Figure 26G). These results suggest a 
promising and effective therapeutic strategy of combining doxorubicin and 
salinomycin to treat breast cancer patients who have high levels of LMW-E 
expression and high CSC population.  
 
3.3g. Identification of human EL/CDK2 and LMW-E/CDK2 substrates  
 To elucidate the signaling pathway downstream of LMW-E, we utilized two 
distinct methods to discover potential substrates/interacting partners for EL/CDK2 
and LMW-E/CDK2 on a proteome-wide scale: (1) the ProtoArray® Human Protein 
Microarray from Invitrogen and (2) the chemical/genetic manipulation of CDK2 
approach.  
 In the first approach, we purified recombinant EL/CDK2 and LMW-E/CDK2 
complexes from insect cell lysates and confirmed that the complexes were active 
using GST-Rb as substrates in a kinase assay (Figure 27A & B). The microarrays, 
which contain more than 9,000 unique human proteins, were incubated either with 
recombinant active EL/CDK2 or LMW-E/CDK2 at a concentration of 50 nM in the 
presence of 33P-γ-ATP for 1 hour at 30°C. The radioactive signals were directly 
compared to generate a list of proteins that were most differentially phosphorylated 
by EL/CDK2 and LMW-E/CDK2 complexes (Figure 27C). Our screen identified a 
total of 146 potential substrates to both EL/CDK2 and LMW-E/CDK2 complexes 
(Table 10). Interestingly, we only identified 4 proteins (myotilin, tomosyn, PRP38 
pre-mRNA processing factor 38 (PRPF38A), and p27Kip1) that were phosphorylated 
by EL/CDK2 significantly more than by LMW-E/CDK2 as compared to the 14 
(histone acetyltransferase binding to ORC (Hbo1), RAD51 associated protein 1 
(RAD51AP1), non-metastatic cells 1/2 (NME1/E2), protein regulator of cytokinesis 1 
(PRC1), cyclin-dependent kinase 2-interacting protein (CINP), ligase III (LIG3), 
mitochondrial GTPase 1 (MTG1), polypeptide N-acetylgalactosaminyltransferase 
10, mitochondrial ribosomal protein L40 (MRPL40), tektin 2 (testicular) (TEKT2), 
Ribosomal protein S6 kinase alpha-5, interleukin-1 receptor-associated kinase 3 
(IRAK3), FAD-dependent oxidoreductase domain containing 1 (FOXRED1), and cell 
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Figure 27: Identification of human EL/CDK2 and LMW-E/CDK2 substrates
using the ProtoArray microarray. (A) FLAG-EL/CDK2 and FLAG-LMW-E/CDK2
complexes were expressed in sf9 insect cells, purified by IP with FLAG-tagged
antibody, eluted with 3X FLAG peptide and visualized by silver stain and Western
blot analysis. (Only LMW-E/CDK2 results are shown here). (B) In vitro kinase
assay using purified EL/CDK2 and LMW-E/CDK2 kinase complexes with GST-Rb
as substrate to confirm the relative amount of the kinase complexes for use in the
microarray analysis. The kinase assay was performed with 32P-γ-ATP, separated
by SDS-PAGE and exposed to x-ray films. (C) The microarrays were incubated
either with recombinant EL/CDK2 or LMW-E/CDK2 in the presence of 33P-γ-ATP
and the radioactive signals were exposed to x-ray films. (D) Venn diagram showing
the number of proteins whose phosphorylation signal by EL/CDK2 is greater than
LMW-E/CDK2 by more than 1.5 (red), LMW-E/CDK2 signal is greater than
EL/CDK2 signal by 1.5 (blue) and EL/CDK2 and LMW-E/CDK2 signals are
between 0.5 and 1.5 (black).
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Protein
1 cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
2 myotilin (MYOT)
3 syntaxin binding protein 5 (tomosyn) (STXBP5)
4 PRP38 pre-mRNA processing factor 38 (PRPF38A)
5 E2F transcription factor (E2F)
6 Proto-oncogene tyrosine-protein kinase MER
7 hydrolethalus syndrome 1 (HYLS1)
8 Phosphatidylinositol 4-kinase beta
9 Ribosomal protein S6 kinase 
10 sciellin (SCEL)
11 Rho GTPase-activating protein 15
12 Bruton agammaglobulinemia tyrosine kinase (BTK)
13 Fibroblast growth factor receptor 2
14 Peripheral plasma membrane protein CASK
15 BRCA1 associated protein-1 (BAP1)
16 ankyrin repeat and sterile alpha motif domain containing 3 (ANKS3)
17 schlafen-like 1 (SLFNL1)
18 BMP-2-inducible protein kinase
19 Receptor tyrosine-protein kinase erbB-2
20 Dual specificity protein kinase CLK1
21 platelet-derived growth factor receptor (PDGFR)
22 BTB (POZ) domain containing 12 (BTBD12)
23 anaplastic lymphoma kinase (Ki-1) (ALK)
24 met proto-oncogene (MET)
25 serum/glucocorticoid regulated kinase (SGK)
26 pim oncogene (PIM)
27 fms-related tyrosine kinase 1 (FLT1)
28 WEE1 homolog (WEE1)
29 Interleukin-1 receptor-associated kinase (IRAK)
30 PRKR interacting protein 1 (IL11 inducible) (PRKRIP1)
31 Ephrin type-B receptor 1
32 cyclin E2 (CCNE2)
33 Rho-associated protein kinase 2
34 PTK2B protein tyrosine kinase 2 beta (PTK2B)
35 REX2, RNA exonuclease 2 homolog (REXO2)
36 ret proto-oncogene (RET)
37 epidermal growth factor receptor (EGFR)
38 tau tubulin kinase 2 (TTBK2)
39 Dual specificity tyrosine-phosphorylation-regulated kinase 1B
40 Eukaryotic translation initiation factor 2-alpha kinase 3
41 F-box/WD repeat-containing protein 11
42 p21 (CDKN1A)-activated kinase (PAK)
43 Proto-oncogene tyrosine-protein kinase FER
44 inhibitor of kappa light polypeptide gene enhancer in B-cells (IKBKB)
45 death-associated protein kinase (DAPK)
46 tropomyosin 4 (TPM4)
47 Receptor tyrosine-protein kinase erbB-4
48 CHK1 checkpoint homolog (CHEK1)
49 mitogen-activated protein kinase kinase kinase kinase (MAP4K)
Table 10. Potential substrates to both EL/CDK2 and LMW-E/CDK2 complexes 
from the ProtoArray Microarray analysis. Proteins that are phosphorylated by 
EL/CDK2 more than LMW-E/CDK2 are highlighted in yellow. Proteins that are 
phosphorylated by LMW-E/CDK2 more than EL/CDK2 are highlighted in pink. 
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Table 10. Potential substrates to both EL/CDK2 and LMW-E/CDK2 complexes 
from the ProtoArray Microarray analysis. Proteins that are phosphorylated by 
EL/CDK2 more than LMW-E/CDK2 are highlighted in yellow. Proteins that are 
phosphorylated by LMW-E/CDK2 more than EL/CDK2 are highlighted in pink. 
Protein
50 TTK protein kinase (TTK)
51 TANK-binding kinase 1 (TBK1)
52 MAP kinase-interacting serine/threonine-protein kinase
53 doublecortin and CaM kinase-like 2 (DCAMKL2)
54 bone morphogenetic protein receptor, type IB (BMPR1B)
55 transforming growth factor, beta receptor II (TGFBR2)
56 B lymphoid tyrosine kinase (BLK)
57 cyclin-dependent kinase 5 (CDK5) 
58 Basic fibroblast growth factor receptor 1
59 BMX non-receptor tyrosine kinase (BMX)
60 dystrophin
61 Activin receptor type-2A
62 Cartilage intermediate layer protein 2
63 Inhibitor of nuclear factor kappa-B kinase
64 Tyrosine-protein kinase ABL2
65 TYRO3 protein tyrosine kinase (TYRO3)
66 protein kinase D (PRKD)
67 SFRS protein kinase 3 (SRPK3)
68 alanine-glyoxylate aminotransferase 2-like 2 (AGXT2L2)
69 calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2)
70 3-phosphoinositide dependent protein kinase-1 (PDPK1)
71 RIO kinase (RIOK)
72 Cas scaffolding protein family member 4
73 protein kinase C (PRKC)
74 Insulin receptor
75 Wolf-Hirschhorn syndrome candidate 1 (WHSC1)
76 spleen tyrosine kinase (SYK)
77 leukocyte tyrosine kinase (LTK)
78 phosphorylase kinase
79 microcephaly (MCPH1)
80 NCK adaptor protein 2 (NCK2)
81 SNF1-like kinase 2 (SNF1LK2)
82 suppressor of cytokine signaling 2 (SOCS2)
83 MAP/microtubule affinity-regulating kinase (MARK)
84 Macrophage-stimulating protein receptor
85 polo-like kinase 1 (PLK1)
86 Protein tyrosine kinase 2 
87 MAP kinase-activated protein kinase 2
88 Glycogen synthase kinase-3 beta
89 IL2-inducible T-cell kinase (ITK)
90 Tyrosine-protein kinase FRK
91 CDC-like kinase (CLK)
92 myomegalin (PDE4DIP)
93 casein kinase 1
94 hypothetical protein MGC42105 (MGC42105)
95 male-specific lethal 3-like 1 (MSL3L1)
96 PTK2 protein tyrosine kinase 2 (PTK2)
97 cGMP-dependent protein kinase 1
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from the ProtoArray Microarray analysis. Proteins that are phosphorylated by 
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98 Band 4.1-like protein 4A
99 ephrin receptor B4 (EPHB4)
100 homeodomain interacting protein kinase (HIPK)
101 TBC1 domain family, member 22A (TBC1D22A)
102 splicing factor, arginine/serine-rich 2B (SFRS2B)
103 fyn-related kinase (FRK)
104 Small conductance calcium-activated potassium channel protein 2
105 Cyclin-dependent kinase-like 2
106 family with sequence similarity 122A (FAM122A)
107 inositol(myo)-1(or 4)-monophosphatase 1 (IMPA1)
108 G patch domain containing 2 (GPATCH2)
109 testis-specific serine kinase 2 (TSSK2)
110 chromodomain helicase DNA binding protein 2 (CHD2)
111 mitogen-activated protein kinase kinase kinase (MAP3K)
112 casein kinase 2
113 ets variant gene 3 (ETV3)
114 TAO kinase 3 (TAOK3)
115 HIRA interacting protein 3 (HIRIP3)
116 PRP40 pre-mRNA processing factor 40 (PRPF40A)
117 feline sarcoma oncogene (FES)
118 Focal adhesion kinase 1
119 SH3 and cysteine rich domain (STAC)
120 cyclin G associated kinase (GAK)
121 phytanoyl-CoA 2-hydroxylase interacting protein-like (PHYHIPL)
122 mitogen-activated protein kinase (MAPK)
123 SMAD family member 3 (SMAD3)
124 G protein-coupled receptor kinase (GRK)
125 ribosomal protein S10 (RPS10)
126 ribosomal protein L41 (RPL41)
127 NUAK family  (NUAK2)
128 SLAIN motif family, member 2 (SLAIN2)
129 Cytoplasmic tyrosine-protein kinase BMX
130 cell division cycle associated 7 (CDCA7)
131 Ephrin receptor A1 (EPHA1)
132 tripartite motif-containing 63 (TRIM63)
133 mitochondrial GTPase 1 (MTG1)
134 non-metastatic cells 1 (NME1)
135 Polypeptide N-acetylgalactosaminyltransferase 10
136 MYST histone acetyltransferase 2 (MYST2)
137 mitochondrial ribosomal protein L40 (MRPL40)
138 tektin 2 (testicular) (TEKT2)
139 Ribosomal protein S6 kinase alpha-5
140 interleukin-1 receptor-associated kinase 3 (IRAK3)
141 FAD-dependent oxidoreductase domain containing 1 (FOXRED1)
142 cell division cycle 2 (CDC2)
143 RAD51 associated protein 1 (RAD51AP1)
144 protein regulator of cytokinesis 1 (PRC1)
145 cyclin-dependent kinase 2-interacting protein (CINP)
146 ligase III (LIG3)
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division cycle 2 (CDC2)) potential substrates that were preferentially phosphorylated 
by LMW-E/CDK2 suggesting that by losing the N-terminal portion, the LMW-
E/CDK2 kinase complex is able to specifically interact and phosphorylate additional 
proteins (Figure 27D). We chose 6 top candidates from the list of 14 potential 
substrates that were phosphorylated by LMW-E/CDK2 at higher intensity than by 
EL/CDK2 (Hbo1, CINP, LIG3, PRC1, RAD51AP1, and NME1/E2) to further validate 
using in vitro kinase assay (Table 11). These 6 genes were tagged with a Myc-tag, 
expressed in HEK293T cells, and purified by IP using Myc-tagged antibody. The 
purified proteins were then subjected to the in vitro kinase assay as substrates to 
the EL/CDK2 and LMW-E/CDK2 kinase complexes (Figure 28). The results from the 
kinase assay revealed that Hbo1, CINP, LIG3, and PRC1 were indeed 
phosphorylated by both the EL/CDK2 and LMW-E/CDK2 kinase complexes, and the 
phosphorylation was efficiently inhibited with addition of roscovitine (Figure 28A-D). 
However, we could not detect any phosphorylation signal with RAD51AP1 and 
NME1/E2 as substrates (Figure 28E & F).  
 The second screening approach involves generating a modified CDK2 kinase 
that can accept an ATP analog to facilitate covalent modification and subsequent 
purification of substrate peptides (Figure 29A & B) (305). CDK2 F80G mutant was 
generated by amino acid exchange at a conserved bulky phenylalanine residue in 
the ATP binding pocket to a smaller glycine amino acid to allow this mutant CDK2 to 
use PE-ATP-γS as a substrate. The γ sulfur group in the PE-ATP-γS analog allows 
for specific tagging of the substrates with the thiophosphate group, which can be 
used to identify any peptide that has been phosphorylated by CDK2 F80G. Then 
incubated with GST-Rb, both EL/CDK2 F80G and LMW-E/CDK2 F80G kinase 
complexes can use both ATP and PE-ATP-γS to phosphorylate GST-Rb as 
indicated by its electromobility shift while the wild type CDK2 kinase complexes can 
only use ATP, but not PE-ATP-γS (Figure 29C). The next steps will be to 
phosphorylate cell lysates in vitro using EL/CDK2 F80G and LMW-E/CDK2 F80G 
with PE-ATP-γ-S as substrate, digest the protein mixture, capture the 
thiophosphopeptides with thiopropyl sepharose, and the thiophosphopeptides will 
be specifically released by treatment of the resin with a strong base. The recovered 
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Table 11.
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    Purified kinase - + + - + +
           Myc-Hbo1 + + + + + +
Roscovitine (50uM) - - + - - +
EL/CDK2  LMW-E/CDK2
SFB-LMW-E (60kD)
SFB-CDK2 (48kD)
Myc-Hbo1 (80kD)
SFB-EL (65kD)
   Purified kinase - + + - + +
         Myc-PRC1 + + + + + +
Roscovitine (50uM) - - + - - +
EL/CDK2  LMW-E/CDK2
    Purified kinase - + + - + +
           Myc-LIG3 + + + + + +
Roscovitine (50uM) - - + - - +
EL/CDK2  LMW-E/CDK2
     Purified kinase - + + - + +
           Myc-CINP + + + + + +
Roscovitine (50uM) - - + - - +
EL/CDK2  LMW-E/CDK2
SFB-LMW-E (60kD)
SFB-CDK2 (48kD)
Myc-CINP (36kD)
SFB-EL (65kD)
SFB-LMW-E (60kD)
SFB-CDK2 (48kD)
Myc-PRC1 (72kD)
SFB-EL (65kD)
SFB-LMW-E (60kD)
SFB-CDK2 (48kD)
SFB-EL (65kD)
Myc-LIG3 (110kD)
A
B
C
D
Figure 28: Hbo1, CINP, LIG3 and PRC1 are phosphorylated by both
EL/CDK2 and LMW-E/CDK2 kinase complexes. (A) Purified EL/CDK2 and
LMW-E/CDK2 kinase complexes were subjected to in vitro kinase assay using
purified Myc-tagged Hbo1 (A), CINP (B), LIG3 (C), PRC1 (D), NME1/E2 (E) and
RAD51AP1 (F) as substrates. The kinase assays were performed with 32P-γ-
ATP, separated by SDS-PAGE and exposed to x-ray films.
    Purified kinase - + + - + +
  Myc-RAD51AP1 + + + + + +
Roscovitine (50uM) - - + - - +
EL/CDK2  LMW-E/CDK2
    Purified kinase - + + - + +
     Myc-NME1/E2 + + + + + +
Roscovitine (50uM) - - + - - +
EL/CDK2  LMW-E/CDK2
SFB-LMW-E (60kD)
SFB-CDK2 (48kD)
Myc-RAD51AP1 (38kD)
SFB-EL (65kD)
SFB-LMW-E (60kD)
SFB-EL (65kD)
Myc-NME1/E2 (38kD)
SFB-CDK2 (48kD)
E
F
Figure 26
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CF80A CDK2 
Figure 27
Adapted from PNAS 2008, 105(5):1442-7.
EL/CDK2 (wt) EL/CDK2 (F80G)
LMW-E/CDK2 (wt) LMW-E/CDK2 (F80G)
pGST-Rb
pGST-Rb
             ATP - + - - + -
  PE-ATP-γS - - + - - +
Figure 29: EL/CDK2 and LMW-E/CDK2 substrate screening using ATP analog
and F80G CDK2. (Adapated from PNAS 2008, 105(5):1442-7.) (A) Schematic of
the screening approach demonstrating that the ATP analog (PE-ATP-γS) can fit
into the ATP pocket of the F80G CDK2 but not the wild-type CDK2 kinase. The
replacement of the γ-phosphoryl oxygen with sulfur allows for specific tagging of
the substrates with the thiophosphate group. (B) Thio-containing groups can react
with iodoacetyl-agarose to form covalent bond while unbound peptides are washed
away. Thiophosphopeptides are specifically liberated by oxidation-promoted
hydrolysis of the sulfur-phosphorus bond and recovered peptides can be analyzed
by nanoscale liquid chromatography coupled to a Q TRAP tandem mass
spectrometer. (C) In vitro kinase assay with wild-type and F80G CDK2 mutant in
complex with EL or LMW-E in the presence of either ATP or PE-ATP-γS and GST-
Rb. The samples were separated by SDS-PAGE and stained with Coomassie blue.
The top band represents pGST-Rb and the bottom band represents the
unphosphorylated form. 141
peptides will be subjected to liquid chromatography-MS/MS analysis to identify and 
to compare the substrate peptides phosphorylated by EL/CDK2 and LMW-E/CDK2 
kinase complexes. Since the first screening method produced a number of 
interesting hits and given the time constraint, we decided to postpone this 
experiment and focus our studies on the discovered potential hits.  
 
3.3h. Hbo1 is a novel substrate of the cyclin E/CDK2 complex 
 From the 2 independent ProtoArray microarray experiments, Hbo1 (histone 
acetyltransferase (HAT) binding to ORC1 (origin recognition complex 1)) was 
among the top potential hits with phosphorylation signal by LMW-E/CDK2 being 3 
folds higher than that by EL/CDK2 (Figure 30A). Hbo1 is a member of the MYST 
family (named after its original 4 founding members: MOZ, Ybf2/Sas3, Sas2, 
TIP60), which is highly conserved from yeast to humans, and has been implicated 
in regulating gene expression, DNA replication, and DNA repair (306-311). The 
Hbo1 protein structure contains a defining MYST domain consisting of an acetyl-
CoA binding motif, a zinc finger, and a serine-rich region. During S phase, ORC is a 
key protein for initiating DNA replication by recruiting components for the formation 
of the pre-replication complex (pre-RC). Hbo1 was first identified to bind to ORC1 
and subsequently shown to interact with MCM-2 to positively regulate the assembly 
of the pre-RC and DNA replication initiation (306, 311-313). 
 The coding region of Hbo1 has been shown to be a common site for 
retroviral integration and has been linked to B/T-cell lymphoma and myeloid 
leukemia in mice (314). Additionally, in a screen for genetic alterations and 
oncogenic pathways in breast cancer, Hu and colleagues identified the coding 
region of Hbo1 with recurrent chromosomal gain in ER+/PR+/HER2+ tumors (315). 
Furthermore, ectopic overexpression of Hbo1 in MCF7 and SKBR3 cells enhanced 
soft agar colony formation while knockdown of Hbo1 with siRNA blocked S phase 
progression and reduced cell proliferation (315, 316). These data suggest that Hbo1 
plays a role in supporting the oncogenic transformed state, and genetic 
amplification at this chromosomal region implicates Hbo1 as an important oncogene 
in breast cancer. Aside from interacting with the pre-RC, Hbo1 has been 
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Figure 28
FLAG-cyclin Ea - EL LMW-E - - EL LMW-E EL LMW-E
HA-CDK2a - - - + - + + + +
Myc-Hbo1a - - - - + - - + +
IP:Myc
IB:Myc
EL
LMW-E
IB:CDK2
IP:FLAG
IgG
EL
LMW-E
IB:CDK2
IB:Myc
IB:FLAG
IB:FLAG
B
Kinase EL/
CDK2
LMW-E/
CDK2
EL/
CDK2
LMW-E/
CDK2
Phosphorylation signal 1.0 3.5 1.0 2.5
Array spots
TRIAL 1                  TRIAL 2A
Hbo1 
+ - + + + + + - + + + +
- + + + + + - + + + + +
- - - - - + - - - - - +
SFB-cycE/CDK2
Myc-Hbo1
Roscovitine (100µm)
Myc-Hbo1
EL/CDK2               LMW-E/CDK2
KINASE ASSAY
C IP:FLAGIB:FLAG
SFB-EL 
SFB-LMW-E 
SFB-CDK2
D
SFB-EL 
SFB-LMW-E 
Figure 30
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Figure 28
E
+ - + + + + + + + +
- wt wt wt S57A T85A T88A S124A S506A T606A
- - - + - - - - - -
SFB-LMW-E/CDK2
Myc-Hbo1
Roscovitine (100µM)
SFB-LMW-E
Myc-Hbo1
KINASE ASSAYG
IP:Myc
IB:Myc
Myc-Hbo1
wt     S57A   T85A  T88A  S124A S506A T606A
F
Figure 30: Hbo1 is a novel substrate of the cyclin E/CDK2 complex. (A) The
ProtoArray microarray experiment was performed in two independent experiments.
The phosphorylation signals indicate relative radioactive signal detected in the
microarray spots. (B) FLAG-EL or LMW-E, HA-CDK2, and Myc-Hbo1 constructs
were transfected into HEK293T cells and IP with either Myc-tagged or FLAG-
tagged antibodies and probed with the indicated antibodies. (C) SFB-EL or SFB-
LMW-E was co-transfected with  SFB-CDK2 into HEK293T cells, purified using
FLAG-tagged antibody, eluted with 3X FLAG peptide and visualized by Western
blot analysis. Myc-Hbo1 was transfected into HEK293T cells, purified using Myc-
tagged antibody and the bead-Myc protein complex was resuspended in 1X wash
buffer. (D) The EL/CDK2 or LMW-E/CDK2 kinase complex was incubated with
purified Hbo1 in the presence of 32P-γ-ATP and with or without roscovitine. The
samples were separated by SDS-PAGE and exposed to x-ray films. (E) Schematic
of the Hbo1 gene construct with the potential phosphorylation sites predicted
based on the CDK2 consensus phosphorylation motif (S/T-P-X-R/K/H). (F & G)
The six potential phosphorylation sites were mutated to alanine, expressed,
purified and subjected to similar kinase assay as in (D).
S Zn Motif A
330                                    451                                                                 611
S506PERPL
S57PVRNL
1                                          170
T88PKK
S124PPR
T606PPK
MYST
S/T-P-X-R/K/H
T85PVTPK
N’ C’
Hbo1
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demonstrated to bind to AR (androgen receptor) and NF-κB to mediate 
transcriptional repression (308, 309). Furthermore, Hbo1 is highly expressed in 
breast cancer tissues and correlates positively with histology grade in ERα positive 
tumors (317). Given the important role of Hbo1 in breast cancer, we decided to 
further investigate its relationship with cyclin E/CDK2 in mediating mammary 
tumorigenesis.  
 Since the ProtoArray results showed that Hbo1 was phosphorylated by the 
cyclin E/CDK2 complex, the first question to address is does Hbo1 interact directly 
with this kinase complex? DNA plasmids containing FLAG-EL or LMW-E, HA-
CDK2, and Myc-Hbo1 were transiently transfected into HEK293T cells followed by 
IP/Western analysis. Immunoprecipitation using Myc-tagged antibody showed that 
EL and LMW-E as well as CDK2 were pulled-down along with Hbo1 (Figure 30B). 
Moreover, IP using FLAG-tagged antibody also pulled-down Hbo1 along with EL or 
LMW-E, and CDK2. These results indicated that Hbo1 exists in the same protein 
complex with EL/CDK2 and LMW-E/CDK2, at least in this in vitro experimental 
condition. 
 To confirm whether Hbo1 is a substrate of the cyclin E/CDK2 kinase 
complex, the EL/CDK2 and LMW-E/CDK2 kinase complexes and Myc-Hbo1 
proteins were purified by IP with FLAG-tagged and Myc-tagged antibodies (Figure 
30C). Results from the in vitro kinase assay showed that both EL/CDK2 and LMW-
E/CDK2 kinase complexes phosphorylate Hbo1 at relatively similar levels, and 
addition of roscovitine efficiently inhibited the phosphorylation signal (Figure 30D). 
Perhaps the reason that we cannot detect a difference in the extent of Hbo1 
phosphorylation between the EL/CDK2 and LMW-E/CDK2 complexes is due to the 
saturated concentrations of the kinase as well as the substrate in this in vitro kinase 
assay condition compared to the condition performed for the ProtoArray. (The 
kinase concentration was 50 nM in the microarray experiment and was 
approximately 500 nM in this in vitro kinase assay.) Additionally, since the LMW-E 
isoforms are overexpressed in breast cancer, we speculate that it is these truncated 
forms of cyclin E in complex with CDK2 that phosphorylate Hbo1 and not the full-
length cyclin E form.  
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 Based on the consensus CDK2 phosphorylation motifs (S/T-P-X-R/K/H and 
R-X-L), there are six potential phosphorylation sites on the Hbo1 gene sequence 
(Figure 30E), and these sites were mutated to alanine to identify which site is being 
phosphorylated by the LMW-E/CDK2 complex. The mutant proteins were 
transfected into HEK293T cells, purified by IP, and then followed by kinase assay 
(Figure 30F). Of the six potential sites, LMW-E/CDK2 phosphorylate Hbo1 at T88 
since the T88A mutant showed abolished radioactive signal (Figure 30G). 
Collectively, the Protoarray analysis led us to discover Hbo1 as a novel substrate of 
the LMW-E/CDK2 complex that may mediate critical downstream signaling to 
contribute to the oncogenic potential of LMW-E in breast cancer.  
 
3.3i. Cyclin E/CDK2 phosphorylation of Hbo1 does not affect the HAT activity 
of Hbo1  
 A recent study reported that CDK11p58 interacts with Hbo1 in the nucleus and 
enhances Hbo1’s HAT activity leading us to speculate that the interaction and 
phosphorylation of Hbo1 by the cyclin E/CDK2 complex may also affect the HAT 
activity of Hbo1 (318). The Myc-Hbo1 (wt, T88A, and T88D), SFB-EL, SFB-LMW-E, 
and SFB-CDK2 constructs were purified by IP with Myc or FLAG-tagged antibody 
and then subjected to an in vitro HAT activity colorimetric assay (Figure 31A & B). 
As shown in Figure 31C, phosphorylation of Hbo1 at T88 did not alter Hbo1’s HAT 
activity since the T88A and T88D mutants exhibited similar HAT activity levels to 
wild type Hbo1. Furthermore, inhibition of the kinase activity of EL/CDK2 and LMW-
E/CDK2 by addition of roscovitine did not affect the HAT activity level. Perhaps the 
phosphorylation of Hbo1 at T88 may affect its binding to other proteins or to DNA 
but not necessarily alter its function as a HAT. In fact, it has been demonstrated that 
CDK1 phosphorylates Hbo1 at T85/T88 to create a docking site for polo-like kinase 
1 (Plk1) (319). The recruited Plk1 subsequently phosphorylates Hbo1 at S57 and 
activates the HAT enzymatic activity of Hbo1. We speculate that in the cellular 
context, phosphorylation of Hbo1 by the LMW-E/CDK2 complex at T88 may also 
create docking site for Plk1 or perhaps other kinases/proteins to be recruited to 
regulate Hbo1’s HAT activity. Alternatively, the HAT activity of Hbo1 is not required 
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for its transcriptional repression function. In fact, two independent reports indicated 
that the N-terminal region of Hbo1 (in which the T88 site is located) is necessary to 
repress AR and NF-κB transcriptional activation while the C-terminal domain (which 
contains the HAT domain) displays no effect (317,318).  
 
3.3j. Hbo1 is overexpressed in breast cancer cell lines and co-expression with 
LMW-E/CDK2 enhances self-renewal capability of hMECs.   
 If Hbo1 is a novel downstream substrate of the cyclin E/CDK2 complex, we 
next hypothesize that Hbo1 may play a role in inducing the CSC properties of the 
LMW-E-expressing cells. We first determined that Hbo1 is highly expressed in 13 of 
the 18 breast cancer cell lines tested compared to the relatively low levels in the 3 
hMEC cell lines (Figure 32A). Interestingly, we observed no significant correlation 
between Hbo1 expression and the different breast cancer subtypes (Figure 32A). 
Furthermore, in our cell line model system, the 76NE6-LMW-E, T1G2.2, T1G3.1, 
and T1G4.2 cells also express high level of Hbo1 protein compared to the 76NE6-
vector and 76NE6-EL cells (Figure 32B). To determine if transient co-expression of 
Hbo1 with EL/CDK2 or LMW-E/CDK2 enriches for the CSC population, these 
constructs were transfected into HEK293T cells and examined the change in the 
CD44hi/CD24lo population four days later. Results from FACS analysis clearly 
showed that while expression of EL/CDK2 and LMW-E/CDK2 led to an increase in 
the CD44hi/CD24lo population compared to control cells, co-expression with Hbo1 
further doubled this population (Figure 32C). More importantly, the increase in the 
CD44hi/CD24lo population by LMW-E expression was significantly more than with 
EL expression (p = 0.042). Additionally, Western blot analysis confirmed that co-
expression of Hbo1 with EL/CDK2 and LMW-E/CDK2 resulted in reduced CD24 and 
elevated ALDH protein levels (Figure 32D). While the HEK293T cells facilitate 
efficient overexpression of proteins, they are however not an ideal model system to 
examine physiologically relevant biological processes. Therefore, we co-expressed 
cyclin E (EL or LMW-E), CDK2, and Hbo1 in the 76NE6 cells via lentiviral infection 
and generated stable cell lines through antibiotic selection (Figure 32E). 
Examination of the CD44hi/CD24lo population by FACS analysis revealed no 
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Figure 32
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Figure 32: Hbo1 is overexpressed in breast cancer cell lines and co-
expression with LMW-E/CDK2 enhances self-renewal capability of hMECs.
(A) Cell lysates from 3 hMECs lines and 18 breast cancer cell lines were
subjected to Western blot analysis with antibodies to Hbo1 and β-actin. (B) The
76NE6 stable cell panel and the TDCs were subjected to similar analysis as in
(A). (C) SFB-EL or SFB-LMW-E, HA-CDK2, and Myc-Hbo1 constructs were co-
transfected into HEK293T cells. Four days later, the cells were subjected to
CD24/CD44 FACS and (D) Western blot analysis. The FACS results were
averaged from 3 independent experiments and the statistical analysis used was
unpaired student’s t-test. (E & F) Lentivirus were generated in HEK293T cells
carrying the EL, LMW-E, CDK2, or Hbo1 (wt, T88A, or T88D) constructs were
used to infect the 76NE6 cells and stable expression was achieved by selection
with 20 µg/ml blasticidin for 2 weeks. The cells were then subjected to
CD44/CD24 FACS analysis (E) and mammosphere culture (F). The FACS and
mammosphere formation results were averaged from at least 2 independent
experiments and the statistical analysis used was unpaired student’s t-test.
p = 0.0027
p = 0.0449
p = 0.0004
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statistical difference between the different stable cell lines (Figure 32E). In contrast, 
when we tested the ability of these cells to form mammospheres, we found that the 
76NE6 cells co-expressing wild-type Hbo1 with the LMW-E/CDK2 complex (76NE6-
8) formed significantly more mammospheres than those co-expressing the 
EL/CDK2 complex (76NE6-7) (p = 0.0027) (Figure 32F). Additionally, co-expression 
of the T88A Hbo1 mutant in the 76NE6 cells (76NE6-9,10) reduced the number of 
mammospheres to similar levels as in the cells without Hbo1 overexpression 
(76NE6-5,6) suggesting that the phosphorylation of Hbo1 by the cyclin E/CDK2 
complex is critical for the enhanced self-renewal capability of these cells. 
Interestingly, the cells with the T88D Hbo1 phosphorylation mimetic expression 
(76NE6-11,12) also demonstrated reduced mammosphere formation compared to 
wild-type Hbo1 (76NE6-7,8). We speculate that the aspartic acid substitution is not 
an ideal phosphorylation mimetic for phospho-threonine as it has one less chemical 
bond. Perhaps glutamate will be a better substitution for phospho-threonine mimetic 
and may explain the importance of the phosphorylation of Hbo1 at T88 by the cyclin 
E/CDK2 complex to generate a docking site for protein recruitment. Collectively, 
these results indicate that Hbo1 along with LMW-E/CDK2 function to alter the 
physiology of the cell as manifested in the properties associated with CSCs. 
 
3.3k. Knockdown of Hbo1 reduced the properties associated with CSCs. 
 To investigate whether Hbo1 plays a role in enriching for the CSC population, 
shRNAs targeting the Hbo1 mRNA transcript with an internal ribosome entry site for 
GFP were packaged into lentivirus with HEK293T cells and used to infect the 
76NE6-V, EL, LMW-E, T1G2.2, T1G4.2 and Sum159 cells. After two week of 0.5 
µg/ml puromycin selection, approximately 98% of the cells express high levels of 
GFP suggesting that the shRNAs were integrated successfully (Figure 33A). 
Western blot analysis indicated that the two shHbo1 constructs were efficient at 
knocking down Hbo1 protein levels (Figure 33B). Additionally, FACS analysis for 
CD44/CD24 expression revealed that knockdown of Hbo1 significantly reduced the 
CD44hi/CD24lo population as well as the ability of the cells to form mammosphere 
structures compared to the shControl cells (Figure 33C & D). Furthermore, we 
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Figure 33: Knockdown of Hbo1 reduced the properties associated with
CSCs. shControl, shHbo1-4, and shHbo1-5 lentivirus were produced in
HEK293T cells and used to infect the 76NE6 stable cell panel, two of the TDCs
and Sum159 cells. After selection with 0.5 µg/ml puromycin for 2 weeks, the
cells were subjected to (A) GFP FACS analysis, (B) Western blot analysis, (C)
CD44/CD24 FACS analysis, and (D) mammosphere formation assay. These
cells were then infected with lentivirus carrying the shHbo1-5R construct and
selected with 20 µg/ml blasticidin for 2 weeks followed by similar in vitro
analysis. The FACS and mammosphere formation results were averaged from
at least 2 independent experiments and the statistical analysis used was
unpaired student’s t-test (*p<0.05).
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rescued Hbo1 expression by infecting the cells with an shHbo1-5 resistant construct 
(shHbo1-5R) by taking advantage of the wobble effect of the amino acid code and 
select for stable expression with 20 µg/ml blasticidin for two weeks (Figure 33B). 
Analysis of the CSC properties of these cells showed that re-expression of the 
shHbo1-5R construct rescued the reduced CD44hi/CD24lo population as well as the 
number of mammosphere formation (Figure 33C & D). Collectively, our findings 
implicate that the presence of Hbo1 in LMW-E-expressing cells enhanced the 
properties associated with CSCs, which can be reduced by knockdown of Hbo1 
expression. 
 
3.4. CONCLUSIONS 
 The role of LMW-E in breast cancer was first strongly established by its 
association with patient samples and poor clinical outcome and was subsequently 
reinforced by the demonstration that transgenic mice with ectopic LMW-E 
expression develop mammary carcinoma and metastasis at significantly higher 
frequency compared to transgenic mice with EL expression (160, 180). In chapter 2, 
we described similar findings in xenograft mouse model in which hMECs expressing 
LMW-E/CDK2 yielded higher tumor incidence compared to cells with EL/CDK2 
expression. 
 By expressing LMW-E, the 76NE6 mammary epithelial cells underwent a 
morphological switch by adopting mesenchymal characteristics as well as CSC 
properties. That is, these cells altered gene expression that is consistent with the 
EMT and demonstrated increased invasiveness through the basement membrane. 
In addition, LMW-E-expressing cells contain a high percentage of the 
CD44hi/CD24lo population, were able to form mammospheres in non-adherent 
culture, and upregulated the expression and enzymatic activity of ALDH. More 
importantly, the fact that the phenotypes observed were more robust with 
exogenous LMW-E overexpression than with EL overexpression provides evidence 
for the difference in their tumorigenic potential.  
 Furthermore, we observed a strong positive association between LMW-E 
expression and the CD44hi/CD24lo population in the tumor cell line model, 
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particularly in the cells obtained from in vivo passaging in which both the levels of 
LMW-E expression and the CD44hi/CD24lo population showed dramatic elevation 
compared to the stable cell lines. This connection was further strengthened by the 
clinical examination of breast cancer patient tissues in which LMW-E expression 
associated with tumors that contain high CD44hi/CD24lo population suggesting that 
perhaps breast cancer cells with LMW-E expression are CSCs. More importantly, 
statistical analysis also revealed a significant association between LMW-E 
expression and their cytoplasmic localization from IHC staining of the tumor tissues 
thus implicating a more efficient way to identify LMW-E expression in tumor tissues 
by IHC rather than by Western blot analysis.  
 Given that the understanding of breast CSCs has only recently evolved, 
clinical therapy aimed at targeting these cells is currently under active investigation. 
In a large screen for small molecule inhibitors that can specifically kill CSCs, Gupta 
and colleagues identified salinomycin as a potent agent that can abrogate the 
phenotypes associated with CSCs and thereby reduce tumor aggressiveness and 
regrowth (297). Although the mechanism of salinomycin-induced CSC death is 
currently unclear, it is speculated that it may be due to its function as a potassium 
ionophore since nigericin, another potassium ionophore, was also identified as a 
CSC inhibitor in the same screening study (297). Recently, salinomycin was 
reported to sensitize cancer cells to doxorubicin and etoposide leading to increased 
DNA damage and apoptosis (320). In our study, we also demonstrated that the 
combination of doxorubicin and salinomycin effectively targeted both the tumor bulk 
(non-CSCs) as well as the CSCs. Doxorubicin is a strong anti-tumor agent; 
however, due to its life-threatening cardiac toxicity, doxorubicin’s use in the clinic is 
limited (321, 322). Similarly, salinomycin also has a narrow therapeutic window due 
to its high toxicity. However, the synergistic effects mediated by salinomycin and 
doxorubicin in LMW-E tumor cells but not in control and EL-expressing cells may 
allow for administration of these drugs at a lower and thus less toxic dose in 
patients with high LMW-E protein levels. 
 Our screen for novel substrates of the cyclin E/CDK2 complex identified 
Hbo1, which is a HAT that can alter the expression pattern of multiple genes. The 
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consensus phosphorylation motif for CDK2 is S/T-P-X-R/K/H, and we found that 
cyclin E/CDK2 phosphorylated Hbo1 at T88PKK confirming that the phosphorylation 
is specific. T88 is located within the N-terminal serine-rich region of the Hbo1 gene, 
which is the regulatory domain, while the C-terminal region contains the Zn-finger 
and a HAT domain that carries out the enzymatic function (306, 311). Plk1 was 
previously shown to phosphorylate Hbo1 at S57A, which is in the regulatory N-
terminal region, and this phosphorylation exerts positive control over the HAT 
activity indicating that this domain is critical in regulating the enzymatic activity of 
Hbo1 (319). The fact that co-expression of Hbo1 with LMW-E/CDK2 further 
increased the CSC properties of both HEK293T and 76NE6 cells while knockdown 
of Hbo1 expression reduced the CD44hi/CD24lo population and mammosphere 
formation ability suggests that Hbo1 plays a role downstream of LMW-E in enriching 
for the CSC population. Even though results from the in vitro HAT activity assay 
indicated that LMW-E/CDK2 phosphorylation of Hbo1 did not directly affect its HAT 
activity, in the cellular physiological context, this phosphorylation may create a 
docking site to recruit other kinases to further phosphorylate Hbo1 and thereby alter 
its HAT activity. Indeed this phenomenon has been previously observed in which 
CDK1 phosphorylates Hbo1 to recruit further phosphorylation by Plk1 to increase 
the HAT activity of Hbo1 (319).  
 Although the role of cyclin E has been strictly confined to the control of the 
cell cycle, our data suggest that when deregulated, such as cleavage into LMW 
isoforms, this oncogene is capable of inducing phenotypes associated with the EMT 
and CSCs, which are further enhanced with the co-expression of Hbo1. Moreover, 
phosphorylation of Hbo1 in the regulatory N-terminal region by the LMW-E/CDK2 
complex implicates potential alteration in the regulation of gene transcription 
associated with the EMT and CSCs. More importantly, combination treatment using 
doxorubicin and salinomycin produced synergistic effect on cancer cellular toxicity 
and thus further encourages investigation onto other drug combinations that target 
both the CSC and non-CSC populations to bring to the clinic. 
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CHAPTER 4: CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
4.1. HIGHLIGHT OF MAJOR FINDINGS 
 The role of LMW-E in breast cancer has been well documented for more than 
a decade, and research from this dissertation has shed light into our understanding 
of how LMW-E deregulate the cells in the mammary gland as well as provide 
possible therapeutic implications to intervene this process. The central hypothesis 
of this dissertation is that LMW-E initiates and maintains mammary tumor via 
deregulation of mammary acinar morphogenesis, induction of the EMT, and 
generation of cells with CSC properties. The data obtained from this dissertation 
provided answers to the following five questions that were raised at the end of 
chapter 1. 
1. Is LMW-E capable of initiating and maintaining tumor development? 
• Both stable and inducible LMW-E expression systems are capable of 
rendering a nontumorigenic hMEC tumorigenic. Moreover, the tumorigenic 
potential mediated by LMW-E is approximately 10 folds stronger compared to 
that of EL.  
2. What effect does LMW-E have on the proliferation and architecture of the 
mammary acini, and if so, can inhibition of LMW-E by pharmacological 
agents rectify these defects?  
• LMW-E induced hyper-proliferation during mammary acinar morphogenesis 
causing formation of large and misshapen acinar structures. Treatment of 
these acini using combination of rapamycin and roscovitine or sorafenib and 
roscovitine prevents development of these phenotypes. 
3. What signaling pathway is deregulated in breast tumors with high LMW-
E expression? 
• Proteomic analysis identified the b-raf/ERK2/mTOR pathway is activated in 
both breast cancer patient tissues and cells with high LMW-E levels. More 
importantly, expression levels of the proteins from this pathway along with 
LMW-E predicted poor clinical outcome. 
4. Does LMW-E induce tumor initiation, progression, and metastasis by 
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altering gene expression to enhance invasiveness and self-renewal 
capability?  
• LMW-E altered the gene signature associated with the EMT thereby reducing 
cell-cell contact and enhancing cellular invasion. Furthermore, LMW-E 
enriched for cells with CSC properties and, in breast cancer patient samples, 
cytoplasmic cyclin E significantly correlated with the CD44hi/CD24lo mammary 
CSC population. Combination treatment using salinomycin and doxorubicin 
demonstrated synergistic toxicity in LMW-E-expressing cells but not in control 
and EL-expressing cells. 
5. Are these phenotypes driven by previously unidentified substrate(s) of 
the LMW-E/CDK2 complex?  
• ProtoArray microarray analysis identified Hbo1 as a novel substrate of cyclin 
E/CDK2. Co-expression of Hbo1 with LMW-E/CDK2 resulted in an enrichment 
of the CSC population while knockdown of Hbo1 expression significantly 
reduced the CSC population. 
 
4.2. FUTURE DIRECTIONS 
 While research from this dissertation has addressed some of the critical 
aspects of LMW-E deregulation in mammary tumorigenesis, the data generated 
inevitably raised new questions that are essential to further understand this process 
in order to apply therapeutic intervention in the clinical setting.  
 Firstly, we identified several different therapeutic strategies involving 
combining pharmacological agents to specifically target mammary tumor cells with 
high LMW-E expression. The first strategy was to target the activated b-Raf-
ERK1/2-mTOR pathway by combining roscovitine with rapamycin or sorafenib, 
which was effective at preventing the formation of hyperproliferative mammary 
acinar structures in LMW-E-expressing cells. In the inducible transgenic mouse 
model with LMW-E expression, we also observed similar hyperproliferation of the 
terminal end buds and activated MAPK pathway. Therefore, this mouse model is 
valuable to test the preclinical effectiveness of combining roscovitine with rapamycin 
or sorafenib at both preventing LMW-E-induced mammary tumor development as 
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well as inducing tumor toxicity post tumor formation. This therapeutic strategy is 
anticipated to demonstrate strong anti-tumor effect in the mouse model since we 
observed activation of the MAPK pathway in this mouse model and strong 
correlation between high LMW-E expression and activation of the b-raf/ERK/mTOR 
pathway with patient survival outcome. 
The second therapeutic approach that we identified was by combining 
salinomycin with doxorubicin to target the LMW-E-induced CSCs. Again, the 
inducible transgenic mouse model with LMW-E expression is valuable to test the 
effectiveness of this drug combination. However, it is necessary to first determine 
whether the LMW-E-induced mammary tumors in the transgenic mice also 
demonstrate features of the EMT and enrichment for mammary CSCs. We 
speculate that the LMW-E-mediated mammary tumors likely undergo the EMT to 
facilitate metastasis development since it was reported that approximately 25% of 
LMW-E-tumor-bearing mice formed distant metastasis (180). If the salinomycin and 
doxorubicin combination proves to be effective at targeting the LMW-E-induced 
mammary tumors in the mouse model, this therapeutic strategy will undoubtedly 
implicate possible clinical application for breast cancer patients with high LMW-E 
expression given the fact that we have also provided evidence demonstrating a 
positive correlation between cytoplasmic cyclin E and the CD44hi/CD24lo CSC 
population. 
We ended this project with the finding that Hbo1 is a novel substrate of the 
cyclin E/CDK2 kinase complex. Given that the cyclin E/CDK2 complex has been 
shown to be involved during the assembly of the prereplication complex (pre-RC), it 
is not surprising that Hbo1 (a HAT binding to ORC1) was found to be a substrate of 
this kinase complex. DNA replication requires the assembly of the pre-RC, which is 
formed by the sequential loading of Cdc6/Cdcl8, Cdtl, and MCM2-7. More 
specifically, the interaction between cyclin E/CDK2 and Cdc6 was found to be 
critical for the initiation and maintenance of DNA replication at the G1-S phase 
boundary (115, 116). Recently, Hbo1 was reported to be important for the chromatin 
loading of the MCM2-7 since depletion of Hbo1 blocked MCM2-7 assembly into the 
pre-RC and subsequently inhibited DNA replication (313). Therefore, it is intriguing 
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to investigate the mechanistic function of cyclin E/CDK2 phosphorylation of Hbo1 on 
DNA replication licensing in the normal cellular context as well as the consequence 
of deregulated phosphorylation of Hbo1 due to hyperactive LMW-E/CDK2 activity in 
tumor cells. Perhaps phosphorylation of Hbo1 by the cyclin E/CDK2 complex 
provides a docking site on Hbo1 to recruit other proteins required for the assembly 
of the pre-RC. However, aberrant cyclin E/CDK2 kinase activity manifested by 
LMW-E/CDK2, whose activity has been shown to be deregulated throughout the cell 
cycle, can cause untimely DNA replication leading to genomic instability (173,184). 
Indeed, one mechanism of cyclin E-mediated oncogenesis is through inducing 
genomic instability (162-164) and tumor cells with p53 loss and cyclin E 
overexpression were observed to have elevated frequency of centrosomal 
hyperamplification (120). In fact, in response to DNA replication fork arrest and 
hyperosmotic shock, stablized p53 has been shown to interact with Hbo1 and 
negatively regulates its HAT activity (307). Therefore, aberrant Hbo1 HAT activity 
due to lack of repression by p53 and overexpression of cyclin E may lead to 
deregulated DNA replication and predispose the cell to genomic instability. 
 Studies have shown that Hbo1 is the major HAT for histone H4 acetylation in 
vivo, however recent work by Kueh and colleagues demonstrated that Hbo1 is also 
necessary for H3K14 acetylation to transcriptionally activate genes associated with 
embryonic development (313, 316, 323, 324). While H4 acetylation is linked with 
DNA replication, H3 acetylation is thought to control transcriptional activity 
suggesting that aside from playing an important role during replication licensing in 
S-phase, Hbo1 also exerts control over gene expression (323). In fact, Hbo1 has 
been shown to affect the transcriptional activity of a few transcription factors such 
as ER, PR, AR and NF-κB (308-310). Interestingly, the N-terminal region of Hbo1 
exerts repression of AR and NF-κB transcriptional activation while the C-terminal 
domain displays no effect suggesting that the HAT activity of Hbo1, which is located 
in the C-terminal region, is not necessarily required for Hbo1 to mediate 
transcriptional regulation (308, 309). Particularly, Contzler and colleagues further 
demonstrated that the mechanism of Hbo1-mediated suppression of NF-κB 
transcriptional activity is not through binding directly to NF-κB nor to the κB 
161
consensus sequence but perhaps via interaction with NF-κB’s coactivator(s) and 
thereby squelching them from NF-κB (309). One likely possible coactivator is SRC-
1 since it has been shown to co-IP with the N-terminal domain but not the C-
terminal region of Hbo1, and the interaction between these two proteins cooperates 
to enhance the transcriptional activities mediated by ER and PR (310). Finally, 
studies have shown that the N-terminal domain of Hbo1 is able to mediate 
transcriptional control both in trans and in cis thus implicating that this domain of 
Hbo1 is critical for the recruitment and binding of other factors to Hbo1 to regulate 
gene expression (325, 326). Therefore, phosphorylation of Hbo1 at T88 by the 
cyclin E/CDK2 complex may affect the ability of Hbo1 to regulate the transcriptional 
activities of PR, AR, NF-κB, and perhaps other transcription factors yet to be 
identified. This speculation can be addressed by using the T88A and T88D (or 
T88E) Hbo1 mutants to examine the extent of Hbo1’s regulation on the 
transcriptional activities of ER, PR, AR and NF-κB through the use of a luciferase 
gene reporter assay.  
 In addition, in vitro HAT activity assay also showed that phosphorylation of 
Hbo1 at T88 by the cyclin E/CDK2 complex did not affect the HAT activity of Hbo1. 
Similar to the context of CDK1 phosphorylation and subsequent recruitment of Plk1 
to Hbo1, we speculate that phosphorylation of Hbo1 by cyclin E/CDK2 also provides 
docking site for other proteins to bind to Hbo1. Again, T88A and T88D (or T88E) 
Hbo1 mutants can be used to co-IP possible interacting proteins and then identified 
via mass spectrometry. Alternatively, the retrovirus-based protein-fragment 
complementation assay can also be used to screen for interacting proteins to Hbo1 
when phosphorylated at T88. This approach involves fusing the N-terminal half of 
the GFP gene to the Hbo1 mutants and the C-terminal half of the GFP gene is 
fused to an endogenously expressed protein through an in-frame exon trap. The 
difference in the hits obtained between the two mutants will uncover the proteins 
that interact specifically to Hbo1 when the T88 site is phosphorylated. Given that the 
N-terminal domain of Hbo1 is critical for its regulation of gene transcription, the 
identified interacting proteins to pT88 Hbo1 will further reveal other transcription 
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factors and co-activators that are critical in controlling the gene transcriptional 
activity of Hbo1.  
 Although the in vitro kinase assay was understandably not adequate in 
distinguishing the difference in the extent of phosphorylation between EL/CDK2 and 
LMW-E/CDK2 complexes, it is likely that high LMW-E levels in the tumor tissues of 
patients are responsible for phosphorylation of Hbo1. To address this hypothesis, 
an antibody specific to phospho-T88 Hbo1 can be produced and used for 
immunoblot analysis of our patient data set to correlate with LMW-E protein levels. 
Furthermore, the level of Hbo1 phosphorylation can also be analyzed for 
association with the percentage of the CD44hi/CD24lo population as well as survival 
outcome in patients. These findings will better define the molecular deregulation 
mediated by LMW-E and thus bring us closer to identifying a therapeutic approach 
that is specific for patients with high LMW-E expression. For instance, a 
combination between a CDK inhibitor (i.e. roscovitine) and salinomycin might be 
effective at inhibiting the CSC population in patients with high LMW-E expression. 
Although CDK inhibitors such as flavopiridol and roscovitine have demonstrated 
unimpressive response in clinical trials as a single agent, it must be noted that the 
patients in these trials were not selected based on LMW-E levels (327, 328). By 
inhibiting the CSC population in the high LMW-E-expressing tumors, we may be 
able to achieve favorable outcome and avoid tumor relapse due to the specific 
targeting of the CSCs. In addition, another possible target is Hbo1 using HAT 
inhibitor if the HAT activity of Hbo1 were found to be important in enriching for the 
CSC populations. However, similar to HDACs, HATs also have both oncogenic and 
tumor suppressive roles in cancer biology thus complicating its use in the clinic. To 
date, there are a few HAT inhibitors available for mechanistic studies as possible 
antitumor agents such as garcinol, anacardic acid, and curcumin, which are among 
the natural inhibitors found in plants. Particularly, anacardic acid was shown to be a 
radiation sensitizer while garcinol and curcumin demonstrated strong cytotoxic 
effect in human leukemic cell lines (329, 330). As with all natural compounds, their 
mechanism of action is typically complex and non-specific and thus warrants more 
extensive investigation prior to use in the clinic. In contrast to the plant-derived 
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inhibitors, lys-CoA, which is a synthetic HAT inhibitor (lysine amino acid conjugated 
to coenzyme A), has been shown to exhibit highly specific and potent activity 
against HAT activity although its use in vivo has been limited due to high metabolic 
instability and cell impermeability (331). While HAT inhibitors are currently not ideal 
for clinical therapy, they can serve as valuable tools for mechanistic studies as 
proofs of principle.    
 
4.3. SIGNIFICANCE 
 The incident rate of breast cancer worldwide is steadily increasing over the 
past few decades, and the problem of tumor recurrence remains difficult to address. 
Clinical studies demonstrated that a high percentage of breast cancer patients 
express LMW-E, and this occurrence is linked to adverse clinical outcomes (160). In 
this dissertation, we identified two therapeutic approaches of targeting breast tumor 
cells with high LMW-E expression: 1) combination of roscovitine with sorafenib or 
rapamycin and 2) combination of doxorubicin and salinomycin. We believe that the 
results from this study provided important preclinical basis for the use of these 
agents first in the animal model and hopefully into the clinic in the near future. 
Furthermore, the identification of Hbo1 as a downstream substrate of the LMW-
E/CDK2 complex undoubtedly unveils additional mechanism of how LMW-E 
mediates mammary tumorigenesis. 
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